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ABSTRACT
Systemic acidosis is associated with bone loss and impaired bone mineralisation. 
The aim of this PhD project was to further investigate the action of extracellular pH 
on the function of osteoclasts and osteoblasts. I showed that blood-derived human 
osteoclasts exhibited a highly reproducible acid-activation response, with maximal 
activation close to pH 7.0, and little activity at blood pH (7.4). These experiments 
also provided strong evidence that accessory cells, such as osteoblasts or stromal 
cells, are not required for acid-activation of resorption. The pH-activation profile of 
human osteoclasts was similar to that of the recently discovered H+-sensing human G- 
protein-coupled receptor OGR1. Expression of OGR1 and TDAG8 (another GPCR) 
was detected in human osteoclasts and was upregulated by low pH. I obtained 
evidence that the multifunctional receptor TRPV1, which senses protons, heat and 
capsaicin, was expressed by human osteoclasts and was also upregulated at pH 7.0. 
Moreover, I showed that the alkaloid capsaicin strongly stimulated osteoclasts in non­
acidified conditions. To date, only pertussis toxin has been reported to activate 
osteoclasts without co-stimulation by fT. Using mouse bone organ cultures I found 
that resorption-associated factors TRACP, cathepsin K and TRAF-6 were also 
upregulated by acidosis. The effect of PTH on human osteoclasts was also studied. I 
showed that PTH directly stimulates human osteoclasts in the absence of osteoblasts, 
but only when acid-activated. This finding suggests that the dogma that PTH 
stimulation of osteoclast is osteoblast-mediated may not be correct. Studies using 
primary rat osteoblast cultures showed that the formation of mineralised bone nodules 
is inhibited by acidosis. The same pH reduction, which increases Ca2+ and PC>43* 
solubility of hydroxyapatite by 2- and 4-fold respectively, did not alter collagen 
production or osteoblast proliferation but decreased alkaline phosphatase activity and 
expression. Thus, the primary effect of acidosis on osteoblast function is to cause a 
selective inhibition of bone mineralisation. In conclusion, this study showed that the 
important “double negative” action of acidosis on bone cells is consistent with a 
pathophysiological role of bone as a reserve of base to buffer excess protons when the 
kidneys and lungs are unable to maintain acid-base balance within narrow 
physiological limits.
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CHAPTER 1
General introduction
SKELETAL SYSTEM
The skeletal system is composed of bone and cartilage. Bone is a specialised 
connective tissue, which has a variety of functions. It provides a rigid framework for 
the body, protects vital organs, houses the bone marrow and it serves as a reservoir of 
ions (Ca2+ and PO4 3') for the maintenance of body homeostasis; the skeleton contains 
99% of total body calcium (Baron 2003).
Macroscopically, bones can be classified as compact (cortical) or trabecular 
(cancellous). Compact bone, which is mainly found in the shafts of long bones and 
surfaces of flat bones, is much denser and less metabolically active than trabecular 
bone and comprises -80% of the skeleton. This type of bone is arranged 
concentrically around central canals, the Haversian canals, which contain blood and 
lymphatic vessels, nerves and connective tissue. Trabecular bone is found mainly at 
the ends of long bones and in the inner parts of flat bones. Trabecular bone is 
composed of interconnecting plates within which lies the bone marrow (Baron 2003).
Microscopically, bone can be classified on the basis of its organisation into two 
types: woven or lamellar bone. Woven bone is an immature form with randomly 
arranged collagen fibres. This type of bone is generated when osteoblasts produce 
osteoid rapidly; e.g. during embryonic life, childhood and also in adults with 
pathological disorders characterised by rapid bone formation such as in Paget’s 
disease (Meunier et al. 1980). Lamellar bone is composed of regular parallel bands 
of collagen arranged in sheets. Virtually all bone in a healthy adult is lamellar (Baron 
2003).
Mature bone by weight is made up of 70% inorganic salts (mainly hydroxyapatite 
(Caio(P04)6(OH)2) crystals) and 30% organic matrix. Type I collagen represents the 
majority of bone collagen but trace amounts of types III, V and X and fibril-
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associated collagen with interrupted triple helix (FACIT) which may function in 
regulating collagen fibril diameter during bone formation have also been reported 
(Robey and Boskey 2003). The remaining 10% of the organic matrix is composed of 
non-collagenous proteins such as osteocalcin (OCN), osteonectin, osteopontin (OPN) 
and bone sialoprotein (BSP) (Lian et a l 2003). The organic component of bone also 
contains traces of growth factors and cytokines that have an important local 
regulatory role in bone remodelling (Baron 2003). Bone is comprised of three main 
cell types: osteoblasts, osteocytes and osteoclasts; these are described below in detail.
OSTEOBLASTS 
Phenotype
Osteoblasts are specialised bone-forming cells that work in groups to secrete 
osteoid and are involved in the subsequent process of mineralisation (Ducy et al. 
2000b). Histologically, active osteoblasts appear as plump, cuboidal cells sitting on 
the bone surface and express large amounts of alkaline phosphatase (ALP), an 
enzyme involved in the mineralisation process (Fedde et a l 1999; Wennberg et a l 
2000). At the ultrastructural level osteoblasts are characterised by the presence of a 
well-developed rough endoplasmic reticulum and Golgi complex. Cytoplasmic 
processes coupled with gap junctions are in contact with osteocyte processes and are 
also found between adjacent osteoblasts (Doty 1981). Quiescent bone surfaces are 
covered by a near-continuous single layer of flattened, inactive osteoblasts, often 
referred to as ‘bone-lining cells’ (Hughes and Aubin 1998).
Osteoblast origin and differentiation
Osteoblasts are derived from pluripotent mesenchymal cells (Figure 1.1) that 
also give rise to myocytes, under the transcriptional control of myogenic regulatory 
factors (MRFs) and myocyte enhancer factor 2 (MEF2), to adipocytes, under the 
control of CCAAT enhancer binding protein <x,P,a (C/EBP a,P,a) and peroxisome 
proliferator activator receptor y (PPARy), and to chondrocytes under the control of 
sex determining region Y box 5, 6 and 9 (Sox 5, 6, 9) and runt-related transcription
13
factor 2 (Runx2) (Arnold and Winter 1998; Akiyama et a l 2002; Lecka-Czemik et 
a l 2002).
CX>
myoblasts
MRF MEF2
myocytes
C/EBP a,p,CT 
PPAR y
pre­
adipocytes adipocytes
mesenchymal 
stem cell
Sox 5,6,9 
Runx2Sox 5,6,9
chondrocytes
hypertrophic
chondrocytes
Msx2, Dlx 5,6 Runx2
Osx
pre­
osteoblasts matureosteoblasts
Figure 1.1. Transcriptional control of cells from mesenchymal origin. 
Osteoblasts differentiate from mesenchymal progenitor cells that also give rise to 
myocytes, adipocytes and chondrocytes. MRF = myogenic-regulatory factors, MEF2 
= myocyte-enhancer factor 2, C/EBP a, p, ct = CCAAT-enhancer-binding protein a, p 
and o, PPARy = peroxisome proliferator-activated receptor y, Sox 5,6,9 = sex 
determining region Y-box 5,6 and 9, Runx2 = runt-related transcription factor 2, Msx2 
= muscle-segment homologue 2, Dlx5 = homeobox containing transcription factor 
distal-less gene 5, Osx = osterix.
Differentiation and activity of osteoblasts is regulated by a variety of factors 
including transcription factors, hormones, cytokines, and growth factors (Ducy et al. 
2000b). A summary of the developmental stages of the osteoblastic phenotype and 
characteristic features of each stage is shown in Figure 1.2.
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Figure 1.2. Regulation of osteoblast growth and differentiation. The diagram 
Illustrates the morphological features of differentiating osteoblasts at each stage 
from stem cell to osteocyte and lists some of the signalling molecules that promote 
differentiation of the precursor cell populations (shown in italics).
There are many transcription factors involved in the regulation of osteoblast 
differentiation (Harada and Rodan 2003). Runt-related transcription factor 2 (Runx2) 
also known as core-binding factor 1 (Cbfal), osteoblast-specific transcription factor 2 
(Osf2) and acute-myeloid-leukaemia protein 3 (AML3), was first thought to be an 
osteoblast-specific transcription factor (Ducy et a l 1997). Runx2 can induce 
osteoblast-specific gene expression in fibroblasts and myoblasts in vitro (Ducy et al. 
1997) and Runx2-deficient mice develop a skeleton made exclusively of cartilage 
with no osteoblasts present (Otto et al. 1997; Komori et al. 1997). However, further 
histological studies showed that Runx2-null mice have delayed chondrocyte 
maturation, suggesting that this factor is also involved in chondrogenesis (Inada et al 
1999). Most recently, another transcription factor was discovered: osterix (Osx). 
Like the Runx2-null mice, the Osx-knockout mice develop a skeleton composed 
entirely of cartilage, lacking osteoblasts and mineralised bone matrix. However, the 
hypertrophic chondrocytes in these mice are fully differentiated, indicating this is a
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specific transcription factor of the osteoblast differentiation pathway. Moreover, 
Runx2-null mice do not express Osx, suggesting that this factor acts downstream from 
Runx2 (Nakashima et a l 2002) .
Muscle-segment homologue 2 (Msx2) and homeobox containing transcription 
factor distal-less gene 5 (Dlx5) are two transcription factors that are expressed at 
early stages of osteoblast differentiation (Bendall and Abate-Shen 2000). Msx2 
expression in osteoblast precedes the osteoblast marker osteocalcin (Newberry et al
1997) and prevents terminal differentiation of osteoblasts, demonstrating that this 
factor maintains a balance between osteoblast proliferation and differentiation steps 
(Bidder et a l 1998). Dlx5, meanwhile, has both a positive and negative regulatory 
activity on the osteocalcin promoter by either inhibiting or stimulating Msx2 
expression (Newberry et a l 1998).
Transcription factors of the activating protein-1 (AP-1) complex are also involved 
in osteoblast differentiation. Overexpression of AFosB, a fosB splice variant, and fra- 
1 causes enhanced differentiation of osteoblasts, possibly as a result of altered 
progenitor cell differentiation, and increased osteoblast activity (Sabatakos et a l 
2000; Jochum et a l 2000).
Endocrine factors involved in regulating osteoblast differentiation and activity 
include l,25(OH)2-vitamin D3, parathyroid hormone (PTH), parathyroid hormone 
related protein (PTHrP), glucocorticoids and oestrogen. The role of these factors 
will be discussed in detail in the regulation of bone cell function section.
Members of all major families of growth factors have been implicated in the 
control of osteoblast differentiation (Lian et a l 2003). One family of growth factors 
that has been studied in detail is that of transforming growth factor (3 (TGF- (3) and 
bone morphogenetic protein (BMP) superfamily, including TGF-(3 itself and BMP 2, 
4 and 7 (Wang et a l 1990; Ahrens et a l 1993; Maliakal et a l 1994). TGF-P is 
produced by osteoblastic cells and functions in an autocrine manner as a potent 
chemotactic factor by recruiting osteoblast precursors to sites of bone formation 
(Pfeilschifter et a l 1990). This factor promotes the differentiation of osteoblasts and 
production of bone matrix, but it inhibits matrix mineralisation and expression of 
osteocalcin by osteoblasts (Pirskanen et a l 1994; Bonewald 1999). When injected
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subcutaneously, TGF-P has been shown to induce rapid production of new bone 
matrix in mice (Marcelli et al 1990). BMPs are secreted by osteoblasts into the 
extracellular matrix during bone formation. It is understood that BMPs regulate 
osteoblast and chondrocyte differentiation during skeletal development, as abnormal 
expression of BMP genes in mice and human is associate with skeletal defects in limb 
formation (Kingsley et a l 1992; Thomas et a l 1997).
TGF-P and BMPs bind to serine/threonine kinase membrane bound receptors, 
termed type I and II receptors (ten Dijke et a l 1996). These receptors, once 
activated, phosphorylate signal transducers called Smads. TGF-P stimulates Smad 2 
and 3 whereas BMPs activate Smads 1, 5 and 8 . Smad molecules form complexes 
among themselves that are capable of translocating to the nucleus where they regulate 
transcription of various target genes such as osteopontin and osteoprotegerin via 
interactions with Runx2 and Hox homeodomain proteins (Yang et a l 2000; Ito and 
Miyazono 2003). BMPs are also able to activate the MAPK signalling pathway, 
which is involved in the activation of alkaline phosphatase and osteocalcin expression 
in osteoblasts (Guicheux et a l 2003).
Recently leptin, a hormone produced by adipocytes, was shown to be involved in 
osteoblast differentiation and activity. Mice deficient in leptin (ob/ob) and its 
receptor (db/db) were found to have a higher bone mass compared to the wild-type. 
As both knockout models produced normal osteoblasts, it was believed at first that 
leptin acted on the hypothalamus to regulate body weight and fat mass (Ducy et al 
2000a). However, other investigators found that osteoblast precursors also express 
leptin receptors, thereby suggesting that this hormone has a central and peripheral 
action on bone (Thomas et a l 1999; Khosla 2002). These studies provide an 
explanation for the protection that obesity gives against osteoporosis (Ducy et al 
2000a).
Lipoprotein-receptor-related protein (LRP5) is another key molecule linked to 
bone mass disorders. Overexpression of this factor is responsible for the creation of 
high bone mass syndrome, whereas an inactivating mutation has been linked to 
osteoporosis-pseudoglioma syndrome, characterised by reduced bone mass (Gong et 
al 2001; Little et a l 2002). Genetic studies on LfcP5-knockout mice showed that 
this receptor is required for osteoblast proliferation and bone matrix deposition.
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LRP5 is also a co-receptor of the Wnt signalling pathway, which regulates survival, 
proliferation and differentiation of osteoblasts (Kato et al 2002).
Bone matrix and mineralisation
As mesenchymal cells become committed to the osteogenic lineage they start to 
express a number of proteins that characterise the osteoblast phenotype (Ducy et a l 
2000b). Since the expression pattern of these proteins change as osteoblasts mature, 
they have become useful markers for osteoblast differentiation (Table 1.1). It is 
important to note that there may be significant variations in the temporal expression 
of osteoblast markers between different species, cell lines and even between different 
cells in the same culture conditions (Hughes and Aubin 1998).
Table 1.1: Changes in the expression of some phenotypic markers 
during osteoblast differentiation in culture
Markers Pre­osteoblast
Osteoblast - early 
bone Formation
Osteoblast - late 
bone formation
type 1 
collagen ++++ ++++ +++
alkaline
phosphatase +++ ++++ ++
osteonectin + +++ ++
BSP ++ ++++ ++
OPN + ++++ ++
OCN - ++ ++++
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Bone is comprised of a number of extracellular matrix proteins that function as 
structural proteins. They are involved in matrix mineralisation and are also 
responsible for the recruitment and attachment of bone cells to specific sites. Some 
of these matrix proteins are type I collagen, alkaline phosphatase, osteonectin, 
osteocalcin, osteopontin and bone sialoprotein (Hughes and Aubin 1998).
The principle component of the organic matrix of bone is type I collagen, which 
functions both as a structural framework for bone and as a scaffold for mineral 
formation. Mature type I collagen are composed of three alpha-chains twisted in a 
rigid helix. Flanking the ends of the alpha chains are 32 amino acids forming the. 
amino-terminal (-NH2, NTX) and carboxy-terminal (-COOH, CTX) telopeptides 
(Eyre 1995). Crosslinking molecules are formed at the telopeptide ends of the 
collagen to provide a structural relationship between fibrils (Eyre 1995). To support 
mineral deposition, the post-translational modifications of bone collagen are 
significantly different from other type I collagen matrices (Knott and Bailey 1998). 
This fact has been exploited in the development of biochemical markers; for example, 
urine measurements of collagen cross-links are used clinically to assess the degree of 
bone resorption (Apone et a l 1997).
Alkaline phosphatase, is a homodimeric metalloenzyme that catalyses the 
hydrolysis of almost any phosphomonoester with the release of inorganic phosphate 
(Pi) and alcohol (Femley 1971). Tissue non-specific ylLP-knockout mice displays 
defect in bone mineralisation that mimic the phenotypic abnormalities of infantile 
hypophosphatasia (Fedde et a l 1999). Osteoblasts derived from these animals 
differentiate normally but are unable to initiate mineralisation in vitro (Wennberg et 
al 2000). Osteonectin is a glycoprotein that is abundantly expressed in the skeleton. 
In vitro studies suggest that this protein binds to collagen and hydroxyapatite and can 
regulate cell proliferation and cell-matrix interactions (Young et a l 1992). Its exact 
function in bone remodelling remains to be determined, but osteonectin-deficient 
mice develop osteopenia with decreased bone formation (Delany et a l 2000).
Osteocalcin is widely used as a phenotypic marker for osteoblast differentiation 
due to its relative specificity (also expressed by hypertrophic chondrocytes) (Ducy et 
al 1996). Osteocalcin and matrix-Gla protein are post-transcriptionally modified by 
the action of vitamin-K dependent y-carboxylases. In the late-90s, these two proteins
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were linked to an inhibitory effect on matrix mineral deposition. Matrix-Gla- 
knockout mice develop calcification in extraskeletal sites such as the aorta, and 
osteocalcin-deficient mice have increased bone mineral density (Ducy et al 1996; 
Luo et a l 1997; Murshed et al 2004). Moreover, osteocalcin may also be involved 
in recruiting and promoting attachment of osteoclasts at sites of resorption (Ducy et 
a l 1996).
Osteopontin and bone sialoprotein are members of the SIBLING family (small- 
integrin-binding ligand glycoproteins) and contain the RGD (arginine-glycine- 
aspartic acid) motif that binds to the integrin class of cell-surface molecules. 
However, there are also some cell attachment interactions that are not mediated via 
this motif (Baron 2003). Like MGP, OPN has been shown to be involved in 
inhibition of mineralisation (Speer et a l 2002).
There is also another class of proteins that can be considered non-collagenous 
bone matrix proteins. They consist of growth factors that are trapped in the bone 
matrix and may be released during bone resorption. These factors may not play a role 
in bone mineralisation as such, but are known to be very important in the bone 
remodelling process. These growth factors include TGF-p, and BMPs (Hughes and 
Aubin 1998).
The precise nature of bone mineral is still unclear but it is believed that it 
contains mainly hydroxyapatite (Caio(P0 4 )60H2). However, the crystal itself is not 
pure, making the mineral more like a carbonate apatite. This imperfect 
hydroxyapatite is more soluble than its geological counterpart facilitating the role of 
the skeleton as a reservoir for calcium, magnesium and phosphate ions (Glimcher
1998).
The first step of the mineralisation process happens inside of the extracellular 
matrix vesicles. Their formation occurs by polarized budding and ‘pinching-ofF 
from specific regions of the outer plasma membrane of osteoblasts. Polarised release 
of matrix vesicles into selected areas of developing matrix determines the non- 
random distribution of calcification (Boyan et a l 1988; Anderson 2003). These 
organelles contain a high concentration of Ca2+ and Pi, which creates an optimal 
environment for deposition of the initial amorphous mineral complexes (nucleation)
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and formation of needle-like crystals of hydroxyapatite. The second step of the 
mineralisation process begins with the release of the mineral complex through the 
matrix vesicle membrane, exposing preformed hydroxyapatite crystals to the 
extracellular fluid. The extracellular environment normally contains sufficient Ca2+ 
and PO4 3' to support continuous crystal proliferation, with preformed ones serving as 
templates for the formation of new crystals (Anderson 2003). The initial bone 
mineral deposition occurs at discrete sites throughout the collagenous matrix and as it 
matures the crystal becomes purer and larger in size; this increase in dimension 
results from the addition and aggregation of crystals already present (Landis 1995). 
Annexins, tissue non-specific alkaline phosphatase, osteonectin, osteocalcin and 
osteopontin have all been reported to be involved in the nucleation process (Glimcher 
1989; Balcerzak et a l 2003).
OSTEOCYTES
Osteocytes are the most numerous cells in mature bone (Knothe-Tate et a l 2004). 
These cells originate from osteoblasts that became entrapped within the extracellular 
matrix. Osteocytes communicate with osteoblasts and each other by means of 
processes coupled by gap-junctions housed in little channels (canaliculi), of about 
0.2-0.3 pm diameter (Doty 1981).
Osteocyte maturation and functional activity defines their morphology. Young 
osteocytes are similar to osteoblasts except for lower cell volume and protein 
synthesis machinery. Older osteocytes are even smaller and have an accumulation of 
glycogen in the cytoplasm (Knothe-Tate et al 2004). Osteocytes are thought to 
mediate adaptive bone remodelling by responding to mechanical deformation (Burger 
and Klein-Nulend 1999). These cells respond in vitro and in vivo to increased loads 
by producing and modifying a number of molecules such as upregulation of nitric 
oxide (Pitsillides et a l 1995) and release of PGE2 (Ajubi et al. 1996). Transmission 
of mechanical signals to the osteocyte cytoskeleton via cell surface receptors can 
occur directly through the solid matrix structure of the tissue as well as indirectly via 
fluid pressure and shear stresses imparted by fluid moving through the 
lacunocanalicular system due to load-induced fluid flow (Knothe-Tate 2003). Most 
recently, Noble and colleagues suggested that osteocyte apoptosis might trigger the
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mechanism by which osteoclasts sense and remove damaged or redundant bone by 
releasing signals to attract osteoclasts to resorb bone (Noble et a l 2003).
OSTEOCLASTS 
Phenotype
Osteoclasts are giant multinucleated cells responsible for bone resorption. They 
are usually located in resorbed cavities called Howship’s lacunae. The cytoplasm of 
these cells is “foamy,” with many vacuoles. Characteristic features of osteoclasts are 
the abundant Golgi complexes usually disposed around each nucleus, the 
mitochondria and transport vesicles loaded with lysosomal enzymes (Baron 2003).
Ultrastructural studies showed that resorbing osteoclasts are highly polarised cells 
and have four specialised membrane domains: 1) sealing zone also called clear zone, 
2) ruffled border, 3) functional secretory domain and 4) basolateral (upper) 
membrane. The sealing zone is a region rich in filamentous actin (F-actin) organised 
as a ring surrounding the ruffled border. In the sealing zone the cell membrane forms 
a tight attachment to the bone surface, thereby isolating the resorption lacunae from 
the extracellular fluid and permitting the maintenance of a specific microenvironment 
in the lacunae. The pH of resorption lacunae has been shown to be very acidic (~ 
4.0), therefore this space has generally been considered to be a extracellular 
lysosome'. (Fallon 1984; Baron et a l 1985). The ruffled border is formed by the 
fusion of intracellular acidic vesicles with the region of plasma membrane facing the 
bone (Blair et a l 1989), it is characterised by long-finger-like projections that 
penetrate the bone matrix. The degradation products from the resorption lacunae are 
released into the extracellular space at the functional secretory domain (FSD) (Nesbitt 
and Horton 1997) (Figure 1.3).
22
•  Bone degradation products 0 V-ATPase
•  HCO3' /Cl' exchanger #  Clc 7
( 2 )  nucleus
•  FSD
Basolateral
membrane
CO,
CO2 H2O O  H 2 C O 3 O  HCO3 +
sz sz
c r
Ruffled
borderResorption
Bone matrix ( hydroxyapatite, type I collagen)
Figure 1.3. Schematic diagram of a resorbing osteoclast SZ = sealing zone; 
FSD = functional secretory domain.
Osteoclast origin and differentiation
Osteoclasts are formed from the fusion o f  mononuclear precursors derived from 
haematopoietic stem cells o f macrophage/monocyte lineage at or near the bone 
surface. This was first established by transplantation experiments in vivo in the 1970s 
(Walker 1975; Kahn and Simmons 1975). The pro-myeloid precursor can give rise 
to osteoclasts, macrophages or dendritic cells depending on whether they are exposed 
to receptor activator o f NFkB ligand (RANKL), macrophage colony-stimulating
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factor (M-CSF) or granulocyte macrophage colony-stimulating factor (GM-CSF), 
respectively (Lacey et a l 1998; Yasuda et a l 1998; Miyamoto et a l 2001). One of 
the key advances in the understanding of osteoclastogenesis occurred when murine 
systems using co-cultures of bone marrow or spleen cells and stromal cells generated 
osteoclasts. These studies showed that in vitro maturation of monocytes into 
osteoclasts requires the presence of osteoblasts and their precursors (Takahashi et al 
1988; Udagawa et a l 1990). This is because osteoblasts produce M-CSF and 
RANKL, the two molecules essential to promote osteoclastogenesis (Lacey et a l 
1998; Yasuda et a l 1998; Burgess et a l 1999; Hsu et a l 1999). Together M-CSF 
and RANKL induce the expression of genes that typify the osteoclast lineage 
including TRACP, cathepsin K, calcitonin receptor (CTR) and vitronectin receptor 
and allow these cells to perform their main physiological role: resorption of calcified 
matrix (Lacey etal. 1998; Hsu et al 1999; Shi et a l 2004).
The osteoclast differentiation pathway is summarized in Figure 1.4. At least 24 
genes or loci have been described to positively or negatively regulate 
osteoclastogenesis (Boyle et a l 2003). Mice lacking genes that act early in the 
lineage such as PU.l, M-CSF and c-Fos are osteopetrotic and lack either 
macrophages and osteoclasts or only osteoclasts. Mice lacking factors that act later in 
the lineage such as c-src and TRAF-6 have substantial numbers of osteoclasts that are 
not functional. Mutants of genes involved in the resorption process such as chloride 
channel 7 (C/C-7) and vacuolar ATPase (V-ATPase) have morphologically normal 
osteoclasts that are unable to resorb bone (Wagner and Karsenty 2001). A brief 
overview of the main factors involved in the osteoclast differentiation pathway will 
be discussed in more detail below.
PU. 1 is a transcription factor that plays a pivotal role in the differentiation of a 
number of cell types such as macrophages, osteoclasts and B-cells (Simon 1998). 
The suggestion that PU. 1 may regulate the expression of c-fms (the gene that encodes 
M-CSF receptor) has led to the investigation of the relationship between PU.l and 
osteoclastogenesis. Mice lacking this gene show an osteopetrotic phenotype and lack 
macrophages and osteoclasts indicating that this factor is involved at the very early 
stages of myeloid differentiation (Tondravi et a l 1997).
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Another transcription factor involved in osteoclast differentiation is c-fos, this is a 
cellular homologue of the v-fos oncogene and a key component of the AP-1 pathway. 
c-fos overexpression in different tissues and cell types cause mice to develop 
chondrosarcoma or osteosarcoma (a malignant tumour of mesenchymal origin with 
the ability to form bone tissue) and deletion studies produce osteopetrotic mice with a 
high number of macrophages (Wang et a l 1993; Grigoriadis et al. 1993; Grigoriadis 
et a l 1994). Therefore, c-fos was placed downstream from PU.l in the 
differentiation pathway. This study was also very important as it confirmed that 
osteoclasts are derived from the same lineage as macrophages.
Haematopoietic Pre- Inactive Active
stem cell osteoclast osteoclast osteoclast
M-CSF M-CSF RANK RANK
op ATP6i
Fos c-src
p50/p52 CatK
RANK TRACP
RANKL ocvf3
mitf Clc7
TRAF6
Figure 1.4. Osteoclast differentiation pathway. M-CSF and RANKL are essential 
molecules required for formation and activation of osteoclasts. OPG 
(osteoprotegerin) can bind to RANKL and regulate negatively both 
osteoclastogenesis and mature osteoclast activation. In the lower half of the diagram 
(in italics), shown are some of the single-gene mutations that block 
osteoclastogenesis and activation (adapted from Boyle et al 2004).
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Two other transcription factors that have been reported to play an important role 
in osteoclast differentiation are microphthalmic transcription factor (mitf) and NFkB. 
Mice in which the mitf gene is disrupted exhibit an osteopetrotic phenotype caused by 
failure of mononuclear precursors to mature into multinucleated osteoclasts capable 
of bone resorption. This factor is also suggested to physically interact with PU. 1 to 
regulate the expression of osteoclast genes such as TRACP and cathepsin K (Mansky 
et al. 2002). NFkB is a dimer composed of various combinations of proteins: p50, 
p52, p65, c-Rel and Rel-B. The p50/52 double knockout shows an osteopetrotic 
phenotype due to arrested osteoclast differentiation (Franzoso et al 1997). Further 
studies showed that it is a transcription factor involved in the RANK-RANKL 
pathway (Lomaga et al. 1999). Most recently, nuclear factor of activated T-cell 2 
(NFAT2) was found to be the transcription factor that is most strongly induced during 
RANKL-stimulated osteoclast differentiation and it is also essential for 
osteoclastogenesis (Takayanagi et al. 2002; Ishida et al. 2002).
The requirement for secreted molecules to control osteoclast differentiation was 
first shown by studies of the osteopetrotic (op/op) mouse. These homozygous 
mutants lack osteoclasts and macrophages due to the failure of their haematopoietic 
stromal cells to release functionally active M-CSF (Yoshida et al. 1990; Takahashi et 
al. 1991). Further studies showed that the osteopetrotic phenotype of op/op mice 
could be partially reversed by overexpressing Bcl-2, a gene that prevents apoptosis in 
monocytes. These studies led to the conclusion that M-CSF binds to its receptor, c- 
fms, on osteoclast precursors to induce signals required for survival of osteoclast 
progenitors (Lagasse and Weissman 1997).
Another very important molecule involved in the osteoclast differentiation 
pathway is RANKL. This molecule, a member of the tumour necrosis factor family, 
is produced by osteoblasts, activated T-lymphocytes and endothelial cells. It is not 
only a stimulatory factor for the formation of osteoclasts but it is also essential for 
their survival (Wong et al. 1997). RANKL activates its specific receptor RANK that 
is present in osteoclasts and dendritic cells. The effects of RANKL are counteracted 
by OPG, which is secreted ubiquitously as an endogenous soluble receptor antagonist. 
OPG, which is a glycoprotein related to the TNF receptor superfamily, strongly
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inhibits osteoclast differentiation by binding to RANK and therefore preventing the 
interaction between RANK and RANKL (Simonet et al. 1997; Yasuda et al. 1998).
RANKL is produced as a membrane bound protein on murine osteoblasts and 
stromal cells and is cleaved into a soluble form by a metalloprotease (Wong et al. 
1997; Lacey et al 1998). The discovery of RANKL constitutes a major advance in 
bone biology as it has greatly facilitated in vitro osteoclastogenesis. Purified cells of 
the monocyte/macrophage lineage, obtained from bone marrow or peripheral blood, 
can now be differentiated in vitro into mature osteoclasts by adding pure M-CSF and 
RANKL to the culture medium, replacing the requirement for stromal cells. (Yasuda 
et al. 1998; Suda etal. 1999).
RANK signalling is mediated by cytoplasmic factors, which control osteoclast 
function by activating downstream signalling pathways. There are at least six 
signalling cascades that are induced during osteoclastogenesis: inhibitor of NFkB 
(IKK), c-Jun N-terminal kinase, p38, extracellular signal regulated kinase (ERK), 
calcineurin-calcium regulated NFAT2 and src pathways (Boyle et al. 2003). The 
preliminary step in RANK signalling is the binding to the TNFR-associated 
cytoplasmic factor or TRAFs. TRAF 2, 5 and 6 all bind to the cytoplasmic domain of 
RANK but only TRAF-6 mutation results in osteopetrotic mice (Lomaga et al. 1999; 
Kobayashi et al. 2001). TRAFs in turn activate the signalling pathways described 
above. The transcription factors that are activated by the stimulation of RANK 
control the expression of resorption-associated genes such as TRACP, cathepsin k, c- 
src, integrin 03 and CTR. The absence of these genes produces osteoclasts that are 
incapable of effective bone resorption (Boyle et al. 2003).
c-src, the cellular homologue of the v-src oncogene, is a cytoplasmic protein of 
the tyrosine kinase family, which is expressed ubiquitously, c-src deficient mice 
develop an osteopetrotic phenotype as osteoclasts present are unable to resorb bone 
(Boyce et al. 1992). This protein kinase is stimulated by a variety of signalling 
pathways, including RANK/RANKL. It binds to TRAF-6 to allow the RANK- 
mediated signalling to proceed through the lipid phosphatidylinositol 3-OH kinase 
(PI3K) and protein kinase AKT. These two molecules act downstream of c-src to 
induce cell survival, cytoskeletal rearrangement and osteoclast cell motility (Wong et
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al. 1999). The function of the other factors mentioned above will be explained in 
detail below.
Recent studies have shown that cytokines such as TNF-a and IL -la can 
substitute for RANKL in generating osteoclasts from mouse marrow precursors and 
from peripheral blood mononuclear cells (Kobayashi et al. 2000; Kudo et al. 2002). 
Osteoclasts and their precursors express other receptors including TNF- a  receptor, 
IL -la receptor, IL-6 receptor and TGF-p/BMP receptor superfamily. These receptors 
are most probably involved in signalling pathways that will eventually lead to 
regulation of osteoclast differentiation and/or activation, however, whether these 
receptor - ligand interactions augment or replace RANKL signalling is still 
controversial (Blair et al. 2005).
Resorption of mineralised matrix by osteoclasts
The sequence of cellular events needed for bone resorption can be divided into 5 
main steps: 1) migration of osteoclasts to the resorption site, 2) attachment of 
osteoclasts to bone, 3) polarisation, 4) resorption, which includes the dissolution of 
the hydroxyapatite and removal and degradation of matrix products from the 
resorption lacunae and 5) osteoclast apoptosis or return of osteoclasts to the non- 
resorbing stage.
Cytokines, such as M-CSF, are likely to mediate osteoclast recruitment to the 
resorption site. In in vitro cultures, osteoclasts have been shown to migrate towards 
source of M-CSF (Fuller et al. 1993; Owens and Chambers 1993). Other cytokines 
suggested to be involved in this process are vascular endothelial growth factor 
(VEGF) and RANKL. It has been reported that the addition of antagonists of VEGF 
and RANKL in ex vivo cultures of embryonic bones reduces osteoclast recruitment. It 
has also been shown that both of these cytokines induce osteoclast recruitment in the 
Boyden chamber invasion assay in a dose dependent manner (Engsig et al. 2000; 
Henriksen et al. 2003).
Osteoclasts have been reported to attach preferentially to bone surfaces that have 
been exposed to collagenase. It is believed that this enzyme, expressed by 
osteoblasts, osteocytes, chondrocytes and bone lining cells, removes the non­
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mineralised material lining the bone surfaces facilitating osteoclast attachment (Fuller 
and Chambers 1995). It has also been proposed that osteoid matrix degradation by 
this enzyme produces collagen fragments that are able to activate osteoclasts 
(Holliday et al 1997). The molecular interactions that happen between the osteoclast 
plasma membrane and the bone matrix at the sealing zone are still unclear. The 
sealing zone is a region rich in filamentous actin (F-actin) organised as a ring (the 
actin ring) surrounding the ruffled border. The a v^3 or vitronectin receptor (a 
member of the integrin family of adhesion molecule) has been established as an 
important molecule in osteoclast adhesion to bone (Davies et al 1989). Osteoclast 
attachment to the bone matrix has been reported to occur due to interactions between 
vitronectin receptors on the osteoclast cell membrane with proteins in the bone matrix 
that contain the RGD amino acid sequence, such as osteopontin, fibronectin and bone 
sialoprotein (Miyauchi et al 1991; Flores et al 1992). The integrin a vP3 has been 
the main subject of research because antibodies against this integrin are effective 
inhibitors of bone resorption in vitro and in vivo (Horton et al 1991). However, it 
has been shown that this molecule is not present in the sealing zone and consequently 
does not mediate the tight attachment of osteoclasts to the bone surface (Lakkakorpi 
et al 1991). Other integrin adhesion molecule receptors that have been identified in 
osteoclasts are OC2P1 receptor, which binds to collagen, and a vPi that binds to collagen 
and fibronectin (Nesbitt et al 1993; Helfrich et a l 1996). Other studies 
demonstrated that proteins of the cadherin family may also be involved in the tight 
attachment of osteoclasts to the bone matrix as pan-cadherin antibodies recognise the 
sealing zone membrane (Ilvesaro et al 1998).
After migration and attachment to the bone surface, osteoclasts develop the 
sealing zone, form the ruffled border and start to extrude protons, Cf and proteolytic 
enzymes into the extracellular resorption zone between the ruffled border and the 
bone surface. The degradation of bone matrix is started by the action of carbonic 
anhydrase II (CAII); this enzyme is responsible for the production of protons in the 
cytoplasm which are pumped into acidic vesicles via the action of V-ATPase proton 
pump (Blair et al 1989; Vaananen et al 1990). The acidic vesicles then migrate and 
fuse to the cell membrane facing the bone matrix forming the ruffled border. The 
ruffled border formation and/or expansion seems to be mediated via avp3 integrin as 
^-knockout mice develop an osteopetrotic phenotype due to abnormal ruffled border
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formation (McHugh et al. 2000). Following fusion with the ruffled border the 
contents from the acidic vesicles (including H+) are pumped into resorption lacunae. 
The acid secreted into the lacunae has two main functions: 1) to solubilise the 
hydroxyapatite, revealing the organic matrix for degrading proteases, and 2) to 
provide the acidic pH required for protease activity (Vaananen et al 2000).
Accumulating evidence shows that cathepsin K, the most abundantly expressed 
cysteine proteinase in osteoclasts, is a key protease required for bone degradation; 
this enzyme is able to cleave collagen at multiple sites within the triple helical 
structure (Drake et al 1996; Gamero et al 1998). Cathepsin K may be present in 
transcytotic vesicles that are responsible for transporting the products of bone 
degradation from the resorption lacunae to the functional secretory domain where 
they are released into the extracellular space (Salo et al 1996; Salo et al 1997; 
Nesbitt and Horton 1997). This enzyme is also responsible for TRACP activity by 
degrading it into two active subunits (Ljusberg et al 1999). Matrix 
metalloproteinase-9 (MMP-9) or gelatinase B is another proteinase that appears to 
play an important role in the degradation process as it is highly expressed in the 
resorption lacunae. Its action does not seem to be as important as cathepsin K, since 
MMP-9 knockout mice exhibit only transient disturbances of bone resorption (Vu et 
al 1998).
Tartrate-resistant acid phosphatase (TRACP) also known as type 5 acid 
phosphatase or purple acid phosphatase is a widely used marker of osteoclasts in bone 
(Minkin 1982) but its function and subcellular localisation still remains unclear 
(Vaaraniemi et al 2004). It has been suggested that TRACP is a lysosomal enzyme 
that is secreted through the ruffled border during bone resorption and may also play 
an important role in modulating intracellular vesicular transport (Hollberg et al
2002). However, Halleen and colleagues (1999) showed that TRACP does not co- 
localise with known lysosomal markers and is not expressed at the ruffled border or 
in the resorption lacunae but to large cytoplasmic vesicles that have been identified as 
part of the transcytotic pathway. These investigators suggested that in osteoclasts, 
biosynthetic vesicles containing TRACP fuse to transcytotic vesicles containing 
degraded collagen fragments ingested by these cells during bone resorption. When 
these vesicles move towards the functional secretory domain their pH rises. This pH
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change inhibits the action of cathepsin K and triggers the reactive oxygen species 
(ROS) activity of TRACP. The ROS generated by TRACP finalise the degradation 
of matrix components during transcytosis. The degraded material is then secreted 
into the extracellular space with active TRACP 5b (Halleen et al 1999; Vaaraniemi 
etal. 2004).
The osteoclast ceases resorbing when its tight seal is broken and it is able to 
move away to a new location for resorption. In vitro studies have shown that 
osteoclasts can take part in multiple resorption cycles before they undergo apoptosis 
(Vaananen et al 2000).
Maintenance of osteoclast intracellular pH
Acidic pH is essential for solubilisation of the hydroxyapatite crystals and 
digestion of the organic matrix by the proteases secreted by the osteoclasts in the 
resorption lacunae. As protons are secreted by the V-ATPase pump located to the 
ruffled border a load of base equivalents, mainly HCO3’, is generated in the osteoclast 
cytoplasm. The osteoclast intracellular alkalinisation is compensated mostly by the 
action of HCO3 /CI' exchanger in the basolateral membrane. This exchanger is 
responsible for the transfer of bicarbonate that accumulates in the cytoplasm, and also 
for the supply of a continuous inward current of Cf for the ruffled membrane chloride 
channel. (Rousselle and Heymann 2002).
The chloride channel is another important regulator of osteoclast intracellular pH 
(pHi). The proton transport by V-ATPase is an electromagnetic process and 
acidification of resorption lacunae is accompanied by an interior positive membrane 
potential which is compensated by pumping anions, usually Cf, into the resorption 
lacunae (Blair et al 1991). The combined activities of the V-ATPase and chloride 
transporter allow acidification of the resorption pit and regulation of pH* but the 
chloride transporter is functionally and structurally dissociable from the proton pump 
(Schlesinger et al 1997). Most recently knockout studies showed that animals 
deficient in C/C-7, a ubiquitously expressed chloride channel, develop an 
osteopetrotic phenotype and patients identified with infantile malignant osteopetrosis 
have mutated chloride channels, confirming that Cf conductance plays a role in 
resorption lacunae acidification and pHi regulation (Komak et al 2001).
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Osteoclasts appear to have different mechanisms of pHj regulation depending on 
their resorptive state; during resorption osteoclast pHi is mainly regulated by the 
activity of HCOs'/Cf exchanger and V-ATPase pump, whereas during 
resting/migration phases, osteoclast pHi is mainly regulated by the Na+/H+ exchanger 
(Hall et al 1992; Lees et al 2001). Osteoclasts may also recover their pHi in a Na+- 
independent manner; Zn+-sensitive proton and K+-conductive pathways have been 
suggested to be involved in pHi maintenance in osteoclasts, particularly when the 
Na+/H+ exchanger is inoperative (Arkett et al 1992; Nordstrom et al 1995; 
Rousselle and Heymann 2002).
BONE DEVELOPMENT AND GROWTH
In the foetus bone is formed from undifferentiated mesenchymal tissue by either 
intramembraneous or endochondral ossification. Intramembraneous ossification is 
the process by which bone is formed directly from the mesenchyme, whereas 
endochondral ossification involves the formation of cartilage before bone is formed 
(Provot and Schipani 2005). Intramembraneous bone formation is the dominant 
process in the formation of the calvarium and clavicle. In these bones, at the 
ossification centres, the mesenchymal cells proliferate and differentiate into 
osteoblasts. These cells secrete the osteoid, which becomes mineralised resulting in 
an island of woven bone. This type of bone is then extensively remodelled by 
resorption and appositional growth (i.e. the deposition of new layers of bony 
materials on preformed surfaces) to form the mature adult skeleton that is made up of 
lamellar bone (Baron 2003).
Most of the foetal skeleton is derived from cartilage, which forms minuscule 
scale models of bone. This process involves a slow degradation of hyaline cartilage 
structures that become transformed into bone by ossification (Provot and Schipani 
2005).
Two major signalling pathways controlling endochondral ossification have been 
described: Indian hedgehog (Ihh) and parathyroid hormone related protein pathways. 
Ihh coordinates chondrocyte proliferation and differentiation as well as osteoblast 
differentiation. During endochondral ossification, Ihh is synthesised by chondrocytes 
and early hypertrophic chondrocytes. This molecule binds to its receptor Patched-1
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(Ptc-1) leading to activation of Smoothened (Smo); active Smo triggers a cascade that 
leads to expression of osteopontin and other characteristic markers of chondrocytes. 
Ihh'1' mice develop bone growth abnormalities after the condensation stage, they have 
a higher number of immature hypertrophic chondrocytes and do not have any 
osteoblasts (St Jacques et al 1999; Long et al 2001). Moreover, the cartilage of 
these knockout mice fails to synthesise PTHrP. This molecule seems to act primarily 
on halting the differentiation process by keeping the proliferating chondrocytes in the 
proliferative pool (Weir et al 1996). Fibroblast growth factor (FGF) and BMPs also 
play important roles in the endochondral ossification process (Provot and Schipani 
2005).
Runx2 and Sox9 are two transcription factors involved in the ossification 
process. Sox9 is essential to convert condensed mesenchymal cells into 
chondrocytes. This transcription factor in culture stimulates expression of cartilage 
matrix genes such as Col2al, Colla2 and aggrecan. Knockout studies showed that 
Sox9 is critical for all phases of chondrocyte lineage and is responsible for the 
expression of other Sox-family members (Sox5, 6) involved in chondrocyte 
differentiation (Bi et al 1999; Akiyama et al 2002).
BONE REMODELLING
Bone remodelling has been characterised by Frost (1969) as a three-step process 
that occurs in discrete locations in the skeleton by a population of cells called basic 
multicellular unit (BMU). The unit consists of a team of osteoclasts in front, forming 
the cutting cone, followed by a team of osteoblasts filling the resorption cavities 
excavated by the osteoclasts. Another component of the BMU is the capillary that 
lies along the whole length of the unit (Parfitt 1994). The first step in the 
remodelling process (origination) involves the digestion of the endosteal membrane 
by enzymes released from the bone lining cells, which expose the mineralised matrix. 
This is followed by osteoclast formation and assembly of these cells to form the 
cutting cone. The remodelling process then enters its second step: progression. 
During progression, the BMU travels in one direction for a finite period of time. 
Progression is sustained by the continual arrival of osteoclast precursors to replace 
those that have undergone apoptosis. Eventually the supply of osteoclast precursors is
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halted; at this stage the BMU comes to the end of its lifespan and the cavity is refilled 
by the osteoblasts, this is the termination step (Parfitt 2002).
Under normal circumstances, in young adults (between the ages of about 20-45), 
remodelling activity keeps bone mass relatively constant. Certain physiological or 
pathological states can alter the balance of the turnover process, so that resorption 
begins to outstrip formation, leading to a net bone loss (see section on osteoporosis 
below). This could be due not only to enhanced osteoclast resorption but also to 
declining osteoblast function (Mosekilde 2001).
REGULATION OF BONE CELL FUNCTION
Bone cell function is regulated by a variety of endocrine, paracrine factors and 
mechanical stimuli (Raisz 1999). Many hormones affect bone remodelling via the 
production of local factors. In general, the pathophysiological roles of local factors 
are not well understood; these tend to be multifunctional and are not bone-specific 
(Raisz 1999). The action of some key local, hormonal and paracrine factors are 
discussed below in detail.
Parathyroid hormone and PTHrP
PTH, secreted by the parathyroid glands, is a single-chain polypeptide hormone 
consisting of 84 amino acids and its major role is the maintenance of calcium 
homeostasis. PTH is synthesised as a larger 116 amino acid precursor, which 
undergoes significant degradation to pro-PTH and finally to PTH, the secretory 
product. PTH in the circulation is cleaved into 2 subunits: a biologically active N- 
terminal fragment (1-34 fragment) and a biologically inactive C-terminal fragment 
(Gensure et al. 2005). The parathyroid gland maintains the plasma Ca2+ 
concentration within very tight limits by secreting PTH in response to small decreases 
in Ca2+ concentration. A negative feedback control inhibits the secretion of PTH 
when Ca2+ levels are elevated; this control is regulated principally at the level of Ca2+ 
receptors on the parathyroid glands. PTH raises Ca2+ levels directly by mobilizing 
calcium from bone (increased bone resorption) and decreasing renal excretion of Ca2+ 
by stimulating tubular reabsorption and indirectly by enhancing the renal formation of 
l,25(OH)2-vitamin D3.
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PTH-dependent regulation of mineral homeostasis is mediated via its receptor 
PTH type 1 receptor, which is highly expressed in bone and kidney (Juppner and 
Kronenberg 2003). This hormone has been shown to be involved in stimulating 
osteoblast differentiation and activity, leading to increased bone mass when 
intermittently administered at low doses to patients with osteoporosis and in 
ovariectomised rats (Sone et al 1995; Dobnig and Turner 1995). PTH has also been 
shown to have an important role in bone development as P77/-knockout mice have 
impaired cartilage matrix mineralisation, reduced osteoblast numbers and trabecular 
bone (Miao et al 2002). The prevailing view for many years has been that the PTH 
effect on osteoclast is mediated indirectly via osteoblasts (Rodan and Martin 1981; 
Rodan and Martin 1982; McSheehy and Chambers 1986a; McSheehy and Chambers 
1986b). However, there have been several reports over the years indicating that 
osteoclasts from several species possess functional PTH receptors and most recently, 
I showed that isolated osteoclasts are sensitive to PTH in the absence of osteoblasts 
(Dempster et al. 2005). This will be discussed in more detail in Chapter 2.
PTHrP was first discovered as the product of cancer cells; it causes 
hypercalcemia in cancer patients mainly due to increased osteoclast activity (Stewart 
et al 1980; Nakayama et al 1996; Strewler 2000). Further work, showed that this 
molecule is expressed ubiquitously and it binds to the same receptor as PTH (PTH-1 
receptor, also called PTH-PTHRP receptor) and activates the same transduction 
pathway with equal potency. Recently, short-term administration of PTHrP has been 
shown to increase bone density in post-menopausal women by 4-5% without 
stimulating bone resorption and it did not cause increases in blood calcium levels or 
other side effects, suggesting that this peptide may be an important tool in combating 
osteoporosis (Horwitz et al 2003).
1,25(OH)2-vitamin D3
Vitamin D3 is a secosteroid produced in the skin by the action of ultraviolet 
sunlight on precursors. Vitamin D3 itself is an inert molecule until two successive 
hydroxylations in the liver and kidney turn it into the biologically active 1,25- 
dihydroxyvitamin D3 (l,25-(OH)2D3, or calcitriol). Despite two hydroxylation steps, 
l,25-(OH)2D3 is still very lipid soluble and acts like a steroid hormone: it binds to a 
nuclear vitamin D receptor (VDR) which exposes a DNA-binding region, resulting in
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increased and/or inhibited transcription of certain mRNAs (e.g. increases the 
expression of RANK). VDRs are found mainly in the gut, kidney and bone. The 
main biological role of l,25-(OH)2D3 is to maintain the serum Ca2+ levels within tight 
limits in the blood by increasing dietary uptake of Ca2+ in the gut, by facilitating Ca2+ 
reabsorption in the kidneys and by enhancing the mobilisation of Ca2+ stores from 
bone (Holick 1998). l,25-(OH)2D3 increases the number of mature osteoclasts by 
inducing stem cells to differentiate into osteoclasts. However, this appears to be 
regulated indirectly through its action on osteoblasts, since mature osteoclasts do not 
express VDRs and also it is believed that the action of vitamin D3 is also 
RANK/RANKL dependent (Suda et al. 2003). In osteoblasts, vitamin D3 is known to 
act by increasing the expression of a number of osteoblast phenotypic genes at later 
stages of osteoblast differentiation such as osteocalcin (van Leeuwen et al 2001).
Calcitonin
Calcitonin, a Ca2+ regulating hormone, is synthesised by the C-cells of the thyroid 
gland. This hormone is rapidly released in response to a moderate rise in circulating 
Ca2+ reflecting its physiological role as an “emergency” hormone to protect against 
development of hypercalcemia. The effects of calcitonin are mediated via its 
receptors, which are expressed on committed osteoclast precursors, and are used as a 
differentiation marker for mature osteoclasts (Hattersley and Chambers 1989; Lee et 
al. 1995). Calcitonin is a powerful inhibitor of osteoclast activity in vitro and in vivo. 
It has been shown to reduce osteoclast activity in all resorption assays studied to date 
and it also inhibits both basal and stimulated resorption in organ culture (Chambers 
and Magnus 1982; Arnett and Dempster 1987; Meghji et al. 2001). Calcitonin also 
inhibits osteoblast and osteocyte apoptosis (Plotkin et al. 1999). Clinical studies 
showed that decrease of urinary markers of bone resorption occurs within a few hours 
after subcutaneous or intramuscular injection of calcitonin, but rarely exceed 24 
hours. Therefore, clinical usage of calcitonin for the treatement of osteoporosis is 
limited, due to its very short-term effect on bone resorption (Gonzalez et al. 1986; 
Zaidi et al. 2002).
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Sex steroids (oestrogens & testosterone)
It has been known for a long time that oestrogen deficiency, such as that 
occurring at menopause, leads to skeletal depletion. Skeletal preservation by 
oestrogens in females may be related to the need of Ca2+ stores for embryonic skeletal 
development (Riggs et al 2002). Oestrogen has been reported to inhibit bone 
resorption by reducing osteoclast numbers. In vitro and in vivo studies have 
demonstrated that oestrogen suppresses RANKL production by osteoblasts, T and B- 
cells (Eghbali-Fatourechi et al 2003) and also increases OPG production (Hofbauer 
et al 1999a). Additionally, bone resorbing cytokines such as IL-6 , TNF-a and IL-1 
have been shown to be potential candidates for mediating the bone loss associated 
with oestrogen deficiency (Krassas and Papadopoulou 2001). The finding that males 
with homozygous deletion of oestrogen receptor alpha (ERa) develop osteopenia and 
have unfused epiphysis, showed that this hormone is also important for male skeletal 
development (Syed and Khosla 2005).
Testosterone hormone can be converted via aromatase to oestrogen, which is 
known to inhibit bone resorption. However, in vitro and in vivo studies showed that 
testosterone can also act directly on bone cells. Gray and colleagues (1992) showed 
that primary rat osteoblast proliferation rate and collagen production are increased by 
testosterone and 5a-dihydrotestosterone (DHT), a compound that cannot be 
converted to oestrogen. Long and short-term in vivo studies showed that androgen 
administration in ovariectomised rats reduced loss of cancellous bone in a dose 
dependent manner (Lea et al 1998). Further studies using androgen antagonists 
showed that this effect is not oestrogen-mediated (Lea and Flanagan 1998).
Prostaglandins
Prostaglandins (PGEs) act on a variety of cells via cell-surface receptor subtypes 
called EP1-4. PGE2 has been shown to induce formation of mouse multinucleated 
osteoclasts from marrow progenitors and has also been reported to stimulate 
osteoclast formation in murine organ cultures but inhibits formation of human 
osteoclasts (Raisz 1995; Mundy 2003). In stromal cell and primary calvarial cell 
cultures, PGE2 stimulates osteoblast differentiation (Flanagan and Chambers 1992; 
Weinreb et al 1997). Systemic administration of PGE2 to animals has been shown to
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stimulate bone formation and increases bone mass, suggesting that prostaglandins 
have an anabolic effect in vivo (Ke et al 1998).
Nucleotides
ATP and other nucleotides are recognised as important messenger molecules for 
cell-cell communication (Ralevic and Bumstock 1998). It has recently become 
evident that extracellular nucleotides play an important role in bone remodelling 
(Dixon and Sims 2000). ATP and other nucleotides can exert impressive stimulatory 
effects on formation and activity of osteoclasts in addition to inhibit bone formation 
by osteoblasts (Hoebertz et al 2003). The effect of these nucleotides on bone seems 
to be mediated via P2Y or P2X receptor subtypes. Because both ADP and ATP are 
potent stimulators of bone resorption, and ATP and UTP are inhibitors of bone 
formation in vitro, this data suggest that nucleotides have an overall destructive 
catabolic effect on bone. Nucleotides are interesting targets for drug development in 
the future for several pathological bone loss conditions. The osteolytic activity of 
ADP could also be relevant to inflammatory conditions such as rheumatoid arthritis 
that lead to sustained systemic and localized bone loss (Hoebertz et al 2003).
Oxygen
The vasculature in bone serves to provide oxygen and essential nutrients to the 
cells in the bone marrow and within the bone matrix. The oxygen tension in blood 
entering the bone via arteries is approximately 95 mmHg (12%). Within the marrow 
cavity of normal volunteers the interstitial pC>2 has been measured at 6 .6% (Harrison 
et al 2002), however, when the blood supply is reduced or disrupted; such as in bone 
fractures and inflammation; the p(>2 could drop much lower (< 1%) (Lewis et al 
1999). It has been proposed that hypoxia may be involved in a novel 
mechanotransduction pathway as the expression of hypoxia induced transcription 
factor 1 alpha (HIFl-a) by osteocytes increases in response to mechanical unloading 
(Gross et al 2001). Osteoblasts and osteoclasts are also sensitive to the effect of 
hypoxia. Reducing p02  from 20% to 2% causes a 90% reduction in the area of bone 
nodules formed by osteoblasts in vitro, probably due to impaired collagen production 
and cell proliferation (Orriss et al 2003). On the other hand, hypoxia strongly 
stimulates the formation of osteoclasts cultured in vitro in all species studied to date
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and also in bone organ culture (Arnett et al. 2003; Utting et al 2003). The effect of 
hypoxia emphasises the importance of the vasculature in bone.
Cytokines and growth factors
Under physiological conditions the immune and skeletal systems are regulated by 
a number of cytokines and growth factors, e.g. IL-1,2,3,4,6,10,11,13, vascular 
endothelial growth factor (VEGF), tumour necrosis factor-a (TNF-a), insulin growth 
factor (IGF), fibroblast growth factor (FGF) and RANKL. These molecules are 
produced by many different cell types and their receptors are widely distributed. The 
function of a some of the cytokines involved in bone metabolism is discussed below.
IL-1 is a family of two active peptides, a  and (3, which appears to have identical 
functions and bind to type I and II receptors (Mundy 2003). In the bone 
microenvironment, this molecule is produced by osteoclast precursors, stromal cells 
and osteoblasts and it has been shown to stimulate osteoclast function by inducing the 
expression of RANKL in osteoblasts (Hofbauer et al. 1999b). Conversely, IL-1 has 
also been reported to stimulate osteoclast activity in the absence of RANKL (Kudo et 
al. 2002).
IL-6 is a member of the gpl30 cytokine family and appears to mediate the 
resorptive activity of osteoclasts directly and indirectly via the RANK/RANKL 
pathway (Kwan et al. 2004). IL-6 has also been reported to stimulate mesenchymal 
cells towards the osteoblastic lineage and to inhibit osteoblast apoptosis (Taguchi et 
al. 1998).
Vascular endothelial growth factor (VEGF) is expressed by osteoblasts, 
osteoclasts and hypertrophic chondrocytes. VEGF allele results in embryonic 
lethality; however, analysis of mice expressing only the VEGF 120 isoform have 
shown that this growth factor is involved in chondrocyte maturation and appears to 
have a direct role in regulating osteoblast activity (Zelzer et al. 2002). Upregulation 
of VEGF by bone cells have been associated with skeletal growth, bone healing and 
mechanical loading (Street et al. 2002).
Tumour necrosis factor (TNF) is produced by osteoblasts and consists of two 
related polypeptides (a and P). TNF-a acts by increasing bone resorption while
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simultaneously decreasing bone formation. TNF-a has been shown to increase 
RANKL expression in osteoblastic cells and act synergistically with RANKL to 
induce osteoclastogenesis. Like IL-la, it remains controversial as to whether TNF-a 
can stimulate osteoclast formation in the absence of RANKL; some authors have 
demonstrated RANKL-independent formation (Kudo et al. 2002), while others have 
shown that RANKL is necessary for osteoclast formation even in the presence of 
TNF-a (Lam et al. 2000).
IGFs are polypeptides that enhance osteoblast proliferation, decrease osteoblastic 
apoptosis and stimulate bone matrix synthesis by mature osteoblasts. Two IGFs have 
been characterized: IGF1 and IGF2, both of which have similar biological activities 
in bone cells. It has been reported that IGF-I-mW mice have decreased bone 
formation, whereas transgenic animals overexpressing this growth factor have 
increased bone formation (Zhao et al. 2000). PTH and growth hormones increase 
IGF expression, while glucocorticoticoids inhibits its expression (Sims et a l 2000; 
Canalis and Giustina 2001; Bikle et al. 2002)
BONE PATHOLOGY
Osteoporosis, the "classic" bone remodelling disorder, is defined as a reduction in 
bone mass associated with disruption of bone microarchitecture, resulting in 
increased bone fragility and increased fracture risk (Consensus development 
conference, 1993). It has been known for some time that oestrogen deficiency, such 
as that occurring during the menopause, leads to bone loss. Consequently, women 
account for most of the hip fractures in the UK (Eastell et al. 2001). However, there 
are other risks that should be taken into account such as genetic factors, sedentary 
lifestyle, excessive protein intake and chronic acidosis.
Osteoporosis treatment represents one of the great success stories of modem 
preventive medicine. Nowadays, there are a number of drugs and treatments used for 
the prevention and cure of osteoporosis. Hormone replacement therapy (HRT) in 
post-menopausal women effectively prevents osteoporosis (Compston 2004). 
However, recent studies showed that HRT increases the risk of both breast cancer and 
cardiovascular disease (Beral 2003). Bisphosphonates, which includes alendronate 
and ridedronate, are orally-active synthetic analogues of pyrophosphate that inhibit
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osteoclast action. These drugs are cost-effective and are thereby increasingly proving 
to be useful in treating a range of bone loss disorders. Teriparatide (1-34 amino acid 
fragment of PTH) has been shown to increase bone mass as explained above. This has 
become a very attractive option as intermittent PTH administration has been reported 
to increase bone mineral density due to an increase in osteoblast formation. 
Moreover, PTH has been shown to suppress osteoblast apoptosis (Jilka et a l 1999). 
It has been reported that oestrogen receptors on bone cells have a second mode of 
action that does not require their transport to the nucleus and this alternate pathway 
attenuates osteoblast apoptosis (Kousteni et al. 2001). Since then, a compound called 
estren has been identified that triggers the same receptor action. These drugs have 
been named ANGELS (activation of nongenotropic oestrogen-like signalling) and are 
also believed to promote osteoclast cell death (Kousteni et al 2001; Moggs et al 
2003).
Osteomalacia is a disease characterised by impaired osteoid mineralisation 
resulting in soft bones with an increased tendency to fractures. In children this 
condition is known as rickets and is often caused by nutritional deficiency in vitamin 
D3, Ca2+ or phosphate. (Prince and Glendenning 2004). Its causes will be discussed 
in detail in Chapter 4.
Inflammatory bone loss is a symptom of rheumatoid arthritis (RA) and 
periodontal disease. In RA, the inflamed synovium produces a variety of cytokines 
e.g. RANKL, IL-1 a  and P, TNF-a, IL-6, M-CSF, IL-17 and PTHrP (Goldring and 
Gravallese 2000). These cytokines act by increasing osteoclast activation and 
formation from precursors present in the synovial fluid, leading to excessive 
osteoclastic resorption, i.e. bone loss (Goldring 2003).
Several cancers have profound effects upon the skeleton, causing an increase in 
osteoclast formation and activity either systemically, as in humoral hypercalcaemia of 
malignancy, or locally, as in bone metastases, e.g. breast cancer derived. One major 
product of breast cancer cells is PTHrP, which promotes osteoclast formation (Guise 
et al. 1996). Tumours are poorly vascularised areas and as a result severe tissue 
acidosis develop in human malignancies; the pH levels in mammary carcinomas 
(measured by the use of a pH-sensitive electrode) for example, has been found to be
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as low as 6.4 (Jirtle 1988). Acidosis by itself is a powerful stimulator of bone 
resorption, a process that contributes to cancer pain (Mantyh et al. 2002).
ACID-BASE BALANCE 
Buffering of hydrogen ions
The importance of the acid-base homeostasis in the maintenance of normal 
cellular responses and physiological integrity has long been recognised. The 
mechanisms regulating the intracellular and extracellular frf concentration are 
important as many cellular responses are diminished by acidosis including cytosolic 
and membrane associated enzyme activities (Lardner 2001). The activity of 
phosphofructokinase, for example, the key enzyme controlling the glycolytic pathway 
of mammals, is inhibited by tT.
Mechanisms exist for buffering frf loads both inside and outside of cells. In the 
extracellular fluid, fT  buffering is largely accomplished by the CO2/HCO3’ system, 
which roughly accounts for 80-90% of total metabolic acid buffering. In the 
intracellular space, however, the pH is mainly controlled by protein- and phosphate- 
buflfer systems (Swenson 2001). In addition to passive chemical buffering, it is clear 
that cells have a capacity to regulate their own intracellular pH levels. Most cells 
appear to have intracellular pH values that are appreciably more alkaline than would 
be predicted if H+ and HCO3’ were passively distributed across the plasma membrane. 
Transmembrane pH differences vary among tissues but range between 0.2 and 0.5 
units in contrast to the 0.8 and 1.5 unit difference that would occur if the intracellular 
pH regulatory mechanism was not present (Roos and Boron 1981). Transmembrane 
ion exchanges not only help maintain intracellular pH above that dictated by passive 
electrochemical forces but are also stimulated selectively in the face of endogenous or 
exogenous acidosis. These include exchange of extracellular Na+ for intracellular H+ 
via the Na+/H+ membrane antiporter and active H+ extrusion via V-ATPase (Swenson 
2001).
Two types of acids are produced in the body as a result of metabolism: carbonic 
acid (H2CO3) and non-volatile or fixed acids. Ultimately, the lungs and kidneys 
together maintain the overall acid-base balance. However, the extracellular fluid
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needs to be protected against sudden changes in H+ concentration. The blood pH, for 
example, must be maintained between 7.35 and 7.45 (35-45 nmol/1 H+) (Green and 
Kleeman 1991); pH values greater than 7.70 (20nmol/l H+) or less than 7.00 
(100nnol/l H+) are usually incompatible with life. In order to maintain the H+ 
concentration within such tight limits in the blood, the body has 4 major buffering 
systems: haemoglobin buffer with its imidazole groups from the histidine residues in 
the erythrocytes, the phosphate buffer, the plasma proteins and most importantly the 
carbonic acid-bicarbonate system.
In the peripheral tissue, CO2 produced as a result of metabolism, diffuses freely 
down a concentration gradient across the cell membrane into the red blood cells. This 
gradient is maintained because the red blood cells do not produce any CO2 due to 
their anaerobic metabolism. The ionisation of carbonic acid occurs spontaneously but 
CAII is required for the production of H2CO3 (Tashian 1992). As CAII is located 
mainly in erythrocytes, these cells are the principal site of fT and HCO3' formation in 
the blood. The haemoglobin protein is a more effective buffer when deoxygenated, so 
as it passes through the capillary beds and gives up oxygen to the tissues, it collects 
the H+ formed from the dissociation of carbonic acid. The HCO3, meanwhile, pass 
from the erythrocytes down their concentration gradient into the plasma, in exchange 
for Cl'ions, to maintain electrical neutrality (Ganong 2001).
In the lungs, the PCO2 in the alveoli is maintained at low levels due to 
ventilation. Therefore, the PCO2 of the pulmonary capillaries is higher than the PCO2 
in the alveoli so the gradient is reversed. CAII is required as a catalyst to convert 
H2CO3 into H20  and CO2, the latter diffuses into the alveoli and is excreted by the 
lungs and the oxygen is transported back to the tissues.
The non-volatile acids are excreted via the kidneys where the phosphate buffer 
plays a major role in the elimination of fT in the urine. Most of the buffer is present 
as HP042\  which can combine with H+ to form H2PO4', which is excreted in the 
urine. Ammonia can also act as a urinary buffer. It is formed by the deamination of 
glutamine under the influence of glutaminase. Ammonia readily diffuses across the 
cell membrane into the tubular lumen, where it combines with H+ to form NHL**. This 
molecule is then excreted in the urine. In order to maintain the acid-base
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homeostasis, the different buffering systems are in constant equilibrium with each 
other (Ganong 2001).
Disturbances of acid-base status
Disturbance of the body's acid-base balance results in the plasma containing 
either too many or too few hydrogen ions resulting in acidosis or alkalosis, 
respectively. These disturbances may be due to respiratory causes (where the primary 
defect is change in CO2 levels) or metabolic (where the primary defect is change in 
HCO3' concentration). Acid-base status can be understood on the basis of the 
relationship represented in the following reaction:
H20  + C02 <-> H2CO3 <-> IT  + HCO3*
Accumulation of H in the system shifts the equilibrium to the left as the extra H+ 
combine with HCO3’ to form H2CO3. However, since there is no ventilatory 
abnormality, any related increase in plasma H2CO3 is transient, as the related increase 
in dissolved C02 is immediately excreted by the lungs (Adrogue and Adrogue 2001).
A common cause of chronic metabolic acidosis in the Western countries is a 
protein-rich diet (New 2003). The average Western diet generates the equivalent of 
lmmol of acid /kg body weight per day (equivalent of 8 ml of concentrated HC1) and 
the more acid precursors a diet contains the greater the extent of systemic acidity 
(Kurtz et al. 1983); food products such as cola drinks, which contain phosphoric acid 
and have a pH of 3, are very popular within these societies (Barzel 1995).
Ageing and the menopause are also contributory factors to acidosis (Orr-Walker 
et a l 1999). As individuals age, their overall renal function declines, and so does 
their ability to excrete acid (Frassetto and Sebastian 1996). Hence, older individuals 
are slightly but significantly more acidic (Frassetto et al. 1996; New 2003). Mild, 
acute or chronic metabolic acidosis has also been reported in connection with 
gastroenteritis, where it is associated with increases in bone resorption indices 
(Yildizdas et al. 2004), fasting (ketoacidosis) and heavy exercise. In renal disease 
(the major cause of chronic severe systemic acidosis), the ability of the kidneys to 
secrete H+ into the urine is impaired or lost. The arterial blood pH in these situations 
may be as low as 7.2.
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Addition of CO2 to the system without changes in HCO3' levels causes a decrease 
in pH and results in respiratory acidosis. During acute respiratory acidosis, a rise in 
PCO2 shifts the equilibrium in the carbonic acid reaction to the right resulting in 
increased [H*] and [HCO3']. Equilibration of H+ with body buffer systems limits its 
potential rise and a new steady state is achieved in minutes. This type of acidosis may 
occur due to chronic respiratory diseases such as emphysema and acutely, due to 
prolonged exercise. For example, it has been reported that the blood pH of men after 
10 second sprints in a cycle ergonometer separated by 30-second recovery intervals 
decreased from pH ~ 7.4 to pH ~ 7.2 (Ratel et a l 2002).
In metabolic alkalosis the equilibrium in carbonic acid reaction is shifted to the 
right due to loss of H+. This is mainly caused due to prolonged vomiting (loss of 
gastric juice). Other causes of severe or mild chronic metabolic alkalosis are due to 
serious medical problems such as congenital chloride diarrhoea, hyperparathyroidism 
and various neoplasms; calcitonin administration for the treatment of osteoporosis, 
vitamin D3 excess or a vegetarian diet, however the latter notion is still controversial 
(Escanero et al. 1991; New 2004).
Respiratory alkalosis is the most common acid-base disorder among seriously ill 
patients. It is brought about by hyperventilation. Humans and other mammals 
hyperventilate at high altitudes and during physical activity; the hyperventilation 
partially compensates for the lower tension of oxygen in inhaled air. This leads to a 
lower concentration of carbon dioxide and carbonic acid in the blood resulting in 
higher pH and respiratory alkalosis.
Acidosis can also occur locally in sites of low blood flow such as in initial stages 
of fracture healing, as a result of inflammation, infection, wounds and tumours 
(Arnett 2003). As individuals age, the general quality of the vascular supply around 
the body tends to decline. It has been reported that ageing results in a progressive loss 
of the medullary blood supply which eventually leads to marrow ischaemia 
(Bridgeman and Brookes 1996). The likely consequence of such ischaemia is 
hypoxia, which causes local acidosis (Arnett 2003).
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Effect o f acidosis on the skeleton
The negative effect of acidosis on the skeleton has been known for many years. 
Early in the twentieth century, in vivo studies showed that skeletal depletion (Goto 
1918) and calcium and phosphate loss (Shohl and Sato 1923) were associated with 
experimental acidosis. In humans with normal renal function, the provision of 
additional dietary acids leads to an increase in urine calcium excretion without a 
parallel increase in intestinal calcium absorption, resulting in a net loss of calcium 
from the body, suggesting that the source of the additional urinary calcium is the bone 
mineral. Besides serving as a Ca2+ reservoir, the skeleton contains 80% of the body’s 
carbonate, which, in response to a metabolic acid challenge, can be acutely released 
to buffer protons in an acellular physicochemical reaction (Barzel 1995). Bone is also 
relatively well vascularised, which allows a rapid mobilisation of the bone ions 
(Green and Kleeman 1991). Patients with a defect in renal acid excretion, distal renal 
tubular acidosis, have osteopenia that is substantially corrected by long-term 
administration of base (Domrongkitchaipom et al. 2002). Treatment of 
postmenopausal women with oral potassium bicarbonate to neutralize endogenous 
acid production leads to improved calcium retention, reduced bone resorption, and 
increased bone formation (Sebastian et al. 1994). It is possible that calcium 
supplements may be favourable to bone, not just through the additional mineral that 
they provide but also through their provisional of additional alkali. This notion is in 
agreement with previous work that showed the anti-osteoporotic effect of calcium 
supplementation is due to an inhibition of osteoclastic bone resorption and that 
elderly individuals who are mildly acidotic may benefit most from ingestion of 
calcium salts (Dawson-Hughes et al 1990; Reid et al. 1995).
Although high protein intake has often been associated with low bone mass, 
strong data also exist for the opposite effect. Randomised controlled trials showed 
that protein supplements reduce bone loss at the contralateral hip in patients with 
upper femoral fracture, possibly due to protein-induced increase in insulin-like 
growth factor I, which is known to be osteogenic (Bonjour et al. 1996; Schurch et al. 
1998). Moreover, it has been found that bone loss over a 4-year period was greatest 
in individuals with the lowest protein intake (Hannan et al 2000). It must be borne in 
mind that vegetable proteins deliver high levels of sulphur and grain products, which
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is consumed by many vegetarians and vegans, have a high potential renal acid load 
(Remer and Manz 1995).
It had long been thought that buffering of acid loads by bone was only due to 
short-term physicochemical reactions (Barzel 1995); however, as will be discussed in 
the subsequent chapters, it is now widely accepted that acidosis predominantly 
activates more long-term cellular mechanisms, involving both osteoclasts and 
osteoblasts.
Effect o f acidosis on other cell types
In contrast with the response of osteoclasts, generally cell function appears to be 
impaired by acidosis (Lardner 2001). However, studies on the effect of acidosis on 
the behaviour of immunocompetent cells show that this condition may have a 
‘positive’ effect depending on the function analysed. Lymphocyte motility, for 
example, has been shown to increase at pH 6.5 compared to pH 7.1 (Ratner 1992). 
Extracellular acidosis also increases the expression of 02 integrin, CD 18 and delay the 
rate of spontaneous apoptosis in human neutrophils (Trevani et al 1999). Most 
recently, it has been reported that lowering pH markedly increases the antigen 
presenting capacity of dendritic cells, the professional antigen-presenting cells in 
immune responses (Vermeulen et al 2004). This is a potentially important, as 
dendritic cell and osteoclasts are derived from myeloid precursors. Oxidisation of low 
density lipoprotein (LDL) by macrophages also appears to be increased by low pH 
(Morgan and Leake 1993). This could be relevant to the pathogenesis of 
atherosclerosis since LDL oxidation occurs in atherosclerotic plaques.
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HYPOTHESES
In this PhD project I tested the following hypotheses:
1) Are normal human osteoclasts activated by low pH in a similar manner to 
rodent and chick osteoclasts in vitro? Is this effect mediated via osteoblasts?
2) Does acidosis alter the expression of resorption-associated factors such as 
cathepsin K and TRACP?
3) Does chronic metabolic acidosis affect the function of normal osteoblasts in 
the pH range that is critical for modulating osteoclast function, i.e. pH 7.5 -  6.8?
4) Are known proton-sensing receptors (e.g. TRPV1, ASIC, OGR1, TDAG8 and 
GPR4) expressed by bone cells?
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CHAPTER 2
Effect of acidosis on the formation and activity of 
osteoclasts
INTRODUCTION
Acute effects o f pH on mature osteoclasts
The direct effect of pH on osteoclasts was first discovered by Arnett and 
Dempster in 1986. They reported that resorption pit formation by rat osteoclasts 
increases remarkably as medium pH is reduced, i.e. lowering the pH from 7.4 to 6.8 
causes a 14-fold increase in resorption. In these experiments, culture media were 
buffered by HEPES in the absence of bicarbonate so that the main independent 
variable was the proton concentration. They also found that the low pH effect was 
completely abolished by physiological concentrations of human calcitonin, 
suggesting that the acid response is mediated by living osteoclasts.
Further studies showed that in media buffered physiologically with HCO37CO2, 
resorption pit formation by rat osteoclasts is stimulated when pH is reduced either by 
increasing PCO2 or by decreasing HCO3’ concentration (Arnett et al. 1994). The 
issue whether metabolic or respiratory acidosis are more potent stimulators of bone 
resorption remains controversial. In calvarial cultures, metabolic acidosis is more 
potent than respiratory acidosis in stimulating resorption, suggesting that decreased 
medium HCO3’, and not just a fall in pH, is necessary to enhance net Ca2+ efflux from 
calvaria (Bushinsky 1989; Meghji et al. 2001). Interestingly, the resorption response 
curve of mouse calvarial bones and that of mature rat osteoclasts to metabolic 
acidosis are very similar (Arnett and Spowage 1996; Meghji et al. 2001). This will 
be discussed in more detail in Chapter 3.
Investigations using physiological HCCV/CCVbuffered media showed that rat 
osteoclasts are particularly sensitive to pH changes in the region close to pH 7.1. In 
this region, small shifts in extracellular pH (between pH 7.15 and 7.25) were
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sufficient to produce a six-fold increase in the rat osteoclast resorptive activity; below 
7.0 this effect begins to plateau (Arnett and Spowage 1996).
The stimulatory effect of low pH has also been observed in osteoclasts derived 
from mouse (Hoebertz and Arnett 2003), rabbit (Shibutani and Heersche 1993) and 
chick (Teti et al. 1989b; Walsh et al. 1990; Morrison and Arnett 1997). Chick 
osteoclasts, however, have a basal rate of resorption in non-acidified conditions (pH 
-7.40) that is generally much higher than that of neonatal rat osteoclasts (Arnett and 
Dempster 1987; Morrison and Arnett 1997).
Surprisingly, osteoclasts are able to resorb bone efficiently even at pH -6.3 
(Murrills et al. 1993). These authors carried out a time-course experiment over a 72- 
hour period on the effect of pH on bone resorption and cytotoxity in both rat and 
chick osteoclasts. Their results showed a consistent stimulatory effect of low pH on 
bone resorption in both species, which was enhanced remarkably in the first 24 hours 
of the assay. They also showed that a significant cytotoxic effect of low pH was only 
observed in the accessory cell population suggesting that osteoclasts are more 
resistant than other cell types to the cytotoxic effect of low pH.
Longer-term effects ofpH on osteoclasts and osteoclast formation
Osteoclast activation by low pH is not merely a short-term effect from which 
tachyphylaxis (“escape”) occurs, as can be the case for some hormone-mediated 
phenomena. Longer-term cultures of mature rat osteoclasts show that H -activated 
cells continue to resorb over periods of 7 days, magnifying effects of modest pH 
differences (Hoebertz and Arnett 2003). Long-term stimulatory effects of low pH on 
osteoclastic resorption may be pertinent to in vivo situations such as rheumatoid 
arthritis, where the local pH is reduced and bone resorption is increased (Steen 1992).
Paradoxically, the formation of murine osteoclasts from marrow precursors is 
slightly inhibited by reducing the extracellular pH. However, osteoclasts formed in 
long-term mouse marrow cultures at blood pH (7.4) show no resorptive activity until 
stimulated by acidification (Hoebertz and Arnett 2003). Osteoclast activation can 
then be considered as a two-step process. The initial “switching on” of resorption 
requires acidification of the extracellular environment of the osteoclast below pH 7.2.
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Further stimulation by other osteolytic agents such as RANKL (Hoebertz et al 2000; 
Hoebertz and Arnett 2003), PTH (Arnett and Dempster 1986), 1,25-dihydroxy- 
vitamin D3 (Murrills et al. 1998) and purine nucleotides (Hoebertz and Arnett 2003), 
can then occur.
PTH and bone cells
The parathyroid hormone type 1 receptor (PTH1R) is a G-protein-coupled 
receptor that is highly expressed in bone and kidney. It mediates the PTH-dependent 
regulation of mineral homeostasis, as well as the actions of PTH-related peptide - 
PTHrP (Mannstadt et al 1999). The prevailing view for many years has been that 
osteoclasts do not express PTH receptors and that PTH effects on osteoclasts are 
mediated indirectly via osteoblasts (McSheehy and Chambers 1986a; McSheehy and 
Chambers 1986b). However, there have been several reports indicating that 
osteoclasts from several species possess functional PTH receptors. For example, 
immunocytochemical analysis in fixed rat bone tissue showed that osteoclasts express 
higher levels of PTH compared to osteoblasts and osteocytes (Rao et a l 1983). It has 
also been reported that bovine PTH binds specifically to avian osteoclasts in vitro and 
this binding occurs in a manner that displays the properties of receptor-dependent 
hormone binding, ie. saturability, time-dependence, temperature-dependence, and 
hormone specificity (Teti et al 1991; Agarwala and Gay 1992). Osteoclast 
expression of the PTH1R was demonstrated in deer antler (Faucheux et a l 2002), in 
sections of rat bone (Gay et al 2003) and in human bone biopsies of patients with 
secondary hyperparathyroidism (Langub et a l 2001) and most recently on human 
osteoclasts derived from peripheral blood mononuclear cells (PBMCs) (Dempster et 
al 2005).
Previous reports left open a possibility that the stimulatory effect of acidosis on 
osteoclast was osteoblast mediated. Therefore, in this chapter the effect of acidosis 
on osteoclast formation and activation was studied in a system devoid of osteoblasts 
(Flanagan and Massey 2003). Additionally, I investigated the interaction of the 
effects of PTH and acidosis on osteoclasts in the absence of osteoblasts.
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MATERIAL AND METHODS
Materials
Culture media and buffers were purchased from Invitrogen (Paisley, UK). Bulk 
liquids (organic solvents, acids and bases) were purchased from VWR International 
Ltd (Dorset, UK). Mouse recombinant RANKL was purchased from R&D Systems 
(Abingdon, UK) or obtained from Dr Colin Dunstan (Amgen, Thousand Oaks, USA) 
and mouse recombinant M-CSF was a kind gift of the Genetics Institute (Boston, 
USA). Human peripheral blood was obtained from healthy adult volunteers (age 
range 20-55; males and females), with approval from the UCL Ethics of Human 
Research Committee. Elephant ivory, a homogeneous, resorbable mineralised tissue 
with a composition similar to bone, was kindly donated by HM Customs and Excise 
(Heathrow, London, UK). Whole bovine femurs were obtained from a local butcher. 
Cylinders containing custom mixtures of O2, CO2 and N2 were purchased from BOC 
(London, UK).
Human osteoclast assay
Prior to cultures, dentine discs or bone chips were prepared as per Hoebertz and 
Arnett (2003) and Murrills et a l (1998) protocols, respectively. Elephant ivory was 
prepared by cutting 200-300 pm thick transverse sections on a low speed saw with a 
diamond-wafering blade (Buehler, Coventry, UK). The ivory wafers produced were 
soaked for 2 hours in distilled water to reduce brittleness and 5 mm diameter discs 
were then punched out using a standard, single paper hole punch (Rexel, Aylesbury, 
UK). These discs fit neatly into the wells of 96-multiwell plates. Bone cylinders 
were cut (50-75 mm) from the diaphyseal region where cortical bone is thickest, 
using a hacksaw. Surplus adherent tissue was stripped off the periosteal surface using 
a scalpel. The cylinders were then cut radially to create 3-5 ‘arcs’ of bone and 
‘defatted’ by sonicating in 10-minute periods in acetone until bone is clean. 
Transverse slices (4.0 mm2 x 0.2 mm) were cut using a low speed diamond saw 
(Buehler, Evanston, USA). The dentine discs/bone chips were cleaned by sonication 
in multiple changes of distilled water and stored dry at room temperature. Before 
use, dentine discs/bone chips were graphite pencil-numbered, sterilised by brief
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immersion in ethanol, allowed to air-dry completely, and finally rinsed in sterile 
phosphate-buffered saline (PBS).
Mononuclear cells were isolated from 20 ml of human peripheral blood as 
described previously (Massey et a l 2001; Flanagan and Massey 2003). Blood was 
collected from normal volunteers by standard venipuncture into heparinized tubes and 
diluted in 15 ml of PBS. Diluted peripheral blood was gently layered over 15 ml of 
Ficoll-Paque (Amersham International, Bucks, UK) and centrifuged for 30 minutes at 
400 x g  at 25°C with the brake set “off’. The mononuclear cell layer was removed 
from the Ficoll-Paque/plasma interface and washed in 10 ml of PBS (10 minutes at 
400 x g, 4°C). The cells were resuspended in MEM with 15% heat-inactivated fetal 
calf serum (FCS) and plated onto 5 mm diameter ivory discs or 4 mm2 bone chips (2 
x 105 cells per disc) in 96-multiwell plates. Discs were washed gently after 4 hours, 
then cultured in minimum essential medium with 15% heat-inactivated FCS, 5 or 10 
ng/ml M-CSF (depending on the age of the batch) and 5 mmol/1 OFT (as NaOH) in 
5% CO2 / 95% atmospheric air. After 4 days, discs were transferred to 25 cm2 flasks 
with polyethylene ‘plug-seal’ caps (Falcon, Becton Dickinson, Oxford, UK), 
containing 1 ml of medium per disc plus 1 ng/ml RANKL (R&D Systems) or 5 ng/ml 
RANKL (Amgen). Flasks were purged via a needle inserted through the loosened 
cap with gas mixture containing 5% O2, with 5% CO2 (balance N2) in order to 
increase osteoclast yield as hypoxia stimulates osteoclast formation (Arnett et al
2003). The sealed flasks were incubated up to 16 days at 37°C in 5% CO2 / 95% 
atmospheric air. Culture medium was replaced every 2-3 days; the final replacement 
was with control or test medium modified by the addition of 15, 10, 5, 0 mmol/1 H+ 
(as HC1), or 5 mmol/1 OH' and 0-100ng/ml hPTH (Sigma-Aldrich, Poole, UK). In 
order to study the effect of acidosis on osteoclastogenesis, the cells were cultured 
from day 1 in the presence of 10 mmol/1 OH+ (as NaOH) or 15 mmol/1 H+ (as HC1), 
depending on total media volume.
Culture medium pH, PCO2 and PO2 were monitored using a blood gas analyser 
(ABL 705, Radiometer, Crawley, UK). The blood gas analyser automatically 
equilibrates two buffer solutions (high and low pH) by means of air and pure CO2. 
The equilibrated solutions are used for electrode calibration, which was set to occur 
every 2 hours. Moreover, the high degree of accuracy of the blood gas analyser is
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achieved via internal calibration; the regular use of known quality control standards is 
also necessary. The results obtained are within 0.2% of the expected values. 
Measured PCO2 typically drops for each subsequent reading, causing pH values to 
rise accordingly. The pH readings for each group were then back-corrected to the pH 
value associated with the initially measured PCO2 value, by using pH -  PCO2 
calibration curves previously recorded for the appropriate media (Figure 2.1).
Experiments were terminated by fixing bone chips or ivory discs in 2% 
glutaraldehyde. Discs were then stained for TRACP by using leucocyte acid 
phosphatase kit (Sigma kit 387-A) according to the manufacturer’s protocol. 
Osteoclasts were defined as TRACP-positive with two or more nuclei and /or clear 
evidence of resorption pit excavation (since functional mononuclear osteoclasts are 
often observed in human PBMC cultures). The total number of these cells and area 
resorbed on each discs were assessed “blind” by transmitted/reflected light 
microscopy. Area of resorption was assessed by reflected light microscopy via output 
from a Sony CCD colour video camera (DXC-151A; Sony Corporation, Japan) using 
standard ‘dot-count’ morphometry.
Statistics
Comparison between pairs of means was performed by using t-test and multiple 
comparisons were performed by one-way analysis of variance using ‘InStat’ (Version
1.13, GraphPAD software) with use of Bonferroni correction for multiple 
comparisons; representative data are presented as means ± SEM for 5 or 6 replicates. 
Results are presented for representative experiments that were each repeated at least 
2-3 times.
54
RESULTS
Relationship between pH and PC02 in tissue culture media
Figure 2.1 demonstrates the relationship between pH and PC02 in tissue culture 
media. At equilibrium with 5% CO2 (38 mmHg), unmodified MEM with Earle’s salts 
and 10% FCS has an operating pH of -  7.2. However, unmodified DMEM (used for 
culturing osteoblasts), at equilibrium with 5% CO2 has an operating pH of -  7.4. 
Addition of 82 pi of 11.5 M HC1 to 100 ml of MEM or 205 pi of 11.5 M HC1 to 100 
ml of DMEM provides 10 and 25 mmol/1 H+respectively and results in an operating 
pH of -  7.0 in a 5% CO2 atmosphere (metabolic acidosis).
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Figure 2.1. Relationship between pH and PC02 in tissue culture media.
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Acid-activation of blood-derived human osteoclasts
Osteoclast resorptive activity was markedly increased by a reduction in 
extracellular pH from 7.42 to pH 7.01 (Figure 2.2). Note that human osteoclasts 
cultured at non-acidified conditions (pH 7.42) still retained some resorptive function 
(Figure 2.2 B), unlike rat osteoclasts which are almost completely inactive at pH 7.4 
(Arnett and Dempster 1986; Arnett and Spowage 1996).
Reducing extracellular pH for the final 3 days of culture caused a striking, 
progressive increase in resorption pit formation by blood-derived osteoclasts cultured 
on bone chips. The acid-response was highly reproducible with peak stimulation (5-6 
fold) of resorption close to pH 7.0 and half-maximal activation at pH -7.3 (Figure 
2.3). Osteoclasts behaved similarly when cultured on dentine or bone chips (data not 
shown).
As shown in Figure 2.4, at physiological pH (-7.4), basal level of resorption of 
osteoclasts generated from PBMCs obtained from different donors was low. These 
results are representative of experiments carried out using PBMCs from 8 healthy 
adult volunteers (age range 20-55; males and females). Reducing pH from -7.4 to 
-7.0 increased the area resorbed/osteoclast by ~9-fold for donors 1 and 3 and by -5- 
fold for donors 2 and 4 (Figure 2.4 A). The effect of pH treatment on the total 
number of osteoclasts per dentine disc was either not significant between the 
treatment groups or only modestly different (Figure 2.4 B). However, even modest 
changes in osteoclast number could not account for the marked increase in resorption 
due to acidosis. For example, osteoclast obtained from donor 3 showed a 25% 
increase in the total number of osteoclasts when these cells were cultured at low pH, 
however the increase in resorption activity/osteoclast was 9-fold.
Functional, mononuclear osteoclasts were often observed in hPBMC cultures as 
shown in Figure 2.5.
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Figure 2.2. Stimulatory effect of acidosis on osteoclast activation in human PBMC 
cultures. Representative micrographs (10x objective) of cells cultured on 16 mm2 bone 
chips in MEM for 12 days with RANKL (1 ng/ml), M-CSF (5ng/ml) and 5 mmol/l OH' to 
generate osteoclasts, followed by 2 days in MEM modified by the addition of 15 mmol/l H+ or 
5 mmol/l OH'. A. transmitted light image of osteoclasts cultured at pH 7.42. B. 
corresponding reflected light image. C. transmitted light image of osteoclasts cultured at pH 
7.01 for the last two days of culture. D. corresponding reflected light image. White arrows 
point to examples of TRACP-positive osteoclasts and black arrows to resorption pits. Note 
the presence of very few resorption pits at pH 7.42 (B) whereas abundant pits (dark grey 
areas) are seen when cells are cultured at pH 7.01 (D).
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Figure 2.3. Acidosis stimulates resorption pit formation by human osteoclasts 
formed from PBMCs. Cells were cultured on 16mm2 bovine bone chips in MEM for 
16 days with RANKL (5ng/ml), M-CSF (10ng/ml) and 5 mmol/l OH" to generate 
osteoclasts, followed by 3 days in MEM modified by the addition (from left to right) of 
15, 10, 5, 0 mmol/l H+, and 5 mmol/l OH". Significantly different from respective 
control (pH 7.42 and pH 7.40): *p<0.05, ** p <0.01, ***p<0.001. Values are means ± 
SEM (n = 6).
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Figure 2.4. Effect of acidosis on osteociast number and resorption pit 
formation by human osteoclasts from four healthy donors. Cells were cultured 
on 5 mm diameter dentine discs in MEM for 14 days with RANKL (1 ng/ml), M-CSF 
(5ng/ml) and 5 mmol/l OH’ to generate osteoclasts, followed by 2 days in MEM 
modified by the addition of 15 mmol/l H+ or 5 mmol/l OH\ pH values of control {i.e. 
blood pH) groups for donors 1-4 were 7.41, 7.38, 7.43, 7.39, respectively, and those 
of acidified groups for donors 1-4 were 6.97, 7.01, 6.95 and 6.98, respectively. 
These results are representative of experiments earned out using PBMCs from 8 
healthy adult volunteers (age range 20-55; males and females). Significantly different 
from the respective control group: * p<0.05, ** p<0.01. Values are means ± SEM (n = 
8).
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transmitted light
reflected light
Figure 2.5. Typical appearance of a TRACP-positive mononuclear cell derived 
from human PBMC cultures able to resorb dentine substrate (40x objective).
A. transmitted light image of a typical mononuclear osteoclast. B. corresponding 
reflected light image, showing multiple small resorption pits (grey, cloud-like 
features).
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Effect o f acidosis on normal human osteoclast formation
In order to determine whether acidosis plays a role in osteoclast formation, 
PBMCs were cultured for 14 days in acidified or control medium. To obtain reliable 
and consistent levels of osteoclast formation and bone resorption using the human 
PBMC assay, cells have to be maintained in a 96-multiwell plate for the first 4 days 
in culture. I found that culturing cells from day 1 at low pH in a small medium 
volume (200fil) was difficult as at many times the pH values reached very low levels 
(~ 6.4), which affected cell survival. In order to overcome this problem, lower 
amounts of HC1 were added (10 mmol/l H+ instead of 15 mmol/l H+) to generate a pH 
-7 .0 . Moreover, media were changed every other day up until transfer of discs to a 
25cm2 flask, where excess medium could be added (1ml medium /disc).
Incubation of human PBMCs in the presence of 1 ng/ml RANKL and 5 ng/ml M- 
CSF for 14 days at pH 7.43 resulted in abundant TRACP-positive multinucleated cell 
formation (171 ± 6 osteoclasts/disc), but almost no resorption (0.50 ± 0.05 mm2). 
These cells were still able to resorb at pH -7.45, contrary to rodent and 
osteoclastoma-derived cells that are completely “switched off’ above pH 7.30 and
7.40 respectively (Arnett and Spowage 1996; Hoebertz et al. 1999).
In cultures maintained at control pH (7.45) for 12 days followed by 2 days in 
acidified medium (pH 6.99), formation of human osteoclasts was similar to 14 days at 
pH 7.46, but resorption pit formation was increased 11-fold (Figure 2.6). Continuous 
incubation in acidified media (pH 7.01 for 14 days) reduced osteoclast formation by 
~2-fold, but the area resorbed/disc was not significantly different to that of cells 
cultured at low pH for the last two days in culture only. Moreover, culturing cells 
continuously at low pH increased the ratio of area resorbed/osteoclast by 2-fold. 
0.072 ± 0.008 mm2 compared to 0.036 ± 0.007 mm2 when cells were acidified for the 
last two days in culture.
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Figure 2.6. Effect of extracellular pH on osteoclast formation and activity.
Cells were cultured on 5mm diameter dentine disc in MEM for 14 days with RANKL 
(1 ng/ml), M-CSF (5ng/ml) in the presence of 5 mmol/l OH* or 15mmol/l H+ and for 12 
days in the presence of 5 mmol/l OH* followed by 2 days in the presence of 15mmol/l 
H+. Significantly different from control (14d at pH 7.43): *p<0.5, ** p <0.01. Values 
are means ± SEM (n = 8).
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Interaction between PTH and pH
To test whether PTH influences osteoclast function in the absence of osteoblasts, 
PBMCs were cultured for 12 days in the presence of 1 ng/ml RANKL and 5 ng/ml 
M-CSF and 7.5 mmol/l OH-, followed by 2 days in medium modified by the presence 
of 50 and 100 ng/ml hPTH at control or acidified conditions. In this experiment, a 
larger amount of NaOH was added to the culture media to increase the pH levels of 
the control group from -7.40 (generated when 5 mmol/l H+ is added) to -7.46 in 
order to “switch off’ the cells almost completely. I found that CO2 levels must be 
maintained at constant levels throughout the experiment otherwise even very small 
fluctuations due to opening the incubator door too many times, for example, increased 
the pH levels up to 7.50, which adversely affected cell survival. Surprisingly, even 
when medium pH reached 7.52, osteoclasts were still present, but the number of cells 
was greatly reduced (data not shown). The final pH measurements for the groups 
were as follows: 7.46, 7.45 and 7.48 for 0, 50 and 100 ng/ml PTH respectively for the 
control group, and 7.01, 7.02 and 7.00 for 0, 50 and 100 ng/ml PTH respectively for 
the acidified group. Figure 2.7 shows clearly that the effect of PTH on these cells 
was dependent on extracellular acidification. Culturing cells in the presence of 50 
ng/ml PTH at low pH increased osteoclast resorptive activity by 1.9-fold, whereas no 
effect was seen when these cells were cultured at control pH (~ 7.48) in the presence 
of 50 or 100 ng/ml PTH. Note that the combined effect of acidosis and PTH (100 
ng/ml) caused a 45-fold increase in resorption compared to control group (pH 7.46, 
no PTH). The lack of PTH effect at non-acidified cultures was only observed when 
osteoclasts were completely “switched off’ which only happened pH -  7.45, 
however, the effect was always upmost at pH -7.0. There were no significant 
changes in the number of osteoclasts due to PTH treatment for the last 2 days in 
culture.
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Figure 2.7. Effect of PTH on human osteoclasts derived from PBMCs. Cells 
were cultured on 5 mm dentine discs in MEM for 12 days with RANKL (1 ng/ml), M- 
CSF (5ng/ml) and 5 mmol/l 0 H ‘ to generate osteoclasts, followed by 2 days in MEM 
modified by the addition of 0, 50 or 100 ng/ml PTH in the presence of 15 mmol/l H+ 
or 5 mmol/l OH‘. Significantly different from the respective control (no PTH added): 
*p<0.5, **p <0.01. Values are means ± SEM (n = 8).
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DISCUSSION
The results presented in this chapter show that mature normal human osteoclasts 
are activated by acidosis. However, osteoclast formation was optimal at around pH
7.40 and was inhibited by low pH. In a second series of experiments, the interaction 
between PTH and pH on human osteoclasts was studied. The results obtained 
showed PTH is able to regulate the resorptive function of human osteoclasts directly 
when cells were cultured at acidified conditions.
Reducing extracellular pH for the final 2-3 days of culture caused striking, 
progressive increases in resorption pit formation by normal human osteoclasts, with 
peak stimulations up to 9-fold at pH - 6 .9-7.0. The acid-activation curve of human 
osteoclasts differed from that of rat or mouse osteoclasts, in that it was shifted 
markedly in the alkaline direction, with half-maximal activation at pH -7.3 as 
opposed to pH -7.1 for rodents (Arnett and Dempster 1986; Arnett and Spowage 
1996). Most surprisingly, the pH-activation profile of human osteoclasts corresponds 
with that of the recently discovered H+-sensing human G-protein-coupled receptor 
reported to be present on bone cells (Ludwig et a l 2003; Komarova et al 2005). 
Such pH sensors will be discussed in detail in Chapter 5.
The stimulatory response of normal human osteoclasts to acid was not donor- 
specific. Studies carried out in osteoclasts obtained from individuals from different 
genetic backgrounds, sex and age showed that despite different basal levels of 
resorption, lowering the pH for the final 2 days in culture from -7.4 to -6.9 was 
enough to cause at least 5-8 fold increases in osteoclast resorptive activity.
In contrast to the stimulatory effect of pH on osteoclast activity, the formation of 
osteoclast from PBMCs is optimal at around pH 7.40 and is somewhat inhibited at 
low pH (~2-fold inhibition at pH 7.0). This result is similar to that obtained for 
mouse osteoclasts (Hoebertz and Arnett 2003). However, the resorptive activity of 
these cells was not decreased by continuous incubation at acidified medium. On the 
contrary, the osteoclasts present were more active compared to those cultured in 
acidified medium for the last two days in culture.
In the course of this study, TRACP-positive, human mononuclear cells were 
found to be capable of bone and dentine resorption. These findings are in agreement
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with previous reports that showed mononuclear cells in vitro from chick(Prallet et al 
1992), murine and human sources are capable of resorbing bone (Sarma and Flanagan 
1996; Nicholson et al 2000). Analysis of resorption cavities in human iliac crest 
biopsies has shown that as much as two thirds of the cavity may be excavated by 
mononucleated rather than multinucleated osteoclasts (Eriksen 1986). Most recently, 
it has been demonstrated that CD14+ cultures give rise to a mixed population of 
mononucleated and multinucleated cells capable of resorption, suggesting 
heterogeneity in the maturity of the CD14+ osteoclast precursors. These authors 
suggested that with longer incubation periods the mononucleated cells might become 
multinucleated (Nicholson et al 2000).
In a second series of experiments, the interaction between PTH and pH on mature 
normal human osteoclasts was studied. This is the first study to show a direct effect 
of PTH on osteoclast activity and supports the findings of our collaborators who 
showed that human osteoclasts express functional PTH receptors (Dempster et al 
2005). This is evidence against the belief that PTH effect is osteoblast-mediated 
(Rodan and Martin 1981; McSheehy and Chambers 1986a; McSheehy and 
Chambers 1986b); this will be discussed in more detail in Chapter 6 . Consistent with 
my results, it has been reported that PTH caused a rapid and dramatic increase in 
superoxide anion production (an index of cell activity) by rat osteoclasts, whereas 
treatment of osteoblast-like cells with PTH had no such effect (Datta et a l 1996). 
PTH also appears to activate CAII activity and consequently regulates the acid 
production in avian and rat osteoclasts (Anderson et al 1985; Hunter et al 1988). It 
has also been shown that PTHrP stimulates deer antler osteoclast formation via a 
mechanism that only partially involves the RANKL pathway (Faucheux et a l 2002). 
Recently, Gay and colleagues (2003) have proposed that PTHrP, which is produced 
by both osteoblasts and osteoclasts, may play a role in the communication between 
these two cells, i.e., PTHrP produced by osteoblasts may regulate osteoclast activity 
via PTH1R in osteoclasts, and vice versa.
Osteoclast activation by slight extracellular acidification (pH -1.0) is the key 
initial requirement for the stimulatory action of PTH on resorption to occur. The 
stimulatory action of PTH on osteoclastic resorption is broadly in line with earlier 
reports of the activation of mature rat osteoclasts by this molecule at low pH in low
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density mixed cultures containing cells of the osteoblast lineage (Arnett and 
Dempster 1986). The actions of other osteolytic agents e.g. l,25-(OH)2D3, RANKL, 
ATP and ADP are also enhanced by acidification (Morrison et al. 1998; Murrills et 
al. 1998; Hoebertz and Arnett 2003). Conversely, slight alkalinisation markedly 
attenuates the osteolytic action of PTH, l,25-(OH)2D3 and PGE2 in calvarial cultures 
(Meghji et al. 2001). Thus, osteoclast activation can be regarded as a 2-step process, 
with acidification the obligatory first step. Moreover, the weight of evidence now 
indicates strongly that extracellular protons can be considered to represent the long 
sought “osteoclast activation factor” (OAF).
My observations on the direct action of PTH on osteoclasts reinforce the 
necessity for studies of the effect of many pro-resorptive agents using assays such as 
PBMCs or CD-14+ cells (Flanagan and Massey 2003). It is clear that in the presence 
of cells other than osteoclast precursors, molecules can exert different effects. For 
example, TGF P is known to enhance osteoclast formation from PBMCs (Massey et 
al. 2001) but inhibits osteoclastogenesis in human bone marrow cultures, in which 
there is a stromal cell population (Sarma and Flanagan 1996).
In summary, the results presented in this chapter give evidence for the important 
role of acidosis on human osteoclasts, and also provides formal proof that accessory 
cells, such as osteoblasts or stromal cells, are not required for the acid-activation 
response of mature osteoclasts. Extracellular pH is clearly an important influence on 
bone homeostasis and must additionally be considered a critical factor in the design, 
monitoring and interpretation of all bone resorption experiments. Moreover, the 
findings presented here suggest that there seems to be a dual regulatory effect of PTH 
on bone cells. This molecule acts directly on human osteoclasts and also, indirectly, 
via osteoblasts. Appreciation of this dual regulatory mechanism may ultimately 
advance our understanding of the complex effects of PTH on the human skeleton.
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CHAPTER 3
Effect of acidosis on resorption-associated factors in 
vitro
INTRODUCTION
Bone organ culture and acidosis
Organ culture of neonatal mouse calvaria studies have been used to investigate 
whether the Ca2+ efflux from bone by acidosis occurs due to physicochemical 
dissolution of bone or by cell-mediated means. This model offers key advantages. 
First, the bone cells exist in their normal histological and anatomical relationship. 
Second, the release of cold Ca gives a more valid representation of bone resorption 
since it reflects changes in total mineral dissolution, whereas measurement of 45Ca2+ 
release, as used previously by other investigators (Dominguez and Raisz 1979; 
Bushinsky et a l 1992), only demonstrate changes in resorption of relatively immature 
mineral (Meghji et al 1998).
Bushinsky and colleagues showed that in short-term neonatal mouse calvarial 
cultures (3 hours), the net Ca2+ efflux observed when the pH was decreased from 
-7.40 (either by reducing HCO3' or by increasing CO2) appeared to be due to 
physicochemical dissolution of bone calcium carbonate (Bushinsky et a l 1983;
Bushinsky et al 1985; Bushinsky and Lechleider 1987). However, after 24-48
2+
hours, cell mediated Ca release predominated in response to metabolic acidosis 
(Bushinsky 1989; Bushinsky et al 1992; 1995). More recently, it has been reported 
that the steep response of mouse calvarial bones to metabolic acidosis is very similar 
to that of isolated mature rat osteoclasts in which resorption is essentially “switched 
off” above pH 7.20 and stimulated maximally at pH -6.90 (Meghji et a l 2001). 
Critically, acid-stimulated Ca2+ release was not observed in dead bones and was 
completely blocked from live bones by calcitonin (Meghji et a l 2001). These 
findings confirmed and amplified the earlier work of Goldhaber and Rabadjija who
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suggested that H+ stimulated Ca2+ release from bone is osteoclast mediated 
(Goldhaber and Rabadjija 1987).
Contrary to the reported behaviour of disaggregated rat osteoclast cultures (Arnett 
et al. 1994), stimulation of resorption in mouse calvarial cultures are more sensitive 
to metabolic than respiratory acidosis (Bushinsky et al. 1992; Meghji et al. 2001). 
The reasons why a reduction in bicarbonate concentration should have a greater effect 
on osteoclastic bone resorption than an increase in the partial pressure of carbon 
dioxide in calvaria are unclear. However, a low extracellular HCO3" concentration (as 
in metabolic acidosis) might be expected to facilitate the exchange of intracellular 
HCO3' for Cf, leading to enhanced H+ availability for increased resorption. 
Increasing CO2 levels (as in respiratory acidosis) could promote calcium carbonate 
accretion and the formation of carbonated apatite (Bushinsky 1995; Meghji et al. 
2001). This may explain the apparent reduction in calcium efflux seen in calvarial 
cultures incubated in medium acidified by increased PCO2. During metabolic 
acidosis however, the low HCO3' concentration would be expected to favour the 
dissolution of bone calcium carbonate and carbonated apatite.
Goldhaber and Rabadjija (1987) were the first to suggest that the stimulatory 
effect of acidosis on bone resorption in whole organ cultures might involve 
prostaglandin synthesis, as addition of indomethacin (lOOng/ml) to the cultures 
strongly inhibited the Ca2+ release by added protons. Indomethacin acts as a non- 
selective inhibitor of cyclooxygenase activity (i.e. COX-1 and COX-2) and thus, 
prostaglandin production (Vane 1971). These findings are in agreement with the 
observation that ibuprofen, another inhibitor of prostaglandin synthesis, produces the 
same effect in whole organ cultures (Meghji et al. 2001). Acid stimulated Ca2+ 
release in mouse calvaria was also shown to be blocked by the 5-lipoxygenase 
inhibitors, MK 886 and BW 70C (Meghji et al. 2001). This finding suggests that 
leukotrienes, stimulators of bone resorption in a number of systems, may also be 
involved in mediating the acidosis effect in mouse calvarial cultures (Meghji et al. 
1988; Garcia et al 1996; Meghji et al. 2001)
The effect of acidosis on bone organ culture is not restricted to osteoclasts. The 
expression of collagen type 1 and alkaline phosphatase decrease when bone cells are 
cultured at low pH (-6.80) compared to control (-7.40) suggesting that osteoblast
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activity is suppressed by acidosis (Krieger et al 1992). RANKL mRNA expression 
has been shown to increase when calvarial bones are cultured at low pH (Frick and 
Bushinsky 2003). This finding led to the conclusion that acidosis stimulates 
prostaglandin production by osteoblasts, which acting in a paracrine manner increases 
osteoblastic RANKL synthesis. RANKL then stimulates osteoclastic activity and 
osteoclastogenesis to promote bone resorption and buffering of proton load (Frick 
and Bushinsky 2003).
Moreover, it has been demonstrated that PTH and insulin-like growth factor 1 
and 2 (IGF-1 and 2) enhance medium acidification by primary rat osteoblasts and 
osteoblast-like UMR-106 and SaOS-2 cells. These authors measured real time 
changes in the pH beneath osteoblasts after stimulation with either IGF-1, IGF-2 or 
PTH; the drop in medium pH could conceivably explain the indirect effect of these 
factors on osteoclast function (Barrett et al 1997; Santhanagopal and Dixon 1999). 
It has also been shown that treatment of calvarial bones with PTH, l,25(OH)2D3 and 
PGE2 is associated with medium acidification which could by itself stimulate 
resorption to some extent in bone organ cultures (Belinsky and Tashjian, Jr. 2000; 
Meghji etal. 2001).
Regulation of osteoclast gene expression by metabolic acidosis
The mechanism by which extracellular acidification stimulates osteoclasts to 
resorb bone is still not clear. However, since the discoveries of H+-sensing receptors 
present on bone cells it seems reasonable to hypothesise that acidosis would alter the 
specific pattern of gene expression in osteoclasts (Ludwig et al 2003; Komarova et 
al 2005).
Studies carried out in mature rat osteoclasts showed that upregulation of 
osteoclastic expression of mRNA for calcitonin receptor (CTR) and carbonic 
anhydrase II (CAII) occurs within 4 hours of acidification (Biskobing and Fan 2000). 
CTR is an osteoclast marker and it is has been reported that calcitonin binding to its 
receptor results in rearrangement of the osteoclast cytoskeleton and decreased bone 
resorption (Baron et al 1990; Komarova et a l 2003). It has been suggested that 
CTR upregulation occurs as the osteoclasts become activated by acidosis to allow a 
rapid downregulation of the cell once the resorptive stimulus is removed, thereby
70
CTR works as negative regulator (Biskobing and Fan 2000). CAII catalyses the 
production of protons, which are actively secreted by osteoclasts into the resorption 
lacunae for the dissolution of bone mineral. In addition to increased CAII mRNA 
expression, the vacuolar ATPase (V-ATPase) pump activity has also been reported to 
be increased by low extracellular pH (Nordstrom et al 1997). The upregulation of 
these two factors augments the capacity of bone resorption by osteoclasts (Biskobing 
and Fan 2000). Other investigators also showed by RT-PCR that CAII mRNA 
expression increased in individual rabbit osteoclasts in response to lowered pH 
(Asotrae/a/. 1994).
In order to understand better the response of osteoclasts to acidosis, I studied the 
expression of mRNAs for the resorption associated genes cathepsin K, TRACP, 
TRAF-6 and c-src at control (pH -7.4) and acidified (pH -6.9) conditions in mouse 
organ bone cultures. The protein expression of TRACP and cathepsin K was also 
investigated in normal human osteoclast cultures when exposed to the same 
conditions.
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MATERIALS AND METHODS
Materials
Culture media and buffers were purchased from Invitrogen (Paisley, UK). Bulk 
liquids (organic solvents, acids and bases) were purchased from VWR International 
Ltd (Dorset, UK). Molecular biology reagents were purchased from Promega 
(Southampton, UK).
Mouse calvarial bone resorption assay
The method, which measures bone resorption as Ca2+ release from neonatal 
mouse calvaria, is similar to that described in detail by Meghji et al. (1998). 
Calvaria were dissected from five-day-old mice (MF1-strain), which had been killed 
by cervical dislocation. The calvaria were pooled and washed in phosphate-buffered 
saline (PBS), before being divided along the sagittal suture and placed in fresh PBS. 
Half-calvaria were cultured individually on 1 cm2 stainless steel grids (Minimesh, 
FDP quality) at the air-liquid interface in 6-well plates with 1.5 ml of Biggers, 
Gwatkin and Heyner medium (BGJb), 5% fetal calf serum (FCS), 100 U/ml 
penicillin, 100 pg/ml streptomycin, in a humidified 5% CO2 incubator. After an 
initial 24-hour pre-incubation period, the medium was removed and replaced with 
control or test media, modified by the addition of 15 mmol/l H+, lpM PGE2 and 
2pg/ml osteoprotegerin (OPG). Each experimental group consisted of five individual 
cultures. The bones were maintained for an extra 72-hour period without further 
medium changes, and without opening the incubator door, so as to ensure constant 
CO2 levels and to minimise pH fluctuations.
After 72 hours, experiments were terminated by withdrawing culture medium. 
Bones were either transferred to Eppendorf tubes containing 1ml of RNAlater 
(Sigma-Aldrich Co., Dorset, UK) and stored at -20°C until use. Incubator CO2 was 
determined by immediately measuring a culture medium sample using the blood gas 
analyser. The mean final pH of each treatment group was determined by removing 
and pooling a 100 pi sample from each replicate; the pooled samples were then re­
equilibrated with CO2 in the incubator before measurement; slight differences in CO2
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tension between groups were normalised to the initially measured value using pH- 
CO2 calibration curves constructed as previously described (Murrills et al. 1998).
Ca2+ measurement
Resorption was assessed as Ca release into the culture medium over the 72-hour 
period. Ca2+ concentrations in culture medium at the end of experiments were 
measured colorimetrically by autoanalyser (Chem Lab Instruments, UK) using the 
following procedure. Samples were acidified with excess 1 M HC1 and subjected to 
continuous flow dialysis against the metal complexing agent, cresolphthalein
^  -4*complexone (CPC), to separate Ca from proteins; 2.5 g/1 of 8-hydroxyquinoline was 
added to samples to eliminate Mg2+ interference. Dialysed Ca2+ bound to CPC was 
then determined following reaction with 2-amino-2-methylpropano-l-ol; the 
absorbance of the resultant purple-coloured solution was measured at 570 nm.
Dr Sajeda Meghji (Eastman Dental Institute, UCL) performed the calvarial assay 
and Ca2+ measurements.
Human osteoclast formation assay
Human osteoclasts derived from PBMCs were obtained as per protocol detailed 
in Chapter 2. At the end of the experiment, the cells were either lysed for RNA 
extraction or immunostained as explained below.
RNA extraction
RNA from bone tissue or osteoclast cells was extracted using TRIzol reagent 
according to the manufacturer’s protocol (Invitrogen, Paisley, UK). The bone tissue 
was immersed in an Eppendorf tube containing 1ml of RNAlater or TRIzol reagent 
and stored at -70°C until cell lysis. When using TRIzol, the Eppendorf tubes were 
covered with tin foil, immersed in liquid nitrogen and then smashed by using a 
hammer. The frozen tissue was transferred to a chilled mortar and samples were 
ground. Care was taken to remove any plastic from the mortar. The bone tissue 
immersed in RNAlater was transferred to a chilled mortar and ground. The ground 
sample was then transferred to an Eppendorf tube and 1ml of TRIzol reagent added. 
Cells were lysed in TRIzol reagent for 5 minutes prior to commencement of
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extraction. After lysis, chloroform (200pl) was added and tubes were mixed by 
inversion for 20 seconds and incubated at room temperature for 3 minutes. At the end 
of incubation period the samples were centrifuged at 12500 x g  for 15 minutes and 
after centrifugation, the aqueous layer was transferred to a clean tube containing 5 pg 
of glycogen (RNA carrier) and 500 pi of isopropanol. At this point the samples were 
stored at -20°C overnight to increase nucleic acid precipitation. The samples were 
then spun for 10 minutes at 12500 x g, the supernatant discarded and 1ml of 75% 
ethanol added. The samples were centrifuged at 7500 x g  for 5 minutes and after 
centrifugation, the supernatant was discarded and the pellet was allowed to air dry. 
RNA was resuspended in 50 pi of DEPC-water and it was quantified by measuring 
the absorbance at 260nm using a spectrophotometer. At 260nm, one absorbance unit 
is equivalent to 40 ng/ml RNA.
DNase treatment
This was carried out by using RQ1 RNase-free DNase (Promega) according to 
the manufacturer’s protocol. The DNase digestion reaction was set up as follows:
• Up to 8 pi RNA
• 1 pi RQ1 DNase lOx reaction buffer
• lu/pg RNA of RQ1 RNase-free DNase
• Nuclease-free water to a 10 pi final volume
The sample was incubated for 30 minutes at 37°C and 1 pi RQ1 DNase stop 
solution added to terminate the reaction, followed by a 10-minute incubation period at 
65°C to inactivate the DNase. At the end of the experiment, the total RNA was 
quantified as explained above. Samples were stored at -70°C until use.
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cDNA reaction
This was performed by using ImProm-II™ reverse transcriptase according to the 
manufacturer’s protocol. The DNase-treated RNA reaction was set up as follows:
• 100 ng/reaction RNA template
• 0.1 pg oligo (dT)i2-i8
• Up to 5 pi of double distilled water
The reaction was incubated at 70°C for 5 minutes and quick chilled at 4°C for at 
least 5 minutes. The reaction mixture was then transferred to a tube containing the 
following reagents:
• ImProm-II™ 5x reaction buffer
• 3mM MgCh
• 0.5mM dNTP mix;
• 20 U recombinant RNasin ribonuclease inhibitor
• 1 pi ImProm-II™ reverse transcriptase
• Up to 15 pi double-distilled water
The final 20pl volume reaction was incubated for 5 minutes at 25°C (annealing 
cycle) followed by incubation for 60 minutes at 42°C (elongation cycle) and the 
reverse transcriptase was heat-inactivated by incubating the reaction for 15 minutes at 
70°C. At the end of the experiment the cDNA was stored at -20°C until use.
Polymerase chain reaction
PCR was carried out on cDNA generated from total RNA. RT-PCR reactions 
were set up as follows:
• 2.5 pi 10 x PCR buffer
• 1.5mM MgC12
• ImM dNTP mix
• ImM forward primer
• ImM reverse primer
• 0.2 pi Taq polymerase (5U/pl)
• 1 pi cDNA
• Up to 25 pi double distilled water
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Amplification was performed in an Eppendorf master cycler gradient PCR 
machine programmed for the following cycles:
• One cycle of two minutes at 94°C
• 28-35 cycles of 30seconds at 94°C, 30sec at annealing temperature, 30
seconds at 72°C
• One cycle for 7minutes at 72°C
The oligonucleotide primers (MWG, Ebersberg, Germany) and the annealing 
temperature used to amplify the different genes under study are shown in Table 3.1 
and 3.2. The annealing temperature and the elongation period were determined 
empirically based on the melting temperature (Tm) of each primer and size of PCR
fragments, respectively. The optimal number of PCR cyles for each set of primers
was established to ensure that the analysis was done on the linear phase of DNA 
amplification
GAPDH served as control for the bone organ culture and human osteoclast 
cultures. P-actin was not used as a control for these cultures as P-actin expression has 
been shown to vary depending on the osteoclast position in the bone tissue and highly 
active osteoclasts have been shown to express higher levels of P-actin compared to 
less active ones (Kukita et al. 2003). The oligonucleotide primers were designed in 
such a manner that they either span the exon/exon boundaries to avoid amplification 
of genomic DNA or anneal to sequences in exons on both sides of an intron so if 
genomic DNA was amplified the product would be much larger than the product 
obtained from the intronless mRNA.
Table 3.1: Primers used for RT-PCR studies in human osteoclasts
Factor Forward primer Reverse primer Ta
GAPDH gtg aac ggg aag etc act gg tga ggt cca cca ccc tgt tg 57°C
Cat K ctt gtg gac tgt gtg act aac act gca tgg ttc aca 57°C
TRACP aga tgg aca tgt gga egg ggt cct caa agg tct cct gg 55°C
Ta = annealing temperature
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Table 3.2: Primers used for RT-PCR studies in mouse calvaria
Factor Forward primer Reverse primer Ta
GAPDH gtg aac ggg aag etc act gg ctt gtg gac tgt gtg act 57° C
B-actin gtt ege cat gga tga cga t tct ggg tea tct ttt cac gg 53°C
Cat K ctt gtg gac tgt gtg act gga tgg att cat ggg tgg tg 57°C
c-src ggg caa caa agt tgc agt c acg ttg tct tea gac acc 55°C
TRAF-6 ate ctg age aga teg act ctt gtg ccc tgc ate cct 55°C
TRACP aga tgg aca tgt ggc egg gtt gta cgt ctt gga gag 55°C
Ta = annealing temperature
Agarose gel electrophoresis of DNA
Agarose gels were generally made up as 1.5% multi purpose agarose (Roche, 
Lewes, UK) in 1 x TAE buffer (0.04M Tris-acetic acid, lOmM EDTA pH 8.0). The 
agarose/TAE solution was heated in a microwave oven on full power (750 W) for ~ 1 
minute and cooled to about 50°C. Then, 2pi of a lOmg/ml solution of ethidium 
bromide was added and the gel solution poured into a gel former and a comb inserted. 
When set, the gel was placed into an electrophoresis tank, the comb removed and 1 x 
TAE added. Care was taken to cover the surface of the gel with the running buffer. 
Samples to be electrophoresed were first mixed with 4 x sample loading buffer (40g/l 
sucrose, 2.5g/l bromophenol blue in distilled water) and loaded into the wells with a 
micropipette. The gel was electrophoresed at 5-10 volts/cm for approximately half 
hour until the bromophenol blue dye had migrated two-thirds of the length of the gel. 
The PCR products were visualised on an UV transilluminator.
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Sequencing of PCR products
Sequencing was carried out by Sequiserve (Germany). The double stranded 
DNA to be sequenced was diluted to a concentration of at least 100 ng/|nl and the 
forward and reverse primers to a concentration of 10 pmol/pl.
Immunocytochemistry
Immunocytochemistry was carried out on osteoclasts obtained from peripheral 
blood mononuclear cells cultured for either dentine discs or bone chips as detailed in 
Chapter 2. Monoclonal cathepsin K antibody was a kind gift of Glaxo Smith Kline 
(Pennsylvania, PA, USA). At the end of the experiment, dentine discs or bone chips 
bearing osteoclasts were transferred to 24-well plates containing MEM, no more than 
2 discs were placed in each well. The cells were washed twice in MEM and then 
fixed in 60:40 mixture of paraformaldehyde fixation buffer (3.5% paraformaldehyde, 
2% sucrose in PBS) with MEM at room temperature for 10 minutes. The discs were 
then washed twice in PBS, transferred to a clean well containing wash buffer (5% 
normal calf serum, 0.05% sodium azide in PBS) and stored at 4°C before 
immunostaining. Discs were then rinsed twice in PBS and cells permeabilized with 
lml of ice-cold Triton X-100 permeabilization buffer (20mM HEPES, 300mM 
sucrose, 50mM NaCl, 3mM MgC12, 0.5% Triton X-100, 0.05% sodium azide in PBS 
at pH 7.0). After permeabilization discs were rinsed twice in PBS and soaked in wash 
buffer for 30 minutes. The excess buffer from the surface of the discs was drained by 
touching their edge onto a tissue paper. The discs were then placed on the lid of a 24 
well plate on 20pl of 5pg/ml primary antibody then the remaining 30 pi of primary 
antibody was added to the top of the discs; the cells were probed for 30 minutes. 
After probing, the discs were washed twice in PBS and allowed to soak for 30 
minutes in wash buffer. The cells were then probed in 50 pi of goat anti-mouse 
fluorescin isothiocyanate (FITC)-conjugated secondary antibody (DakoCytomation 
Ltd., Denmark) at 1:40 dilution in wash buffer for 30 minutes. After incubation the 
cells were washed twice in PBS and stained for phalloidin-rhodamine conjugate 
(Invitrogen Paisley, UK) at 5 U/ml in wash buffer for 30 minutes. At the end of the 
immunostaining procedure, the discs were transferred to a clean well containing 
wash-buffer. The osteoclasts on dentine discs were monitored with a Leica TCS NT 
confocal laser scanning microscope (Heidelberg, Germany). Fluorescent images
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were collected in sequential 16 steps trough the osteoclasts for FITC (488nm filter) 
and rhodamine (568 nm filter) fluorochromes and displayed in xy planes at constant 
photomultiplier tube voltage threshold (PMT) and laser intensity. The negative 
control was scanned prior to samples in order to adjust the PMT of each channel to 
gate out any background signals from non-specific staining and autofluorescence 
from the cells and dentine discs. The fluorescence staining was quantified by 
mapping the area for analysis and measuring the fluorescence intensity/ pm2 of the 
compressed file (stack of images) using Leica Simulator software (Heidelberg, 
Germany). The sample preparation and confocal microscopy was demonstrated by Dr 
Steve Nesbitt (Bone and Mineral Centre, UCL).
Tartrate-resistant acid phosphatase assay
Tartrate-resistant acid phosphatase activity of conditioned medium was 
determined as follows. Human osteoclasts were cultured in medium supplemented 
with RANKL and M-CSF for 12 days at pH ~7.4, followed by a further 48 hour 
incubation in the presence of 5 mmol/1 NaOH or 15 mmol/1 HC1. At the end of the 
experiment, conditioned medium was collected and TRACP activity measured 
colorimetrically by using tartrate-resistant acid phosphatase reagent kit (Biotron 
Diagnostics, Hemet, California, USA) according to the manufacturer’s protocol.
Statistics
Comparison between pairs of means was performed by using t-test and multiple 
comparisons were performed by one-way analysis of variance using ‘InStat’ (Version
1.13, GraphPAD software) with use of the Bonferroni correction for multiple 
comparisons; representative data are presented as means ± SEM for 5 or 6 replicates. 
Results are presented for representative experiments that were each repeated at least 
2-3 times.
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RESULTS
Effect o f acidosis on osteoclast-mediated Ca2* release from mouse 
calvaria
Basal levels of Ca2+ release in non-acidified control bones (pH 7.20 ± 0.02 ) were 
very low after 3 days of culture (~ 0.2 mmol/1). Acidification of culture medium to 
pH 7 .05 ± 0.02 by addition of 15 mmol/1 IT as HC1 resulted in 10-fold increase in 
Ca2+ release from bones and was equivalent to that of a maximal dose of PGE2 
(lpM). HCO3' acidosis stimulated Ca2+ release was completely blocked by the 
addition of 2 pg/ml osteoprotegerin (Figure 3.1).
Effect o f acidosis on regulation of resorption-associated factors in 
mouse calvarial cultures
The mRNA expression of resorbing associated factors TRACP, cathepsin K, c- 
src and TRAF-6 was investigated on mouse calvarial cultures. Bones were cultured 
for 72 hours in control (pH 7.20 ± 0.02) or test medium modified by the addition of 
ImM PGE2 (pH 7.26 ± 0.01), 15 mmol/1 FT (pH 7.05 ± 0.02) or 2 ng/ml OPG (pH 
7.05 ± 0.03). PGE2 was used as a positive control.
Regulation of mRNA for cathepsin K (an enzyme involved in organic matrix 
degradation by osteoclasts), TRAF-6 (an intracellular factor associated with 
osteoclast activation) and TRACP (required for optimal resorption) were elevated 
strikingly by acidosis and PGE2, a known stimulator of resorption in mouse calvarial 
cultures (Meghji et al. 2001). Surprisingly, mRNA for c-src, thought to be required 
for osteoclast ruffled border formation was inhibited by acidosis (Figure 3.2). All 
four factors studied were downregulated when bones were cultured in the presence of 
OPG at low pH, however, c-src downregulation by acidosis was greatest when OPG 
was not present in the culture. In one series of cultures, the expression of cathepsin 
K mRNA was not detected when bones were cultured at pH -7.20 (control group) 
and was only evident in acidified groups (data not shown).
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Figure 3.1. Effect of acidosis on Ca2* release by mouse calvaria. Mouse 
calvarial bones were cultured for 3 days in control (pH 7.20 ± 0.02) or test media 
modified by the addition of 1|aM PGE2 (pH 7.26 ± 0.01), 15 mmol/H+ (pH7.05 ± 0.02) 
or 15 mmol/H+ and 2|ig/ml osteoprotegerin (OPG) (pH 7.05 ± 0.03). Stimulation of 
Ca2+ release from mouse calvaria by metabolic acidosis was equivalent to the 
maximal effect elicited by PGE2 (1pM). The stimulatory effect of acidosis on Ca2+ 
release was completely blocked by OPG (2pg/ml), indicating this is an entirely cell- 
mediated action. Values are means ± SEM (n = 5). Significantly different from 
control: *** p<0.001.
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Figure 3.2. Effect of extracellular pH on expression of mRNAs for resorption 
associated factors in mouse calvarial cultures. Cells were cultured for 3 days at 
pH 7.20 ± 0.02 (C), at pH 7.26 ± 0.01 in the presence PGE2 (P), at pH 7.05 ± 0.02 
(A) or at pH 7.05 ± 0.03 in the presence 2 ng/ml OPG (O). RT-PCR was performed 
on DNase-treated total RNA using GAPDH as control.
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Effect o f  acidosis on regulation o f resorption-associated factors in 
human osteoclast cultures
The effect o f  acidosis on the regulation o f  resorption associated genes were 
carried out in normal human osteoclasts obtained from PBMCs cultured on dentine 
discs or bone chips by using semi quantitative RT-PCR, immunocytochemistry and 
colorimetric analysis. RT-PCR analysis showed that both cathepsin K and TRACP 
mRNA were strongly upregulated on human osteoclast cultures when pH was 
lowered from 7.41 to 7.01 for the last two days o f  culture (Figure 3.3).
GAPDH
TRACP
Figure 3.3. Effect of acidosis on expression of TRACP and cathepsin K 
mRNAs in human osteoclast cultures. Cells were cultured for 12 days in the 
presence of RANKL (1ng/ml) and M-CSF (5ng/ml) and 5 mmol/l IT, followed by a 
further 48-hour in medium at pH 7.41 (control, C) or pH 7.01 (acid, A). RT-PCR was 
performed on DNase-treated total RNA using GAPDH as control.
Using confocal microscopy analysis I found that cathepsin K intensity increased 
by reducing the pH from 7.41 to 7.01 for the last two days in culture (Figure 3.4 A). 
It is noteworthy that resorbing osteoclasts, identified by the immunofluorescent actin 
ring staining, were seen at both control and acidified cultures. Staining intensity for 
cathepsin K was increased ~5-fold based on fluorescence intensity measurements o f  
cultures maintained for the last two days at pH 7.01 (Figure 3.4 B).
A pH reduction from 7.41 to 7.01 caused a 2-fold increase in the levels o f  
TRACP activity in the culture medium as assessed colorimetrically (Figure 3.5).
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Figure 3.4. Acidosis upregulates expression of cathepsin K by human
osteoclasts A. Resorbing osteoclast immunostained for cathepsin K (green)
cultured on bone chip, imaged by confocal microscopy. Rhodamine-phalloidin staining 
was used to demonstrate F-actin distribution (red). B. Quantitative 
immunocytochemical analysis of human osteoclasts generated from PBMCs shows a 
five-fold increase on cathepsin K protein expression in response to acidification for 2 
days. Significantly different from control (pH 7.41): *** p <0.001. Values are means ± 
SEM (n = 15).
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Figure 3.5. Effect of acidification on total tartrate-resistant acid phosphatase 
(TRACP) activity in human osteoclast cultures. PBMCs were cultured on 5mm 
diameter dentine discs in MEM for 16 days with RANKL (1ng/ml), M-CSF (5 ng/ml) 
and 5 mmol/l OH- to generate osteoclasts. For the final 2 days, test medium was 
modified by the addition of 15 mmol/l H+- Activity was measured from conditioned 
media samples. Values are means ± SEM (n = 6); ** p <0.01.
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DISCUSSION
The results presented in this chapter show that the resorption-associated factors 
TRACP and cathepsin K were upregulated by acidosis in mouse calvarial and normal 
human osteoclast cultures. Moreover, the adaptor protein TRAF-6 was also 
upregulated at acidic conditions in mouse calvarial cultures. However, c-src mRNA 
expression was surprisingly downregulated when bone was cultured at low pH. I 
also found that the effect of acidosis on mouse calvaria was completely blocked by 
osteoprotegerin.
The experimental system used to study the mRNA expression of resorption- 
associated genes by normal human osteoclasts had the advantage that RNA was 
extracted from cells cultured on natural, resorbable substrates, such as dentine discs 
or bone chips. These conditions mimic the in vivo situation better than the use of 
glass or plastic surfaces. The latter lack the organic matrix and mineral that plays an 
important role in the regulation of osteoclastic function. It has been shown that 
special structural features of active osteoclasts such as ruffled border and the sealing 
zone are not formed on an artificial surface (Lakkakorpi et al. 1989; Lakkakorpi et 
al. 1996; Lehenkari et al 1997). In order to obtain sufficient RNA for RT-PCR 
analysis, the cells were cultured at low oxygen (5%), which is known to increase 
osteoclast formation in cells derived from murine and human sources (Arnett et al.
2003). Moreover, during RNA extraction the isopropanol incubation was performed 
overnight at -20°C, which increased the nucleic acid precipitation and consequently 
the final RNA yield. The use of glycogen as a carrier during the RNA extraction 
facilitated the visualisation of the RNA pellet during the procedure.
Both TRACP and cathepsin K expression were upregulated when mouse calvaria 
and isolated human osteoclasts were cultured at low pH compared to the control 
group. The function and subcellular localisation of TRACP is still controversial 
although this factor is widely used as a histological marker for osteoclasts 
(Vaaraniemi et al 2004). It has been suggested that TRACP role may be linked to 
the main physiological function of osteoclasts: degradation of the mineralised bone 
matrix. TRACP knockout mice develop mild osteopetrosis and transgenic mice 
overexpressing TRACP develop mild osteoporosis (Hayman et al 1996; Angel et a l 
2000). This phosphatase has been reported to be involved in intracellular vesicular
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transport as deletion of this factor generates osteoclasts with increased ruffled border 
and accumulation of cytoplasmic vesicles (Hollberg et al 2002). TRACP also 
appears to play an important role in dephosphorylation of osteopontin, a 
phosphoprotein of bone that binds to osteoclast cell surface integrins via a RGD 
motif, thereby mediating attachment of osteoclasts to bone as well as activating 
various signalling pathways involving c-src and Akt/PI-3 kinase. When 
dephosphorylated OPN can no longer promote osteoclast RGD-dependent attachment 
(Flores et a l 1992; Andersson et al 2003). In contrast, Vaananen and colleagues 
showed that TRACP is co-localised with collagen fragments in the transcytotic 
compartments of resorbing osteoclasts, not at the ruffled border. They showed that 
TRACP may help in destructing the large amounts of matrix-degradation products 
transported by these vesicles as explained in detail in Chapter 1 (Vaaraniemi et al
2004).
Cathepsin K is a cysteine proteinase expressed abundantly and selectively in 
osteoclasts (Drake et al 1996). This enzyme plays an important role in osteoclast 
function as it degrades the type I collagen bone matrix after the demineralisation of 
the matrix by protons pumped into the extracellular resorption zone. Cathepsin K is 
able to cleave interstitial collagen within multiple sites of the triple helix structure 
(Gamero et a l 1998). Recent evidence suggests that cathepsin K may be present in 
transcytotic vesicles of resorbing osteoclasts and may be responsible for the 
proteolytic activation of the TRACP enzyme into TRACP 5b, which is a specific and 
sensitive marker of bone resorption (Halleen et a l 2000; Vaaraniemi et al 2004).
The finding that TRAF-6 is upregulated in mouse organ cultures by lowering the 
pH to ~ 7.0 fits well with the stimulatory action of acidosis on the resorptive activity 
of bone-resorbing cells in human osteoclast and mouse calvarial cultures (Figure 2.2 
and 3.1). TRAF-6 is one of the essential genes necessary for osteoclast cytoskeletal 
organisation and resorptive function since TRAF-6 knockout mice exhibit severe 
osteopetrosis due to abnormal ruffled border formation (Lomaga et a l 1999; Naito et 
al 1999; Armstrong et al 2002).
The downregulation of c-src mRNA expression in calvaria was most surprising as 
this molecule is one of the essential genes necessary for osteoclast activation, like 
TRAF-6, c-src is reportedly involved in cytoskeletal arrangement and osteoclast
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resorptive activity (Soriano et al 1991; Boyce et al 1992). There are many 
explanations for this discrepant result. First, this kinase is regulated by a variety of 
factors including RANKL and interleukin-1 (IL-1), which may or not be affected by 
acidosis. It is known that osteoclast stimulation by both RANKL and IL-1 induces 
the association of TRAF-6, with c-src, leading to the formation of a huge molecular 
complex and resulting in actin-ring formation and osteoclast activation (Armstrong et 
al 2002; Nakamura et a l 2002). Second, osteoclast function was studied in a 
complex (whole bone) environment, many other cell types normally present in bone 
such as endothelial cells, nerves and osteoblasts may influence the response of 
osteoclasts to an acidotic state by releasing a number of local factors, which could 
eventually regulate c-src expression (Meghji et a l 1998). Therefore, further studies 
will have to be carried out using single cell techniques such as immunocytochemistry 
in bone organ and disaggregated osteoclast cultures at different time points in order to 
elucidate the expression pattern of this kinase to acidosis.
The observation that OPG blocked the effect of acidosis on mouse calvaria is 
remarkably interesting as this compound is being tested by Amgen as a treatment for 
bone cancer (Garber 2003). The experimental conditions used in this study mimics 
that of a tumour microenvironment, which is acidic, supporting the notion that OPG 
may be a powerful treatment for the pain associated with bone cancer (Gerweck and 
Seetharaman 1996; Mantyh et a l 2002). The differentiation of osteoclasts requires 
the interaction of the receptor RANK, which is expressed by precursor osteoclasts to 
RANKL. Sequestration of this compound by OPG prevents the binding of RANKL 
to its receptor (RANK) preventing osteoclast differentiation and activation (Lacey et 
al 1998; Yasuda et al 1998). OPG is likely to be used in cancer patients as the 
tumour microenvironment induces formation and activation of osteoclasts (Mantyh et 
al 2002). The inhibitory action of OPG may also suggest that the effect of acidosis 
on bone may be mediated via RANK and RANKL interaction, supporting previous 
findings by Bushinsky and colleagues who showed that RANKL synthesis is 
increased on mouse calvaria when bones are exposed to low pH (Frick and Bushinsky 
2003).
The work presented in this chapter illustrates that the response of osteoclasts to 
extracellular pH is a cell-mediated process, which is tightly regulated by the
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osteoclasts. The earlier suggestion that low extracellular pH may simply aid 
resorption by reducing the gradient against which osteoclasts must pump H+ is 
unlikely to account for all of the effect (Arnett and Dempster 1986). Extracellular 
protons is most probably perceived primarily by Y t-sensing receptors such as OGR1, 
TDAG8 or TRPV1, which are expressed by bone cells as shown in Chapter 5.
89
CHAPTER 4
Acidosis inhibits mineralised bone formation by 
osteoblasts in vitro
INTRODUCTION
Osteoblast and acidosis
Extracellular acidification (pH 6.9-7.0) is now recognised as a key initial 
requirement for activation of osteoclasts to form resorption pits on bone (see Chapter 
2). However, the effects of acidosis on osteoblast function are less well understood.
Bushinsky and colleagues were the first to suggest that the calcium efflux during 
acidosis in mouse calvarial cultures, results from a combination of inhibited 
osteoblastic and stimulated osteoclastic activity (Krieger et al 1992). They showed 
that bone organ cultures, osteoblastic collagen synthesis and alkaline phosphatase 
activity are both decreased by lowering the extracellular pH (Krieger et al. 1992). 
Further studies using in vitro bone nodule formation as a model system suggested that 
acidosis inhibits nodule formation, with metabolic acidosis causing a greater effect 
than respiratory acidosis (Sprague et al 1994; Frick et al 1997). Changes in 
extracellular pH have also been reported to alter the expression of genes critical to the 
function of mouse osteoblasts (Frick et al 1997). These authors found that 
decreasing pH from 7.4 to 6.8 leads to a parallel reduction in mRNA for egr-1 (an 
immediate early response gene) and type 1 collagen 40 minute after medium change. 
Expression of other matrix protein mRNAs, including osteopontin and matrix Gla 
protein, was also reported to be downregulated by acidosis in long-term cultures 
(Frick and Bushinsky 1998).
Ramp and co-workers found that glycolysis, alkaline phosphatase activity and 
collagen production by primary chick and human osteoblasts are reduced at low pH, 
and hypothesised that pH 7.2 may be the optimal pH for osteoblast function (Ramp et 
al 1994; Kaysinger and Ramp 1998). Moreover, it has been demonstrated that
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increasing extracellular pH from 6.9 to 7.6 increases gap junction connections 
between osteoblast-like MC3T3-E1 cells (Yamaguchi et a l 1995). In vivo studies of 
low blood flow, that occurs in disuse, ageing and initial stages of fracture healing, 
showed that activity of osteoblasts were decreased most probably due to the reduced 
local pH surrounding these cells (Reeve et al. 1988).
The work presented in this chapter was aimed at investigating the direct effect of 
chronic metabolic acidosis on the function of normal osteoblasts, paying particular 
attention to the pH range that is critical for modulating osteoclast function, i.e. pH 7.5 
- 6 .8 .
Mineral deposition in vitro
Wong and Cohn (1975) pioneered the use of mouse calvaria to obtain cells of the 
osteoblastic lineage by sequential collagenase digestion. The cells obtained based on 
this method are either osteoblasts or osteoblast precursors, which are able to form 
bone nodules in vitro when cultured in the presence of dexamethasone, beta- 
glycerophosphate and ascorbic acid (Bellows et al. 1986). The synthetic 
glucocorticoid dexamethasone increases bone nodule numbers in a dose dependent 
manner in human and rat osteoblasts (Bellows et al. 1987; Ishida et al. 1996; Cheng 
et al. 1996). It is noteworthy that the circulating levels of glucocorticoids in both 
humans and rats (10'8 -  10‘7M) are similar to the maximal stimulatory responses of 
osteoblasts to dexamethasone in vitro (Bellows et al. 1987; Cheng et al. 1996). 
Beta-glycerophosphate acts as a substrate for alkaline phosphatase, presumably 
resulting in an increased local concentration of inorganic phosphate and subsequent 
mineral deposition (Bellows et al. 1992). The amount of beta-glycerophosphate 
added to the culture media is very critical as higher concentrations of this compound 
have been reported to promote non-physiological mineral deposition; therefore, its 
concentration should never exceed 2 mM in culture (Bellows et al. 1992). Ascorbic 
acid promotes post-translational modifications of collagen, which are required for its 
maturation (Prockop and Kivirikko 1995). Treatment of post-confluent cells with 
ascorbic acid also increases the expression of osteoblast differentiation markers such 
as alkaline phosphatase and also osteocalcin; this vitamin is essential for nodule 
production and thus matrix mineralisation in long-term cultures (Harada et a l 1991; 
Franceschi et al. 1994). As osteoblasts mature in vitro they sequentially exhibit a
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well-characterised pattern of gene and protein expression, which mimics bone 
formation in vivo (see Table 1.1). About 8 days after reaching confluence, small 
white mineralised nodules can be seen macroscopically in living unstained primary 
osteoblast cultures. Subsequently these nodules increase in size and organised cell 
layers around the nodules can be observed. The nodules formed have a characteristic 
trabecular morphology (see Figure 4.1).
The bone nodule formation assay used in this study has a number of advantages. 
First, it allows the ultimate function of osteoblasts, namely bone formation, to be 
studied quantitatively. Second, cells are exposed directly to environments of precisely 
controlled known pH, in a manner that is not possible using bone organ cultures, or in 
vivo. Third, osteoblast function is studied in a simple environment that is relatively 
free from the influence of the other cell types normally present in bone such as 
endothelial cells, nerves and cells of haematopoietic origin including osteoclasts.
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MATERIALS AND METHODS
Materials
Tissue culture media and sera were purchased from Invitrogen (Paisley, UK). 
Bulk liquids (organic solvents, acids and bases) were purchased from VWR 
International Ltd (Gillingham, Dorset, UK). Radiochemicals were purchased from 
Amersham International (Bucks, UK). All other reagents were purchased from 
Sigma-Aldrich (Poole, Dorset, UK) unless stated otherwise.
Bone nodule assay
The effects of acid on bone nodule formation by primary rat osteoblasts were
studied using modifications of an assay described previously (Hoebertz et a l 2002).
Cells were obtained from calvaria of 2-day-old neonatal Sprague-Dawley rats by
sequential digestion at 37°C in 0.25% trypsin in PBS for 10 minutes, 0.2%
collagenase type II in HBSS for 30 minutes, then 0.2% collagenase type II in HBSS
for 60 minutes, rejecting the first two digests. The cells were resuspended in
Dulbecco’s Modified Eagle Medium (DMEM) + 10% FCS, 100 U/ml penicillin, 100
jig/ml streptomycin and 0.25 pg/ml amphotericin B, and cultured in a humidified
atmosphere of 5% CO2 -  95% air until confluence (2 -4  days). At confluence, cells
4
were subcultured into 24-well plates at a density of 10 / well in DMEM. After a 24- 
hour pre-incubation period, medium was replaced with DMEM supplemented with 50 
jig/ml ascorbic acid, 2 mM P-glycerophosphate and 10'8 M dexamethasone (mixture 
abbreviated ‘supplemented DMEM’). Test media were acidified by adding 5 - 3 0  
mmol/l H+ as concentrated HC1, to give an effective pH range from ~ 7.35 to ~ 6.90. 
Cells were cultured for up to 21 days, with half-medium changes every 3 days.
At the end of the experiment, cultures were fixed in 2% glutaraldehyde for 5 
minutes, washed with 70% ethanol and left to air-dry. Mineralised bone nodules 
were visualised by staining with alizarin red (1% solution w/v in water) for 5 minutes, 
rinsed with 50% ethanol to remove excess stain, then air-dried. The plates were 
imaged at 800 dpi using a high-resolution flat-bed scanner (Epson Perfection 3200). 
Binary images of each individual well were then subjected to automated analysis 
(Scion Image software, Scion Corporation; http://www.scioncorp.com), at constant
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threshold level and minimum particle size, to determine the number and plan surface 
area of mineralised bone nodules.
Some cultures were stained to demonstrate collagen using Masson’s trichrome 
method. Briefly, this entailed fixation in Bouin’s fluid, and staining in 1% Weigert’s 
iron haematoxylin solution for 10 minutes, then 0.5% acid fuchsin, 0.5% glacial 
acetic acid for 5 minutes, followed by treatment with 1% phosphomolybdic acid 
solution for 5 minutes and staining for 5 minutes in 2% methyl blue, 2.5% glacial 
acetic acid solution.
Proliferation assay
Cell proliferation was determined as 3H-thymidine incorporation into DNA, 
essentially as described previously (Gray et a l 1992). Briefly, calvarial osteoblasts 
were cultured up to 15 days in supplemented DMEM in the presence of 0-30 mmol/l 
HC1 and labelled with 1 pCi/ml of [6-3H]thymidine (22.0 Ci/mmol; 814 GBq/mmol) 
for the final 6 hours of culture. Cell layers were washed three times with PBS 
containing ImM unlabelled thymidine, then detached using 0.25% trypsin for 5 
minutes at 37°C, and precipitated with 7.5% trichloroacetic acid (TCA) in the 
presence of 0.2% (w/v) bovine serum albumin (BSA), followed by centrifugation at 
1500 x g. Pellets were washed with 7.5% TCA / 0.2% BSA, recentrifuged, then 
digested overnight at 37°C in 0.2 M NaOH and mixed with scintillation cocktail 
(Wallac Optiphase Hisafe II, Fisher Scientific, Loughborough, UK) for scintillation 
counting.
sH-proline incorporation assay
Collagen production was estimated as 3H-proline incorporation into pepsin- 
resistant protein, essentially as described previously (Webster and Harvey 1979; 
Gray et al 1992). Briefly, L-[2,3, H] proline (42 Ci/mmol; 1.55 TBq/mmol) was 
added to osteoblast cultures to a final concentration of 1 pCi/ml, together with 50 
pg/ml P-aminoproprionitrile monofumarate and 50 pg/ml ascorbate for the final 24 
hours of culture. Experiments were terminated by addition of an equal volume of 
cold ImM acetic acid containing 1 mg/ml of pepsin (EC 3.4.23.1; 2500-3200 U/mg 
protein), followed by incubation for 4 hours at 20°C with gentle shaking.
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Subsequent steps were carried out at 4°C. Carrier rat-tail collagen (100 pg in 1ml 0.5 
mM acetic acid) was added and the mixture was allowed to precipitate for 2 hours, 
and then centrifuged for 20 minutes at 4000 x g. The pellet was discarded and 
pepsin-resistant protein was precipitated from the supernatant by the addition of NaCl 
(0.5 ml of 25% w/v solution in 0.5 mM acetic acid) for 2 hours. The mixture was 
centrifuged for 30 minutes at 4000 x g  and the precipitation step was repeated. The 
final pellet was dissolved in 0.5 ml of 0.5 mM acetic acid, and mixed with 
scintillation cocktail for counting as described above.
Alkaline phosphatase assay
The alkaline phosphatase (ALP) activity of cell lysates from parallel cultures was 
determined as described previously (Bakker and Klein-Nulend 2003). Briefly, 
primary osteoblasts were cultured in supplemented medium up to 6 days in the 
presence of 0-30 mmol/l HC1. The cells were then washed once in PBS, incubated on 
ice and 1 ml of cold ultrapure water added to the monolayer. The cells were then 
harvested by using a cell scrapper and the cell suspension transferred to a 1.5ml 
Eppendorf tube and sonicated on ice for 10 minutes, cell debris was then precipitated 
for 10 minutes at 500 x g. The supernatant was used for the determination of ALP 
activity and total protein content. The ALP activity was measured colorimetrically by 
using alkaline phosphatase reagent kit (Biotron Diagnostics, Hemet, California, USA) 
and the protein content of the cell lysates measured using Protein Assay Reagent Kit 
(Sigma, Dorset, UK) according to the manufacturer’s protocol based on the modified 
Lowry method (Peterson 1977); BSA was used as standard.
RNA isolation and RT-PCR
Osteoblasts cultured as described above were lysed in TRIzol solution at day 3, 5, 
10 and 17 of culture (Invitrogen, Paisley, UK), and total RNA was extracted 
according to the manufacturer’s instructions. RT-PCR was performed as per protocol 
detailed in Chapter 3. The primers used for this experiment were purchased from 
MWG (Ebersberg, Germany) and are shown in Table 4.1.
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Table 4.1: Primers used for RT-PCR studies in osteoblast cultures
Factor Forward primer Reverse primer Ta
p-actin gtt cgc cat gga tga cga t tct ggg tea tct ttt cac gg 53°C
OPN egg tga aag tgg ctg agt gac teg gga tac tgt tea 50°C
MGP ccc tgt get atg aat etc gac tcc gta aca aag cga 50°C
OCN gca gac ace atg agg ace et gca get gtg ccg tcc ata c 59°C
ALP etc att tgt gee aga gaa gtt gta cgt ctt gga gag 50°C
Ta = annealing temperature
Detection of apoptosis
Osteoblast apoptosis was assessed using a kit (Cell Death Detection ELISAplus, 
Roche Diagnostics Ltd, Lewes, East Sussex, UK) according to the manufacturer’s 
protocol. This assay measures cytoplasmic histone DNA fragments (mono and 
oligonucleosomes) produced after cell death using mouse monoclonal antibodies 
against histones and DNA. Briefly, cells were lysed in situ after being cultured in 
supplemented medium, for 3, 7 and 10 days in the presence of 0 or 30 mmol/l HC1. 
Mono and oligonucleosomes released into the cytoplasm were detected by measuring 
the absorbance at 450 and 490 nm; duplicate determinations were made. The results 
were normalised to osteoblast numbers in parallel wells, assessed using a 
haemocytometer, after sequential treatment with 0.2% collagenase type II for 30 
minutes, and 1% trypsin for 10 minutes to release cells.
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Electron Microscopy
Osteoblasts were seeded onto 1 cm diameter Melanex polymer (ICI, Dumfries, 
UK) discs (104 cells / disc) and cultured in 24-well plates in supplemented DMEM for 
up to 21 days in the presence of 0 or 30 mmol/l HC1. Cultures were terminated by 
fixation in 2.5% glutaraldehyde for 1 hour, followed by treatment with 1% osmium 
tetraoxide solution for 30 minutes, washing and immersion in 1% uranyl acetate. 
Samples were then dehydrated through a graded ethanol series, cleared in propylene 
oxide and embedded in Araldite resin. Ultrathin (80-90 nm) planar sections were 
collected on 200 mesh grids, counterstained with lead citrate and viewed in a JEOL 
1010 series transmission electron microscope. Mr Mark Turmaine (Department of 
Anatomy and Developmental Biology, UCL) prepared the samples for electron 
microscopy analysis.
Statistical analysis
Multiple comparisons were made by one-way analysis of variance (ANOVA) 
with use of the Bonferroni correction for multiple comparisons (‘Instat’ version 1.3, 
Graph pad software); representative data are presented as means ± SEM. 
Significance was assumed at p < 0.05. Results presented were for a representative 
experiment that was repeated at least three times unless stated otherwise.
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R E S U L T S
Effect o f acidosis on bone nodule formation and morphology in vitro
The effect of acidosis was tested on bone nodule formation by cultured rat 
osteoblasts. Reducing the extracellular pH from 7.43 to 6.90 had a strong inhibitory 
effect on mineralised bone nodule formation by these cells; at low pH, mineralisation 
was almost completely abolished. This inhibitory effect was easily visible to the 
naked eye as illustrated in Figure 4.1. In spite of the lack of mineralisation at pH 
6.90, the matrix-containing nodules were still formed with distinct edges and a 
defined shape, suggesting that the collagen production/deposition was relatively 
unaffected by lowering the environmental pH. Quantitative analysis (Figure 4.2), as 
assessed by total nodule area and number of nodules/well, shows that lowering pH 
from 7.43 to 6.90 inhibited bone nodule formation in a dose dependent manner. A 
pH reduction from 7.43 to 7.32 was sufficient to halve mineralisation, with complete 
abolition at pH 6.93.
To determine whether the pH effect on mineralised bone nodule formation was 
reversible, primary rat osteoblasts were cultured for 20 days at pH 7.43 or 6.96 then 
incubated for a further 10 days at pH 6.99 or 7.42, respectively. The results show that 
switching medium pH from 7.01 to 7.44 for the final 10 days allowed mineralisation 
of the matrix-containing nodules present in culture (Figure 4.3 A). The opposite 
effect was observed when medium pH was switched from 7.43 to 6.96 at day 20; i.e. 
the mineral deposited onto the matrix was completely dissolved by day 30 (Figure 
4.3 B)
In order to check the role of pH on crystal forming independent of cellular 
effects, osteoblasts were cultured for 20 days at pH 7.44 or 7.03, killed by 
glutaraldehyde fixation, then incubated for a further 10 days at pH 6.97 or 7.42, 
respectively. Decreasing medium pH from -7.4 to -6.9 for the final 10 days, after 
glutaraldehyde fixation, caused mineral dissolution (Figure 4.3 C); the morphology 
of the matrix-containing nodules was similar to those shown in Figure 4.3 B at day 
30, suggesting that mineral dissolution by acidosis is independent of cellular effects. 
Increasing medium pH from 7.03 to 7.42, in the absence of living osteoblasts, was 
sufficient to allow mineral deposition onto the matrix-containing nodules. The
98
mineral, however, precipitated randomly onto the matrix; the mineralised nodules 
formed had a disorganised morphology with less distinct edges in comparison to 
those formed when the pH was increased in the presence of living cells (Figure 4.3. 
A). Quantitative analysis (Figure 4.4), as assessed by total nodule area and number 
of nodules/well, shows that decreasing the pH of the medium from -  7.40 to -7.00 for 
the last 10 days in culture, in the presence or absence of living osteoblasts, decreased 
the area of bone nodules formed by -8-fold compared to those cells cultured at 
physiological pH for 20 days. When osteoblasts were switched from acidified 
(-7.00) to neutral (-7.40) conditions, the area of bone nodules formed increased by 
-20-fold compared to those cells cultured at pH -7.00 for 20 days.
As there were no apparent differences on the morphology of matrix-containing 
nodules when rat osteoblasts were cultured at low pH (6.90) compared to control (pH
7.43), the collagen structure was examined using Masson’s trichome staining and 
transmission electron microscopy (Figure 4.5). Histological staining showed that 
abundant collagen fibres were deposited by the osteoblasts at both pH 7.43 and 6.90 
(Figure 4.5 A, B) and there were no significant differences on collagen ultrastructure 
when cells were cultured at control and acidified media (Figure 4.5 C, D).
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Figure 4.1. Inhibitory effect of acidosis on bone nodule formation. Primary rat 
osteoblasts were cultured in plastic wells for 16 days in control medium at pH 7.43 or in 
acidified medium at pH 6.90, with 10‘8M dexamethasone, 2 mM p-glycerophosphate and 
50 ng/ml ascorbate. A, C. Bone nodules consisting of mineralised extracellular matrix, 
visualised by alizarin red staining, are evident only in control wells at pH 7.43. B, D. 
Appearance of control and acidified cultures at higher magnification (phase contrast 
microscopy, 10x objective); the failure of matrix to mineralise at pH 6.90 is clearly evident.
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Figure 4.2. Inhibitory effect of acidosis on bone nodule formation by cultured 
rat osteoblasts. In 16-day cultures, decreasing pH caused progressive reduction in 
formation of mineralised nodules stained by alizarin red, with complete inhibition at 
pH 6.93. Values are means ± SEM (n=4); significantly different from control (pH
7.43) value, * p<0.05, ** p<0.01.
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Figure 4.3. Role of pH on crystal forming independent of cellular effects.
Primary rat osteoblasts were cultured in bone nodule-forming medium at control 
(-7.40) or acidified (-6.90) pH for 20 days and then switched to different test media 
for the remainder of the experiment. A. Cells were cultured for 20 days at pH 6.96, 
then switched to neutral medium (pH 7.42) for the final 10 days in culture. B. 
Osteoblasts were cultured in neutral medium (pH 7.43) prior to incubation in acidified 
medium (pH 6.99) for the final 10 days in culture. C. Cells were incubated at pH
7 .4 4  for 20 days, killed by glutaraldehyde fixation, then incubated in acidified medium 
(pH 6.97) for the last 10 days in culture. D. At day 20, cells were killed by 
glutaraldehyde fixation and switched from acidified (pH 7.03) to neutral medium (pH 
7.42), for the remainder of the experiment. The presence of mineralised bone 
nodules was determined by alizarin red staining.
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Treatment groups
A = cells cultured for 20 days at pH 7.45
B = cells cultured for 20 days at pH 7.43 followed by 10 days at pH 6.99 
C = cells cultured for 20 days at pH 7.44, fixed in glutaraldehyde and further 
incubated at pH 6.97 for 10 days 
D = cells cultured at pH 7.02 for 20 days
E = cells cultured cells for 20 days at pH 6.96 followed by 10 days at pH 7.42 
F = cells cultured for 20 days at pH 7.03, fixed in glutaraldehyde and further 
incubated at pH 7.42 for 10 days
Figure 4.4. Role of pH on mineralisation independent of cellular effects.
Osteoclasts were cultured for 20 days at control (pH ~7.40) or acidified medium (pH 
-7.00), followed by 10 days in acidified or physiological conditions, respectively, in 
the presence or absence of living osteoblasts. Bone nodule formation was quantified 
by automated analysis of binary images of nodules formed in plastic wells. Values 
are means ± SEM (n=4); significantly different from respective control value: pH 7.45 
for 20 days (A) and pH 7.02 for 20 days (B); *** p<0.001.
104
m• ; v
C ' PH 7.43
Figure 4.5. Effect of acidosis on collagen structure. A, B. Representative 
images showing collagen fibres (stained blue-purple using Masson’s trichrome) laid 
down in 21-day cultures of rat calvarial osteoblasts maintained in both control 
medium at pH 7.43 and acidified medium at pH 6.90 (phase contrast microscopy, 
20x objective). C, D. Transmission electron microscopy showed that collagen fibril 
formation and organisation was similar in cultures at pH 7.43 and 6.90 (3000 x 
original magnification).
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Effect o f acidosis on sH-thymidine and sH-proline incorporation in 
osteoblast cultures
The effect of acidosis on the proliferation rate of osteoblasts cultured at pH levels 
ranging from 7.44 to 6.87 for 5, 9 and 15 days was assessed by using an assay that 
measures 3H-thymidine incorporation into DNA. As expected, cell proliferation rate 
was slightly reduced with time in culture, but it was unaffected by pH reduction from
7.44 to 6.87 (Figure 4.6 A). The same pH reduction had no effect on collagen 
production (Figure 4.6 B) tested as 3H-proline incorporation into pepsin resistant 
protein and did not affect protein measured by Lowry method (data not shown).
Effect o f acidosis on alkaline phosphatase activity
Since the inhibitory effect of acidosis seemed to be exclusive to the 
mineralisation of nodules, the activity of alkaline phosphatase was measured when 
cells were cultured at pH ranging from 7.78 to 6.79. Figure 4.7 shows that acidosis 
exerted an inhibitory effect on alkaline phosphatase activity. A pH decrease of 0.1 
unit (from pH 7.37 to 7.29) was sufficient to halve the alkaline phosphatase activity 
and there was a significant 8-fold decrease in activity when osteoblasts were cultured 
at low pH (6.90) compared to control (7.37).
Effect of acidosis on osteoblast apoptosis
To determine whether the inhibitory effect of acidosis on mineralised nodule 
formation by osteoblasts might involve increased apoptosis, I used an 
immunochemical assay to measure levels of mono and oligonucleosomes in the 
cytoplasm of osteoblasts cultured for 3, 10 and 20 days at pH 7.41 and pH 6.93. 
Apoptosis rate increased with time in culture but no effect of pH was evident (Figure 
4.8)
106
o
2o  a3
e- <?o  ^
.E=S
£  Q
E ->  x
X
CO
300
250
200
150
100
50
0
A pH 7.44 
pH 7.32 
pH 7.21 
pH 7.17 
pH 7.03 
pH 6.87
day 5 day 9 day 15
2  <d 
8 . ^  
O ^
= 1
~  0  o  T~~
Q_ X
30
25
20
15
10
5
0
7.44 7.33 7.29 7.20 7.15 6.94
PH
Figure 4.6. Effect of acidosis on cell proliferation and collagen synthesis in 
primary rat calvarial osteoblasts. A. Progressive acidification to pH 6.87 did not 
affect osteoblast proliferation, assessed by [3H]-thymidine incorporation. Values are 
means ± SEM (n = 4); differences between treatment groups were not significant. B. 
Acidification to pH 6.93 caused no reduction in collagen synthesis in 16-day 
osteoblast cultures, assessed as [3H]-proline incorporation in the presence of (3- 
aminoproprionitrile monofumarate. Values are means ± SEM (n = 8); differences 
between treatment groups were not significant.
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Figure 4.7. Inhibitory effect of extracellular pH on osteoblast alkaline 
phosphatase activity. Confluent cells were cultured for 6 days in bone nodule- 
forming medium at indicated extracellular pH levels. Alkaline phosphatase activity 
was measured colorimetrically from cell lysates and normalised to total Lowry protein 
content. Values are means ± SEM (n = 6); significantly different from control (pH 
7.37) value, * p<0.05, *** p<0.001.
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Figure 4.8. Acidosis does not induce apoptosis in rat osteobiasts. Cells were 
cultured at low (6.93) or ‘physiological’ pH (7.41) for 3, 10 and 20 days. Apoptosis 
was determined colorimetrically in pooled cell lysates using an ELISA kit that detects 
cytoplasmic histone DNA fragments; results are normalised to cell number. Values 
are means of duplicate determinations.
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Effect o f acidosis on osteoblast mRNA expression
RT-PCR experiments showed that expression o f  mRNA for alkaline phosphatase 
(ALP) by primary osteoblasts increased progressively with time in culture at pH 7.42 
but was strongly inhibited at all time points at pH 6.92. Osteopontin (OPN) mRNA 
was also slightly downregulated at low pH but only at the early time point (day 3). 
In contrast, matrix Gla protein (MGP) mRNA was clearly upregulated at all time 
points at pH 6.92. OCN mRNA was upregulated at later time points (days 10 and 17), 
but its expression was not affected by culturing cells at low pH, suggesting that 
acidosis does not impair osteoblast differentiation (Figure 4.9).
d3 d5 d10 d17
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Figure 4.9. Effect of extracellular pH on expression of mRNAs for alkaline 
phosphatase (ALP), matrix Gla protein (MGP), osteopontin (OPN) and 
osteocalcin (OCN) by rat primary calvarial osteoblasts. Cells were cultured for 
3, 5, 10 or 17 days in bone nodule-forming medium at pH 7.42 (control, C) or pH 
6.92 (acid, A). RT-PCR was performed on DNase-treated total RNA using p-actin 
as control. The PCR products were confirmed by sequencing analysis.
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DISCUSSION
The study described in this chapter shows that acidosis inhibits mineralised bone 
nodule formation by cultured rat osteoblasts. This effect appears to be primarily due 
to decreased mineralisation at low pH.
In spite of the complete inhibition of bone nodule mineralisation by acidosis (pH 
6.90), cultures stained using the Masson’s trichrome method showed that 
characteristic nodules containing type 1 collagen fibrils were still deposited by 
osteoblasts, and TEM analysis indicated that collagen ultrastructure and organisation 
was not significantly altered by acidosis. These data, together with the observation 
that lowering the extracellular pH is sufficient to dissolve bone nodules once 
mineralised, in the presence or absence of living osteoblasts, could lead to the 
conclusion that the effect of acidosis on mineralisation is exclusively physico­
chemical mediated. However, further studies demonstrated that in order to form 
morphologically normal mineralised nodules, the presence of living osteoblasts is 
essential, as clearly illustrated in Figure 4.3. Therefore, the inhibitory effect of 
acidosis in bone mineralisation is governed by both physico-chemical and cell- 
mediated means.
Separate lines of evidence help to explain the mechanisms underlying the 
inhibitory effect of acidosis on matrix mineralisation. Alkaline phosphatase (ALP) 
activity, was decreased by lowering pH levels from 7.37 to 6.80. The enzyme activity 
peaked at pH 7.37, which seems to be the optimal pH for bone nodule formation to 
occur. RT-PCR studies showed that acidosis downregulated mRNA for ALP and 
OPN in primary osteoblasts but upregulated matrix Gla protein (MGP) mRNA and 
did not affect the expression of osteoblast differentiation marker OCN. The 
upregulation of MGP by acidosis is consistent with the report that A/GP-knockout 
mice exhibit extensive lethal ectopic calcification and the notion that MGP functions 
as an inhibitor of mineralisation (Murshed et al 2004). Osteopontin is also 
considered to be an inhibitor of extracellular matrix mineralisation (Speer et al. 2002) 
but OPN mRNA was downregulated at low pH, most notably at the earliest time point 
(3 days).
I l l
My results are in line with an earlier report that mouse osteoblasts cultured in 
acidified medium produces fewer nodules over a 3-week incubation period compared 
with cells incubated in neutral medium (Sprague et al 1994). However, my findings 
fit less well with subsequent reports from the same group that acidosis inhibits 
mRNA for matrix Gla protein, osteopontin and type 1 collagen (Frick et a l 1997; 
Frick and Bushinsky 1998).
Surprisingly, the osteoblast proliferation rate and apoptosis levels were 
unaffected when cells were incubated in acidified medium compared with cells 
incubated at control pH. These data together with the collagen analysis suggest that 
the primary effect of acidosis on osteoblasts is to reduce mineral deposition. Earlier 
reports showed that a reduction in medium pH produced a marked increase in 
hydroxyapatite solubility. The effect has been reported to be particularly pronounced 
near pH 7.0, where a small drop in pH (0.1 unit) causes a 10-fold increase in Ca+2 and 
PO4 '3 solubility (Neuman and Neuman 1958). More recently, Larsen and Jensen 
(1989) studied the effect of pH on the hydroxyapatite solubility of human dental 
enamel in the pH range of 4.6 and 7.6. They reported that Ca+2 and PO4 ’3 solubilities 
increased 2 and 4-fold respectively when the pH was decreased from 7.40 to 6.90 
(Figure 4.10).
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Figure 4.10. The solubility of calcium 
and phosphate in hydroxyapatite at 
different pH levels. Adapted from 
Larsen and Jensen, 1989.
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The powerful inhibition of ALP (and the upregulation of MGP) at low pH may 
conceivably involve cell-mediated H+-sensing mechanisms. Proton-sensing G- 
protein-linked receptors have recently been identified to respond sensitively to pH 
changes in the range of 7.5 -  6.8 with increases in inositol phosphate or cyclic AMP; 
one of these novel receptors, OGR1 is functionally expressed on osteoblasts (Ludwig 
et al. 2003).
The data presented here may help explain why some patients with chronic renal 
metabolic acidosis develop osteomalacia, a condition in which the lag time between 
osteoid deposition and mineralisation is increased, (Cochran and Nordin 1969; 
Cunningham et a l 1982). This disorder has been reported in 20-30% of patients with 
renal tubular acidosis, an effect that has been assigned to reduced synthesis of 
l,25(OH)2 vitamin D3. However, my results indicate that acidosis might also directly 
contribute to this condition by reducing mineralisation via increased hydroxyapatite 
solubility and decreased ALP activity. This notion is supported by previous in vivo 
reports that showed alkaline treatment improved this condition (Richards et a l 1972; 
Disthabanchong et al 2004).
It is also important to bear in mind that the normal pH of the extracellular fluid 
bathing cells is likely to be below ‘physiological’ {i.e. blood) pH and subject to 
complex, dynamic gradients, depending on the metabolic activity of the cells and 
their distance from the nearest capillary. Non-invasive pH measurements has shown 
that in normal subcutaneous tissue, pH decrease by -0.32 units over a distance of 50 
pm away from a blood vessel (pH -7.40), a distance equivalent to approximate five 
cell diameters (Martin and Jain 1994). These authors also showed the pH levels in 
normal skin is -7.20. My own results suggest for optimal mineralised bone formation 
to occur in vivo, extracellular pH in the immediate osteoblast environment should be 
> 7.20. My data emphasise the importance of the vasculature for bone health and 
suggest a rationale for the histological observation that bone formation normally takes 
place in proximity to blood vessels (Brandao-Burch et a l 2005).
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In summary, my results indicate that low pH causes an “osteomalacic” condition 
in vitro due to increased CaP043" solubility, decreased alkaline phosphatase activity, 
and possibly increased MGP expression. These effects will be compounded in vivo 
by the strong stimulatory action of acidosis on osteoclast activity shown in Chapter 2.
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CHAPTER 5
Mechanism of pH sensing by bone cells
INTRODUCTION 
it-sensing receptors and bone cells
In vitro, small reductions in extracellular pH close to the physiological range 
result in large stimulation of osteoclast activity both in the absence (Arnett and 
Dempster 1986; Arnett and Dempster 1987) and in the presence of bicarbonate 
(Carano et a l 1993; Shibutani and Heersche 1993; Arnett et a l 1994; Arnett and 
Spowage 1996; Brandao-Burch and Arnett 2004). The mechanisms by which 
extracellular acidification stimulates osteoclasts to resorb bone are still not very well 
understood. Most simply, a low ambient pH may favour resorption by reducing the 
gradient against which osteoclasts must pump H+ across the ruffled border. However, 
given the steepness of the osteoclast response to small changes in extracellular pH 
(Chapter 2), this physicochemical explanation seems unlikely to account for all of the 
effect. Moreover, acidosis leads to an increase in sealing zone formation, indicating 
increased adhesion to the substrate (Teti et a l 1989a; Murrills et al 1993) and 
upregulates the expression of resorption associated factors such as TRACP and 
cathepsin K (Chapter 3). Therefore, it is reasonable to suppose that a “pH receptor” 
coupled to some signalling/ amplification system is present on or in the osteoclast.
Previous work carried out by members of our laboratory showed that lowering 
extracellular pH, in the absence of bicarbonate, does not lead to a parallel intracellular 
acidification and results in prompt and reversible increases in membrane 
conductance. Therefore, a small drop in pH is sufficient to activate osteoclast 
membrane ion transport (Dunina-Barkovskaya and Arnett 1999). This work 
mimicked the conditions that mature rat osteoclasts were exposed to in the original 
experiment performed by Arnett and Dempster (1986), where they showed a 
reduction in medium pH from 7.4 to 6.8 results in a 14-fold increase in resorption.
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Low pH is a key initial requirement for a number of pro-resorptive factors 
including PTH (Chapter 2) ATP, vitamin D3 and RANKL (Morrison et a l 1998; 
Murrills et al 1998; Hoebertz et al. 2000), to be able to stimulate osteoclasts to 
resorb bone. The interaction with ATP is mostly interesting because the receptor 
P2X2, a subtype of the P2 receptor family, has been shown to require extracellular 
acidification to show its full sensitivity to ATP (King et al, 1996). Further work 
showed that acid-induced bone resorption, in the absence of ATP, could be partly 
inhibited by the general P2 receptor antagonist suramin and by apyrase, an ecto- 
nucleotidase ATP scavenger, suggesting that the P2X2 receptor might be the putative 
‘pH receptor’ on osteoclasts (Morrison et a l, 1998). An unusual feature of the P2X2 
receptor is the presence of 8 histidyl residues in the extracellular loop domain (Brake 
et a l, 1994); histidine is exceptional in having an imidazole side chain with a pKb of 
6.8 (Creighton 1993). Thus, small pH shifts in the physiological range will change 
the charge and protonation of histidine side chains, with possible alterations in 
conformation of this domain. However, work using P2X2 knockout animals suggested 
that this receptor does not seem to represent the putative ‘pH receptor’ on osteoclasts, 
since cells derived from these mice were still strongly stimulated by acid alone 
(Hoebertz 2001).
Acidosis accompanies many painful conditions such as cancer (Vaupel et al 
1989; Gerweck and Seetharaman 1996). The finding that afferent sensory neurons 
can be directly excited by protons has generated considerable interest among basic 
and clinical researchers (Sutherland et a l 2000). The two main classes of acid 
sensing ion channels expressed by nociceptors are the acid sensing ion channels 
(ASIC) and transient receptor potential vanilloid subtype 1 receptors (TRPV1) also 
known as vanilloid receptor 1 (VR1) (Waldmann et al 1997; Caterina et a l  1997). 
These receptors are of particular relevance to bone cancer pain as most neurons that 
innervate the bone express ASIC and/or TRPV1 (Olson et a l 1998; Guo et a l 1999). 
Since bone cancer has been associated with increased osteoclast activity, and this cell 
is known to be directly activated by acidosis, it is reasonable to suggest that 
osteoclasts themselves may also express ASIC and TRPV1 receptors. Moreover, 
TRPV1 receptor has been shown to be expressed in macrophages; these cells evolve 
from the same cell lineage and therefore it is likely that they may share similar 
signaling mechanisms with osteoclasts.
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ASICs are members of the amiloride-sensitive Na+ channel/degenerin 
superfamily of ion channels (Waldmann et al 1999). A rapid drop in extracellular 
pH induces opening of this cation channel. ASIC1 has a pH activation profile that 
strongly resembles the pH response of osteoclasts (it is activated below 7.0), whereas 
ASIC2, or mammalian neuronal homologue of degenerins (MDEG1) requires a more 
acidic pH (Lingueglia et al 1997). A third channel, dorsal root ganglion ASIC 
(DRASIC) or ASIC3, is activated by pH < 4.5 (Price et al 2001). 
Immunocytochemical studies showed that despite being specifically expressed in 
osteoclasts; ASIC1 is not expressed in the membrane to serve as an extracellular pH- 
sensing receptor (Hoebertz 2001) .
TRPV1 receptors are non-selective cation channels that detect heat, extracellular 
protons and capsaicin, the irritant alkaloid from plants in the Capsicum family (chilli 
peppers) (Caterina et al 1997; Benham et a l 2003). The convergence of these 
stimuli on TRPV1 channels expressed in peripheral sensory nerves underlies the 
common perceptual experience of pain due to hot temperatures, tissue damage and 
exposure to capsaicin. Protons interact with the channel directly by increasing the 
probability of channel opening and also to potentiate the effects of capsaicin or heat, 
therefore working as activators and modulators of TRPV1 (Tominaga et a l 1998; 
Sprague et a l 2001). Structure-function analyses have shown that protons modulate 
TRPV1 activity by interacting with a glutamate residue (E600) on the extracellular 
surface of this channel protein. This residue serves as an important regulatory site for 
proton modulation of TRPV1 responses to heat over a physiologically relevant pH 
range of 6-8. On the other hand, capsaicin, which is lipophilic, binds to a site close 
to the cytoplasmic side of the receptor. Therefore, protons and vanilloids apparently 
exert their actions on TRPV1 from opposite sides of the membrane, consistent with 
an allosteric mechanism of proton-mediated potentiation (Jordt and Julius 2002). 
Most recently, Mantyh and colleagues reported that administration of TRPV1 
antagonist JNJ-17203212 or blockade of TRPV1 gene in a mouse model of bone 
cancer attenuates the pain associated with this condition. These authors suggest that 
this is because TRPV1 is present on sensory neuron fibres that innervate the mouse 
femur (Ghilardi et al 2005).
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Knockout studies have revealed an important role in bone metabolism for another 
subtype of the TRPV family: TRPV5. These knockout mice display significant 
disturbances in bone structure, including reduced trabecular and cortical bone 
thickness, and dysfunctional Ca2+ homeostasis (Hoenderop et al 2003). Moreover, 
TRPV6, also known as epithelial calcium channel 2 (EcaC2) has been reported to be 
expressed by osteoblasts (Weber et al 2001).
Recent work has described a novel class of human proton-sensing G-protein- 
coupled receptors (GPCRs) that respond to reduction in extracellular pH by eliciting 
rises in intracellular cyclic AMP (TDAG8 and GPR4) or inositol phosphate (OGR1) 
(Ludwig et al 2003; Wang et a l 2004; Ishii et al 2005). These proton-sensing 
GPCRs are of particular interest because their pH response range (pH 7.6-6.8) and 
their half-maximal activation points at 37°C (pH -7.3) correspond closely with that of 
normal human osteoclasts (see Chapter 2). Like the P2X2 receptor, the OGR1 has 
clusters of histidyl residues in its extracellular loop domain (Ludwig et a l 2003). 
Initial localisation studies indicated that OGR1 is expressed by osteoblasts and 
osteocytes but GPR4 was not detected on rat osteoblasts by RT-PCR analysis 
(Ludwig et al 2003). It has been recently reported that OGR1 is also expressed by 
rat osteoclasts and that acidosis increases the accumulation of the transcription factor 
NFAT2 in the nuclei (Komarova et al 2005). They also showed that activation of this 
transcription factor involves calcineurin stimulation and induced transient elevation 
of intracellular Ca2+, which they speculated to be due to OGR1 activation.
The work presented in this chapter investigates the effect of the alkaloid capsaicin 
(the TRPV1 agonist) on osteoclast formation and activation using normal human 
osteoclasts formed from PBMCs. Additionally, expression of different H+-sensing G- 
protein-coupled receptors on bone cells was studied.
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MATERIALS AND METHODS
Cell culture
Capsaicin and capsazepine were purchased from Sigma-Aldrich (Dorset, UK). 
The effects of capsaicin (0 - 20pM) were studied in osteoclasts derived from PBMCs, 
as described in Chapter 2. The effect of capsazepine was tested on osteoclast 
activation by adding 10pM of this TRPV1 antagonist for the last two days in culture 
in the presence of 5 mmol/1 NaOH and 15 mmol/1 tT  as HC1, resulting in an 
operating pH close to pH 7.4 and 7.0 respectively.
Bone nodule assay
Primary rat osteoblasts were obtained as described previously in Chapter 4. These 
cells were cultured in plastic wells for 10, 12 or 15 days in control or acidified 
medium modified by the presence of 0 or 25 mmol/1 HC1.
Reverse transcriptase PCR
RT-PCR analysis on the expression of OGR1, TDAG8, GPR4, ASIC la and 
TRPV1 mRNA was carried out as detailed in Chapter 3. The primers used were 
purchased from MWG (Ebersberg, Germany) and are shown in Table 5.1 and 5.2.
Table 5.1: Primers used for rat RT-PCR analysis
Factor Forward primer Reverse primer Ta
p actin gtt cgc cat gga tga cga t tct ggg tea tct ttt cac gg 53°C
OGR1 ctg age cca tga gga gtg tg ggt agg acg cca gca gca aa 52°C
Ta = annealing temperature
119
Table 5.2: Primers used for human RT-PCR analysis
Factor Forward primer Reverse primer Ta
GAPDH gtg aac ggg aag etc act gg tga ggt cca cca ccc tgt tg 57°C
OGR1 tgg gga aca tea ctg cag atg ttc teg tac agg agg 52°C
TDAG8 ccg gaa gaa ata tgg aag g cac aga tat cag cag ttg g 52°C
GPR4 acc acc tct ttc ege cat cag cac agg aag geg at 53°C
ASIC 1a gca gat cct get ctg gac ttc c aat gac etc gta ggc gta gtc 57°C
TRPV1 gca aga aca tct gca age tgc get gac aga gca ctg gtg ttc 55°C
Ta = annealing temperature
Immunocytochemistry and confocal analysis
Immunocytochemical procedures were performed as described in Chapter 3. The 
OGR1 and TDAG8 antibodies used were purchased from LifeSpan Biosciences 
(Seattle, WA, USA) and Insight Biotechnology Ltd. (Wembley, Middlesex, UK), 
respectively. The fluorescin isothiocyanate (FITC)-conjugated secondary antibodies 
used were purchased from DakoCytomation Ltd., Ely, Cambridgeshire, UK.
Western blot analysis
Isolated osteoclasts or osteoblasts were lysed in ice-cold radio 
immunoprecipitation (RIPA) lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 5 
mM EDTA, 0.1% SDS, 1 mM phenyl methyl sulfonyl fluoride (PMSF), 1 mg/ml 
aprotinin, 1 mM Na3VC>4 and 2.5mg/ml deoxicolic acid). Cell homogenates were 
sonicated for 5 minutes and stored in the -80°C freezer for at least half-hour before 
use. Protein concentrations from lysates were determined using the Bradford assay 
(Sigma-Aldrich, Gillinham, Dorset, UK). Prior to loading total protein samples were 
denatured by incubating samples at 100°C for 5 minutes in the presence of 5x 
reducing sample buffer (60mM Tris-HCl pH 6.8, 25% glycerol, 2% SDS, 10% (3- 
mercaptoethanol and 0.1% bromophemol blue). Protein samples (20 pg/ lane) were 
loaded onto SDS-PAGE (10%) gels and transferred onto a polyvinylidenedifluoride
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(PVDF) membrane (Amersham) by the use of a wet tank blotter (Bio-Rad, Hercules, 
CA, USA) at 150V for 1 hour. Membrane was afterwards blocked with 5% non-fat 
milk and incubated with OGR1 antibody (1:200) or TDAG8 (1:1000) overnight at 
room temperature. After washing, blots were incubated in a horseradish peroxidase- 
conjugated secondary antibodies (for 1 hour at room temperature). The peroxidase- 
detection system (1.25mM luminol, 0.2 mM coumaric acid, 0.1M Tris pH 8.5, 
0.032% hydrogen peroxide) was used for the visualization of the immunoreactivity. 
Western blotting performed without primary antibody served as negative control.
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R E S U L T S
Effect o f capsaicin on normal human osteoclast activation
The effect of capsaicin on the activation of blood-derived osteoclasts at control 
and acidified pH was tested by culturing these cells for 12 days at control (pH -7.40) 
pH followed by a further 48 hours in medium modified by the addition of 5 mmol/1 
NaOH or 15 mmol/1 HC1 in the presence of 0, 2, 20, 200, 2000 and 20000 nM 
capsaicin (TRPV1 agonist). The results shown in Figure 5.1 indicate that capsaicin 
at hormonal concentrations (> 2nM) strongly activates osteoclasts to resorb dentine in 
non-acidified conditions, but does not enhance the resorption activity of these cells at 
low pH. Capsaicin treatment increased osteoclast resorptive activity by 
approximately 4-fold, with maximal activation at 200nM capsaicin at physiological 
pH. Capsaicin did not appear to affect osteoclast survival, cell numbers were not 
significantly altered among treatment groups in either control or acidified media. To 
study the involvement of the TRPV1 receptor on the acid response by osteoclasts 
further, the antagonist capsazepine was tested. The stimulatory effect of low pH on 
osteoclast resorption was halved by treatment with 10 pM capsazepine (Figure 5.2). 
This compound may be marginally toxic to osteoclasts at 10 pM as cell numbers were 
somewhat reduced, although osteoclast morphology was not obviously affected 
(Figure 5.2 A and B).
Effect o f capsaicin on normal human osteoclast formation
PBMCs were treated with 0, 2, 20, 200, 2000 and 20000 nM of capsaicin in the 
presence of 5 mmol/1 NaOH or 15 mmol/1 HC1 from day 4 of culture. The effect of 
capsaicin on the formation of human osteoclasts at control or acidified pH is shown in 
Figure 5.3. Capsaicin treatment inhibited osteoclastogenesis at control pH; an 
increase in capsaicin concentration led to a decrease in osteoclast number, with 
maximal inhibition of 4-fold occurring at 20000nM capsaicin. This was accompanied 
by a 2-4-fold increase in osteoclast resorptive activity with maximal activation at 
200nM capsaicin. Osteoclast formation was not affected by capsaicin when cells 
were cultured at low pH (-7.0).
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Figure 5.1. Effect of capsaicin on the activity of human osteoclasts derived 
from PBMCs. Cells were cultured on dentine discs for 12 days in the presence of 
RANKL (1ng/ml), M-CSF (5ng/ml) and 5 mmol/l OH', followed by a further 48-hour 
incubation in culture medium modified by the addition of 5 mmol/l OH' or 15 mmol/l 
H+ and 0, 2, 20, 200, 2000 or 20000 nM capsaicin. Significantly different from each 
respective control (pH 7.46 or 7.01), * p<0.05, ** p <0.01. Values are means ± SEM 
(n = 8).
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Figure 5.2. Inhibitory effect of capsazepine on osteoclast activation in human 
PBMC cultures. Cells were cultured for 12 days in the presence of 5 mmol/l OH' to 
generate osteoclasts, followed by 2 days in MEM modified by the addition 5 mmol/l 
OH‘ or 15 mmol/l H+ and 0 or 10 pM capsazepine. A. Transmitted light image of 
osteoclasts cultured at pH 7.01 B. Osteoclasts cultured at pH 6.99 in the presence 
of 10pM capsazepine; cells were stained with toluidine blue. C. Quantification 
analysis show that capsazepine inhibits the acid effect by osteoclasts. Significantly 
different from each respective control (pH 7.35 or 7.01), ** p <0.01. Values are 
means ± SEM (n = 8 ).
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Figure 5.3. Effect of capsaicin on the formation of human osteoclasts derived 
from PBMCs. Cells were cultured on dentine discs for 14 days in the presence of 
RANKL (1ng/ml) and M-CSF (5ng/ml). For the final 10 days in culture, medium was 
modified by the addition of 5 mmol/l OH' or 15 mmol/l H+ and 0, 2, 20, 200, 2000 or 
20000 nM capsaicin. Significantly different from each respective control (pH 7.38 or 
7.00), * p<0.05, ** p <0.01, *** p<0.001. Values are means ± SEM (n = 8).
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Effect o f acidosis on if-sensing receptors expression
The mRNA expression of different H+-sensing receptors was investigated in 
primary rat osteoblasts and human osteoclast cultures. Primary rat osteoblasts were 
cultured for 10, 12 or 15 days at pH 7.41 or 6.90. The expression of mRNA for 
OGR1 by primary rat osteoblasts did not change with time in culture at pH 7.41 but 
was upregulated at all time points at pH 6.90 (Figure 5.4 A). PBMCs were cultured 
on dentine discs for 12 days at ~ pH 7.40, followed two days at pH 7.45 or 6.92. RT- 
PCR analysis (Figure 5.4 B) shows that the multifunctional receptor TRPV1 and the 
G-protein-coupled receptors OGR1 and TDAG8 were both expressed by human 
osteoclasts and were upregulated by acidosis. ASIC la was also detected by RT-PCR 
but its expression was downregulated by lowering the pH from 7.45 to 6.92. The 
expression of GPR4 was not detected in human osteoclast cultures by RT-PCR (data 
not shown).
Expression of TDAG8 and OGR1 receptors was also studied on blood-derived 
osteoclasts cultured on dentine discs for the final two days at pH 7.38 or 6.98 using 
immunocytochemistry. No membrane staining was detected for TDAG8 receptor; 
however confocal analysis revealed cytoplasmic staining which appeared to be 
upregulated when these cells were cultured at low pH (Figure 5.5). OGR1 receptor 
was also identified in cultured human osteoclasts and at acidified conditions it was 
expressed in the membrane. OGR1 staining was also observed at the sealing zone 
when cells were cultured at both control (pH 7.38) or acidified (pH 6.98) conditions 
(Figure 5.6). Immunoblotting was performed using total protein samples obtained 
from cultured human osteoclasts and rat osteoblasts (Figure 5.7 and 5.8). 
Immunoblot with OGR1 primary antibody generated a single reactive band of the 
expected weight (43 kDa), which was upregulated at acidified conditions in both 
cultures. A single TDAG8-reactive band at approximately 90 kDa was detected and 
it was overexpressed at acidified conditions in both cultures. This band, however, 
was not in the expected weight range (43 kDa). Protein lysate obtained from rat 
spleen was used as a positive control.
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Figure 5.4. Effect of extracellular pH on expression of mRNA for H*-sensing 
receptors by rat primary calvarial osteoblasts and blood-derived human 
osteoclasts. A. Cells were cultured in plastic wells for 10, 12 or 15 days in control 
(C) medium at pH 7.41 or in acidified medium (A) at pH 6.90. RT-PCR was 
performed on DNase-treated total RNA using p-actin as control. B. PBMCs were 
cultured for 12 days in the presence of RANKL (1ng/ml), M-CSF (5ng/ml) and 5 
mmol/l H \ followed by a further 2 days in medium at pH 7.45 (control, C) or pH 6.92 
(acid, A). RT-PCR was performed on DNase-treated total RNA using GAPDH as 
control. PCR products were confirmed by sequencing.
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Figure 5.5. Effect of extracellular pH on TDAG8 protein expression by human 
osteoclasts derived from PBMCs. Human PBMCs were maintained at pH -  7.40 for 
14 days, then at the indicated pH for a further 2 days. Resorbing osteoclast 
immunostained for TDG8  receptor (green) cultured on dentine disc, imaged by confocal 
microscopy. Rhodamine-phaloidin staining was used to demonstrate the F-actin ‘ring’ 
(shown in red). TDAG8  protein expression was upregulated in human osteoclast 
cultures by acidosis but this receptor does not appear to be expressed in the membrane.
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Figure 5.6. Effect of extracellular pH on OGR1 protein expression by human 
osteoclasts derived from PBMCs. Human PBMCs were maintained at pH -  7.40 for 14 
days, then at the indicated pH for a further 2 days. Resorbing osteoclast immunostained 
for OGR1 receptor (green) cultured on dentine disc, imaged by confocal microscopy. 
Rhodamine-phaloidin staining was used to demonstrate the F-actin ‘ring’ (shown in red). 
OGR1 appears to be expressed in the membrane in acidified conditions (see white arrow). 
Note that it is also localised to the sealing zone regardless of pH levels (yellow).
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TDAG8
Figure 5.7. Western blotting of primary rat osteoblast cell lysates. Primary rat 
osteoblasts were cultured in plastic wells for 15 days at indicated pH. Total protein 
samples (20|ug/well) were loaded onto 10% SDS gel and transferred to PDVF 
membrane. A. A single OGR1-reactive band of approximately 43 kDa was detected. 
B. A single reactive band of approximately 90 kDa was detected. Cell lysate from 
spleen (S) was used as positive control. Molecular markers are indicated on the left.
A
pH
7.38 7.01
75 kD *
50 k D *  
37 kD * ^OGR1
B
pH 
7.38 7.01
100 kD *
75 kD *
50 kD *
37 kD *
<=TDAG8
Figure 5.8. Western blotting of blood-derived osteoclast cell lysates. PBMCs 
were cultured for 14 days at pH ~ 7.40, then for a further 2 days at indicated pH. 
Total protein samples (10pg/well) were loaded onto 10% SDS gel and transferred to 
PDVF membrane. A. The blot was probed with polyclonal antibody to OGR1 
receptor. A single reactive band of approximately 43 kDa was detected. B. The blot 
was probed with a polyclonal antibody to TDAG8 receptor. A single reactive band of 
approximately 90 kDa was detected. Molecular markers are indicated on the left.
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DISCUSSION
The results presented in this chapter suggest that the H+-sensing receptors 
TRPV1, TDAG8 and OGR1 could play important roles in the mechanism of 
osteoclast activation by low pH.
The capsaicin experiments yielded a surprising and dramatic result. Capsaicin 
was found to strongly activate normal human osteoclasts at low nanomolar 
concentrations in non-acidified conditions. Osteoclast formation, on the other hand, 
was decreased by capsaicin at pH ~ 7.4 although this reduction in osteoclast numbers 
was accompanied by a greater increase in resorption. My results showed that 
osteoclast formation was affected in a similar manner by acidosis (see Chapter 2). To 
date, only pertussis toxin (PTX), which inactivates the inhibitory G protein (Gi), has 
been reported to ‘switch on’ osteoclasts without co-stimulation by H+ (Spowage and 
Arnett 1995). Protons have been reported to bind to a glutamate residue (E600) on 
the extracellular domain of TRPV1 channels (Jordt et al 2000). Titration of free Glu 
residues by protons usually occurs at pKa 4.3 (Creighton 1993), which is well below 
the half-maximal proton concentration of pH 7.3 that I found to be effective to 
stimulate osteoclast resorption (Chapter 2; Brandao-Burch and Arnett 2004). 
Nonetheless, interaction of E600 with other residues within the multimeric channel 
complex could greatly alter the electrostatic environment of this Glu residue. For 
example, amino acid carboxyl-carboxylate pairs sharing a single proton can display 
drastically elevated pKa values within the physiological range (Sawyer and James 
1982). Such a mechanism is likely to occur in the TRPV1 channels; E600 may form 
similar pairings with other proton-accepting or -donating amino acid residues across 
the outer surface of the channel. This pH-dependent process could lead to the channel 
opening at higher pH or influence the response of the channel complex to other 
agonists such as heat (Jordt et al. 2000).
My results also showed that the acid-activation effect was marginally inhibited by 
capsazepine, a synthetic analogue of capsaicin itself. The inhibitory effect of 
capsazepine was not obviously due to cell toxicity. However, there are problems 
associated with the use of capsazepine as an antagonist for TRPV1. First, it is a 
relatively weak antagonist which appears to show species-specific activity (McIntyre 
et al. 2001; Oh et al. 2001) and second, at similar concentrations to which it acts on
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TRPV1, it inhibits other voltage gated Ca2+ channels (Docherty et al. 1997). It is 
noteworthy, however, that capsazepine has been reported to block the response of 
capsaicin and heat most strongly to human TRPV1 compared to other species 
(McIntyre et al 2001). Therefore, further work will need to be carried out with the 
use of a more selective TRPV1 antagonist such as SB-366791 (Gunthorpe et a l
2004)
Work by members of our laboratory showed that changes in ambient temperature 
within the pathophysiological range affect the formation and activity of osteoclasts. 
The effect of decreasing rodent osteoclast activity by increasing temperature to 40°C 
was upmost when cells were cultured at physiological pH compared to pH 7.00 (Ms 
Jennifer Utting, UCL, London, personal communication). Since TRPV1 respond to 
heat as well as protons, these results are consistent with my own data as they suggest 
that TRPV1, which responds to heat and is modulated by protons may play a crucial 
role in osteoclast pathophysiology (Andersson et al 2004).
Preliminary results demonstrated that both TDAG8 and OGR1 were expressed by 
bone cells and were upregulated at acidified conditions suggesting that these 
receptors may be involved in the activation of osteoclasts by acidosis. Additional 
evidence for OGR1 expression on osteoclasts is provided by recent work of 
Komarova and colleagues (2005) who reported that OGR1 is expressed on rat 
osteoclasts and RAW 264.7 cells using immunocytochemistry. Surprisingly, western 
blotting results suggest that TDAG8 receptor might be present on bone cells as a 
dimer as a single reactive band of ~ 90 KDa (twice as big as expected) was detected. 
Further work is needed to detect the receptor as a monomer, this can be achieved by 
using harsher denaturing conditions (e.g. increasing the concentration of beta- 
mercaptoethanol and/or boiling the protein for longer periods). Also, the use of a 
different commercially available TDAG8 antibody would also be necessary to check 
for antibody-antigen specificity.
ASIC la mRNA expression was downregulated by acidosis. This is in accordance 
with previous work performed by members of our laboratory who demonstrated that 
despite this receptor being specifically expressed on osteoclasts, it was not expressed 
in the membrane to serve as an extracellular pH-sensing receptor (Hoebertz 2001). I 
was not able to detect the presence of GPR4 mRNA in osteoclast-forming human
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PBMC cultures; however, this result will have to be confirmed by other methods, 
such as immunocytochemistry. Additionally, TRPV1 receptor mRNA was also 
upregulated by low pH. Further work will be needed to confirm the presence of 
TRPV1 on the surface of human osteoclasts and also to check whether these receptors 
are specifically present on these cells.
As capsazepine did not completely inhibit the acid-response by human 
osteoclasts, it is reasonable to hypothesise that other receptors such as P2X2, TDAG8 
and OGR1 may also be involved in this mechanism. It has been reported that GPCRs 
are co-localised with TRPV1 on primary afferent sensory neurons (Julius and 
Basbaum 2001). GPCRs are also known to increase TRPV1 activity indirectly by 
stimulation of intracellular second messengers such as protein kinase A (PKA) and 
protein kinase C (PKC) (Julius and Basbaum 2001). Most recently, Komarova and 
colleagues (2005) showed that in osteoclast-like cells, acidosis leads to activation of 
phospholipase kinase (PLC), which in turn, activates the hydrolysis of inositol 
phosphate and the subsequent stimulation of PKC, known to activate TRPV1. It is 
therefore reasonable to speculate that in osteoclasts TDAG8, OGR1 and TRPV1 (and 
perhaps other putative pH receptors) act together to ensure that bone cells can 
perform the critical pathophysiological role of maintenance of acid-base balance. 
These discoveries could be an important step towards identifying new classes of 
compounds that modulate osteoclast, and also osteoblast activity.
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CHAPTER 6
General discussion and future work
The work presented in this thesis has focused on the actions of extracellular pH 
on the function of normal osteoclasts and osteoblasts. Evidence is also presented for 
the mechanism by which acidosis regulates bone cell function.
This project was planned based on the pioneering work of Arnett and Dempster 
(1986) which demonstrated a direct positive effect of low pH on osteoclast resorptive 
activity, and studies reporting that osteoblasts are also able to respond to small 
changes in culture medium pH (Krieger et al. 1992). Despite these observations the 
mechanism by which low pH affects bone cell function is still not fully understood.
The most basic function of the vasculature is to deliver food and O2 to cells and 
remove waste, such as H+ and CO2. As individuals age, this ability decreases due to 
decline of the vascular supply and renal insufficiency; the consequence of such a 
decline is likely to be a reduction in blood pH. It has been reported that in normal 
individuals, blood [H+] decreases by 6-7% (equivalent to 0.03 pH units) in a 60-year 
period (from 20 to 80 years of age) (Frassetto and Sebastian 1996). In bone, a 
decrease in blood flow leads to a progressive loss of medullary blood supply, which 
results in tissue hypoxia and acidosis (Bridgeman and Brookes 1996). In the first 
experimental chapter, I showed that normal human osteoclasts in vitro are extremely 
sensitive to pH changes, i.e. their resorptive activity increases significantly by 
lowering the extracellular pH. This decrease in pH levels leads to an increase in 
resorption by osteoclasts and over a period of time this could result in a measurable 
loss of bone mass, such as that seen in age-related osteoporosis. It is likely that in 
vivo acidosis strongly amplifies the resorption resulting from increased osteoclast 
formation by hypoxia (Arnett et al. 2003)
Another example of periods of low bone blood flow is at early stages of fracture 
healing. Following a bone fracture, local pH may fall to low levels owing to 
disruption of blood supply. pH measurements of samples taken from the femoral 
neck of rabbits during operation for impacted subcapital fracture has been shown to
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be 6.87 (Richards and Brookes 1968). Following bone fracture, osteoclasts resorb 
away the damaged bone and participate in the remodelling of fracture callus. 
Therefore, the osteoclast’s ability to increase resorption by low extracellular pH is a 
pathophysiological advantage in these situations.
Since the influential papers by Rodan and Martin (1981 and 1982), the prevailing 
view has been that activation of osteoclasts by PTH and other pro-resorptive factors 
are mediated indirectly by osteoblasts. In the mid-80s, Chambers and colleagues 
tested this hypothesis and showed that in vitro osteoblasts not only mediate the effect 
of PTH (McSheehy and Chambers 1986a; McSheehy and Chambers 1986b), but also 
that of IL-1 (Thomson et al 1986), TNF-a and (3 (Thomson et al 1987) and 1,25 
(OH)2 vitamin D3 (McSheehy and Chambers 1987) on osteoclasts. My finding that 
human osteoclasts are activated by PTH in the absence of osteoblasts contradicts 
these observations, and are supported by data from our collaborators who showed the 
PTH receptor, PTH1R, is expressed by human osteoclasts derived from PBMCs 
(Dempster et al 2005). Together, our data suggest that the dogma that PTH 
stimulation of osteoclasts requires osteoblast mediation is not correct. It may be 
reasonable to suppose that PTH exerts a dual regulatory action on bone resorption by 
acting directly on osteoclasts and also, indirectly, via osteoblasts.
A ‘classical’ action of growth factors and cytokines is to activate metabolism, 
resulting in increased proton efflux from cells. Investigations using osteoblast-like 
SaOS-2 cells, primary rat osteoblasts and whole bone organ cultures showed that 
IGF-1 or PTH application stimulates osteoblastic extracellular acidification (Barrett et 
al 1997; Santhanagopal and Dixon 1999; Belinsky and Tashjian, Jr. 2000). This 
model system may resemble an in vivo situation, where acid production by osteogenic 
or stromal cells reduces local pH, through the action of bone-resorbing agents such as 
PTH, to a value optimal for osteoclastic bone resorption. These observations provide 
a plausible mechanism by which PTH, growth factors, cytokines, mitogens can 
influence osteoclast activity in an indirect manner.
The finding that PTH activates osteoclasts only when they have been acid- 
activated is consistent with the notion that acidification is the key initial requirement 
for osteoclasts to be able to excavate resorption pits. Following acid-activation, 
further stimulation with “conventional” pro-resorptive agents such as PTH,
135
l,25(OH)2 vitamin D3 (Munills et al 1998), nucleotides (Morrison et al. 1998; 
Hoebertz and Arnett 2003) or RANKL (Hoebertz and Arnett 2003) can then occur. 
Thus, extracellular H+ may be regarded as the long-sought ‘osteoclast activation 
factor’ (OAF). My results emphasise that extracellular pH is a critical influence on 
osteoclast activity which must be considered in the design, monitoring and 
interpretation of all bone resorption experiments.
In Chapter 3, I showed that the resorption-associated factors TRACP, cathepsin K 
and TRAF6 are upregulated by acidosis. These results add to previous reports 
showing that the expression of other resorption-associated factors such as carbonic 
anhydrase II (CAII), calcitonin receptor (CTR) and V-ATPase are upregulated by low 
pH (Nordstrom et al 1997; Biskobing and Fan 2000). These data provide further 
insight into the “downstream” responses of osteoclasts to extracellular protons and 
indicate the earlier suggestion that low extracellular pH may favour resorption by a 
simple reduction of the gradient against which osteoclast must pump H+ is unlikely to 
account for the activation effect of low pH observed in osteoclasts (Arnett and 
Dempster 1986).
The results presented in Chapter 4 show that bone nodule formation by rat 
osteoblasts may be more sensitive to small pH changes than was previously 
appreciated. The steep response of osteoblasts to acidosis is reciprocal to the acid- 
activation curve for resorption pit formation by cultured rat and human osteoclasts 
(Chapter2; Arnett and Dempster 1986; Brandao-Burch and Arnett 2004). At the 
same pH that activates osteoclasts optimally (i.e. 6.90 - 7.00), mineralisation by 
osteoblasts is completely abolished. It is possible that during chronic metabolic 
acidosis, the bone cells may be exposed to low pH levels and the function of the bone 
tissue will be 1) to liberate alkaline bone mineral due to increased mineral solubility; 
reduce osteoblast alkaline phosphatase activity and increased matrix Gla protein 
expression and 2) to increase osteoclast resorptive activity. The powerful inhibition 
of alkaline phosphatase activity by small pH reductions may conceivably involve 
cell-mediated H+-sensing mechanisms, such as the OGR1 receptor that respond over 
similar pH ranges (Ludwig et al 2003) and is upregulated by acidosis in primary rat 
osteoblast cultures (Chapter 5).
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Although the pH of arterial blood is normally -7.40, and that of venous blood 
-7.36, the pH of the extracellular fluid bathing cells is likely to be below pH 7.36 and 
subject to complex, dynamic gradients, depending on the metabolic activity of the 
cells and their distance from the nearest capillary. There are relatively few reliable 
measurements for interstitial pH in intact tissues. It has been demonstrated by non 
invasive measurements that the pH in normal skin is around -7.2 and the interstitial 
pH decreases by -  0.32 units at a distance of 50pm from a blood vessel (Martin and 
Jain 1994). My own results suggest that for bone turnover to occur in vivo, 
extracellular pH in the immediate bone environment should be in the approximate 
range of 7.15-7.30. My data emphasise the importance of the vasculature for bone 
health and suggest a rationale for the histological observation that bone formation 
normally takes place in proximity to blood vessels.
In Chapter 5, I showed that capsaicin activates normal human osteoclasts in non­
acidified conditions where most pro resorptive factors such as PTH is inactive 
(Chapter 2). Furthermore, this activation response occurred at “hormonal” 
concentrations of capsaicin that are at least 2 orders of magnitude lower than those 
commonly used pharmacologically. These results suggest that the TRPV1 receptor 
may be involved in the osteoclast response to acidosis. This receptor is a non- 
selective plasma membrane cation channel that is activated by protons, heat and 
capsaicin (Caterina et a l 1997).
Ongoing experiments in our laboratory suggest that capsaicin may exert an 
inhibitory effect of bone nodule formation by normal osteoblasts. Further in vitro 
work is required to assess whether the effect of capsaicin on osteoblasts mimics that 
of acidosis. This could be achieved by using a number of methods described in 
detail in Chapter 4. Alkaline phosphatase activity and osteoblast proliferation 
measurement is needed to verify whether capsaicin has an effect on osteoblast 
differentiation. The cultures should also be assessed for apoptosis in order to rule 
out any cytotoxic effect of capsaicin on osteoblasts. Analysis of collagen deposition 
by TEM and quantification by 3H-proline incorporation would provide direct 
evidence of the effects of capsaicin on matrix deposition and subsequent 
mineralisation. Moreover, the expression pattern of proteins involved in osteoid 
production, matrix mineralisation and the nucleation process and osteoblast
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differentiation such as alkaline phosphatase, nucleoside triphosphate 
pyrophosphohydrolase (NTPPase or PC-1), annexins II, V and VI, matrix Gla protein, 
osteopontin, type 1 collagen, osteocalcin and the transcription factor Runx2 could 
also be investigated.
Capsaicin is the active ingredient of chilli peppers. Data are rather limited but 
some reports have shown that this alkaloid can be absorbed in the gastrointestinal 
system in its active form and is metabolised in the liver before reaching the general 
circulation. In rats, traces of capsaicin have been detected systemically in the blood 
and brain in its unchanged form a few hours after intragastrical administration 
(Donnerer et al. 1990). It has also been reported that following oral ingestion of 3 mg 
of capsaicin (an amount similar to that ingested by rural Thai people per meal) in 
experimental rats, 10% of the dose was detected in non-metabolised form in the 
faeces and a further 9% was excreted in the urine, indicating absorption of significant 
quantities into the circulation (Kawada and Iwai, 1985). In rats exposed nasally to 1, 
5 and 50 mg/ml of capsacin, circulating concentrations of up to 90 ng/ml have 
recently been measured (Reilly et al. 2002). Therefore, bone cells could potentially 
be exposed in vivo to the capsaicin concentrations within the range shown to 
modulate osteoclast activity in my study.
It has been reported that systemic injection of capsaicinoids in rats results in a 
decrease of BMD in the metaphyses of the tibia and femur. Further 
histomorphometric analysis showed that the loss of BMD is probably due to an 
increase in osteoclast numbers and impaired osteoblast activity (Offley et al. 2005). 
The results obtained from Offley and colleagues (2005) need to be interpreted with 
caution. The systemic administration of capsaicin is unpleasant and results in 
profound depressions of core body temperature (Dib 1983; Szolcsanyi 2004). We 
have recently shown that temperature reductions cause significant increase in 
osteoclast formation in vitro (Utting et al. 2005).
In the Capsicum genus the content of capsaicin may be up to 1% by dry weight 
{e.g. in a habanero chilli) (Cordell and Araujo 1993). In some countries, such as 
Mexico, Thailand and India, consumption of hot chilli peppers is often high. It has 
been reported that in Mexico City, for example, the average consumption of chilli 
peppers is 20g / person per day, which is equivalent up to 200 mg / person per day of
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capsaicinoids (Lopez-Carrillo et a l 1994). To date, there are no reports in the 
literature of the relationship between chilli pepper consumption and bone mass.
Anandamides, endogenous agonists of cannabinoid receptors (CBi andCB2), have 
been shown to activate both native and recombinant TRPV1 receptors in vitro in a 
manner that is modulated by pH and temperature (Di, V et al. 2002). It has been 
reported recently that the endocannabinoid system plays an important role in bone 
regulation. C2?7-knockout mice were shown to have increased bone mass and were 
protected from ovariectomy-induced bone loss. Additionally, pharmacological 
approaches showed that selective antagonists to these receptors (CBi and CB2), 
expressed by bone cells, inhibit osteoclast activation both in vivo and in vitro, 
whereas the agonist anandamide stimulated osteoclast formation in vitro (Idris et al
2005). In view of the potential ‘cross-talk’ between the vanilloid and cannabinoid 
system, investigation on whether the anandamide effect on bone cells mimics that of 
capsaicin, i.e. stimulation of bone resorption at physiological pH levels, would prove 
very useful for further understanding of osteoclast biology.
In chapter 5, I also showed that the G-protein coupled receptors OGR1 and 
TDAG8, which respond sensitively to pH changes in the range of 7.5 -  6.8 with 
increases in inositol phosphate and cyclic AMP respectively, are expressed by bone 
cells and that the TRPV1 receptor, a non-selective plasma membrane cation channel 
that is activated by protons, heat and capsaicin is upregulated by acidosis in human 
osteoclast cultures. My results provide evidence for a possible mechanism by which 
extracellular protons are sensed by osteoclasts by multiple receptors such as OGR1, 
TDAG8 or TRPV1; the signalling is then transmitted via a cascade that would 
eventually activate transcription factors to bind to promoters of TRACP, cathepsin K, 
CAII, CTR and V-ATPase genes, all known to be upregulated in acidified conditions 
(Nordstrom et al. 1997; Biskobing and Fan 2000; Brandao-Burch et al. 2003). 
Given the importance of H+ sensing receptors to bone cells, it should not be 
surprising that multiple pathways are activated upon exposure of bone cells to H+ as 
outlined in Chapter 5.
Clearly, it will now be important to study bone density, 
histology/histomorphometry, tooth eruption in H+ receptor knockout mice such as 
TRPV1 (Caterina et al 1997) and G2A (a GPCR that belongs to the same family as
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0GR1, GPR4 and TDAG8) (Le et al 2001), together with functional analysis to 
assess osteoclast activation, osteoclastogenesis and bone nodule formation from cells 
obtained from these knockout mice. Knockout mice for OGR1, TDAG8 and GPR4 
will be available to us shortly. Small interfering RNA technology will also enable 
complementary in vitro studies. Recently-published data indicate that this technology 
is effective in gene knockdown in primary osteoclast cultures (Yin 2005). A 
pharmacological approach could also be taken to study further the involvement of 
other pH-modulated receptors on osteoclast and osteoblast activity. Functional 
responses of bone cells to icilin and menthol, which activate the pH-modulated 
TRPM8 ‘cold’ receptor, could be examined in detail (Andersson et al. 2004). Also of 
interest are TASK 1 and 3 receptors (TWIK-related acid-sensing K+ channel 1 and 3), 
members of the background K+ channel family. These channels have been reported 
to respond to extracellular pH in the pathophysiological range and hypoxia (Kemp et 
al 2004).
The actions of extracellular pH on bone cells presented in this thesis suggest 
novel means of manipulating bone cell function, based either on adjustment of 
systemic acid base balance by diet or alkaline salt ingestion, or by pharmacological 
intervention at proton sensing receptors present on bone cells. Awareness of the 
potential risks of hormone replacement therapy in postmenopausal women has 
increased recently (Beral 2003). Moreover, long-term and short-term biphosphonate 
administration has recently been linked with nephrotoxicity (Smetana et a l 2004). 
Therefore, there is a renewed need for research into alternative approaches to limiting 
bone loss in older individuals.
Evidence suggests that in post-menopausal women, administration of 60 to 120 
mmol per day per 60 kg of potassium bicarbonate increases the blood pH from 7.39 
to 7.41. This increase was accompanied by a significant increase in both calcium and 
phosphorus balance and a prompt decrease in net renal acid excretion, indicating that 
endogenous acid was almost completely neutralised (Sebastian et al 1994). It has 
also been shown that thiazide diuretics, which are widely used as anti-hypertensive 
agents (Moser 1998), reduce bone loss in normal post menopausal women (Reid et 
al 2000). The mechanisms by which thiazides influence bone metabolism are not 
fully elucidated, however it has been suggested that thiazide administration causes
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metabolic alkalosis (Peh et al. 1993). Beta-blockers, taken alone or in combination 
with thiazides have also been shown to decrease the risk of fractures in both men and 
women, whether this is due to a decrease in blood acidity still remains to be 
elucidated (Schlienger et al. 2004). Many elderly patients that suffer from 
osteoporosis and hypertension may benefit from treatment with beta-blockers and 
thiazide diuretics. These drugs are of beneficial value as they are very inexpensive 
and do not have many side effects.
Dietary manipulation is currently receiving a lot of attention, a diet which is rich 
in fruit and vegetables may be beneficial to the skeleton although there are some 
controversies associated with this notion as detailed in Chapter 1.
The direct effect of systemic acidosis on osteoclast and osteoblast activity needs 
to be investigated further in vivo. One approach would be to examine changes in 
markers of bone turnover in response to vigorous exercise carried out by healthy 
volunteers. Excessive exercise is known to induce acute, severe systemic acidosis; 
after ten 10-second sprints in a cycle ergonometer separated by 30-second passive 
recovery intervals, the blood pH has been shown to drop from -7.4 to -7.2 in men 
(Ratel et al. 2002). Serum and urine would have to be collected at regular intervals 
and markers for bone resorption such as serum cross-linked C telopeptide of type I 
collagen, urinary cross-linked N telopeptide levels, RANKL, OPG and serum tartrate 
resistant acid phosphatase 5b and for bone formation (e.g. serum type I terminal 
propeptide and bone specific alkaline phosphatase) measured, together with PTH and 
calcitonin levels. If a subsequent rise in bone resorption markers would be observed 
it would provide evidence that there is a net negative effect of acidosis on the 
skeleton.
In conclusion, this study shows that acidosis exerts an important “double 
negative” action on bone cells and provides insights into the underlying mechanisms, 
summarised in Figure 6.1. This is in accordance with the physiological role of bone 
as a reserve of base that is available as a “fail-safe” mechanism to buffer protons if 
the kidneys and lungs are unable to maintain acid-base balance within narrow 
physiological limits (Barzel 1995; Frassetto et al. 1996). The mechanism by which 
acidosis regulates bone cell function may have evolved in vertebrates as a last line of 
defence to protect the body against the effects of systemic acidosis.
141
y  mineralised matrix f»~] active osteoblast
| | osteoid ®  inactive osteoclast
Q 3 resorption pit active osteoclast
ALP = alkaline phosphatase
t  ALP
BONE
pH 7.4 pH 7.2 pH 6.9
Figure 6.1. Schematic of extracellular pH actions on bone cell function.
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Appendix I: Abbreviations
ABBREVIATION FULL NAME
l,25-(OH)2D3 1,25-dihydroxyvitamin D3
AP-1 Activator protein-1
ASIC Acid sensing ion channel
ATP Adenosine 5’-triphosphate
BGJb Biggers, Gwatkin and Heyner medium
BMP Bone morphogenetic protein
BMU Basic multicellular unit
C- Carboxy-
Ca2+ Calcium
CAII Carbonic anhydrase II
CAMP Cyclic adenosine 5’-monophosphate
Cbfal Core binding factor 1
Cl" Chloride
COX Cyclooxygenase
c o 2 Carbon dioxide
DMEM Dulbecco’s Modified Eagle Medium
EDTA Ethylen-diamine tetraacetic acid
ER Oestrogen receptor
F-actin Filamentous actin
FBS Foetal bovine serum
FCS Foetal calf serum
FGF Fibroblast growth factor
Gla y-carboxylated glutamate
GPCR G-protein-coupled receptor
GPR4 G-protein-coupled receptor 4
GTP Guanosine 5’-triphosphate
HBSS Hank’s balanced salt solution
HC1 Hydrochloric acid
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HC03-
h 2c o 3
IFN-y
IGF
Ihh
IL-1
IP3
K+
Li
MAPK
M-CSF
MMP
N-
NFAT
NaOH
NF-kB
OGR1
OPG
PBMCs
Pi
PBS
PDGF
PGE2
PI-3
PKC
PTH
PTHrP
RANK
RANKL
RER
RGD
TDAG8
TGF
Bicarbonate 
Carbonic acid 
Interferon-y
Insulin like growth factor 
Indian hedgehog 
Interleukin-1
Inositol 1,4,5-triphosphate
Potassium
Lithium
Mitogen-activated protein kinase 
Macrophage-stimulating growth factor 
Matrix metalloproteinase 
Amino-
Nuclear factor of activated T-cell
Sodium hydroxide
Nuclear factor kappa B
Ovarian cancer G-protein coupled receptor
Osteoprotegerin
Peripheral blood mononuclear cells 
Phosphate (inorganic)
Phosphate-buffered saline 
Platelet-derived growth factor 
Prostaglandin E2 
Phosphatidylinositol-3 kinase 
Protein kinase C 
Parathyroid hormone
Parathyroid hormone related protein/peptide 
Receptor activator of nuclear factor kB 
Receptor activator of nuclear factor kB ligand 
Rough endoplasmic reticulum 
Arg-Gly-Asn
T-cell death associated gene 8 
Transforming growth factor
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TNF Tumour necrosis-related factor
TRAF TNF receptor-associated factors
TRANCE TNF-related activation-induced cytokine
TRACP Tartrate-resistant acid phosphatase
TRPV Transient receptor potential cation channel
subfamily V
VDR Vitamin D receptor
VEGF Vascular endothelial growth factor
V-ATPase Vacuolar-type ATPase
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